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Summary
Summary
In HSV-1 strain F, one gene product had previously been localised to the region of the 
genome between RL2 and the ‘a’ sequence, and shown to be a determinant of HSV-1 
strain F neurovirulence. This protein was designated ICP34.5.
Sequence analysis of the HSV-1 strain 17+ genome in this region revealed that in HSV-1 
strain 17+, the putative ORF ascribed to ICP34.5 was thoroughly disrupted by a 2bp insert, 
which rendered 60% of the coding-region out of frame. This did not correlate however, 
with data obtained by several laboratories which clearly demonstrated that in HSV-1 strain 
17+ this locus encoded an important neurovirulence determinant.
The initial stage of this project involved reinvestigation of the HSV-1 strain 17+ sequence 
at the terminus of the long repeat, where the expected frame-shift occurred. By comparison 
of two newly sequenced clones with the original clone used to sequence this region of the 
genome, it was demonstrated that the original sequence obtained for this locus of HSV-1 
strain 17+ was inaccurate and came from an atypical plasmid clone. Correction of the 
strain 17+ sequence opens the reading frame proposed by Chou and Roizman to encode a 
protein of 248 amino acids. This ORF has been designated RL1.
Having confirmed that HSV-1 strain 17+ encodes an ICP34.5 homologue, we wished to 
confirm the importance of this gene in neurovirulence following intracerebral inoculation 
of HSV-1 strain 17+. Verification that lack of synthesis of ICP34.5 alone, was responsible 
for a non-neurovirulent phenotype was achieved through the construction and 
characterization of a HSV-1 strain 17+ RL1 variant, 1771, with a stop-codon in only the 
ICP34.5 reading frame, 9 base pairs downstream from the initiating ATG. 1771, did not 
produce ICP34.5 as demonstrated by Western blotting using an ICP34.5 polyclonal 
antiserum which was generated during the course of this study. It was not impaired in 
growth in tissue culture, and following intracerebral inoculation of BALB/c mice it was 
totally non-neurovirulent, with a LD50 of >10^ p.f.u./mouse, compared to 7 p.f.u./mouse 
for the wild-type virus HSV-1 strain 17+. This lack of neurovirulence was shown to
Summary
correlate with an inability to replicate in mouse brain, and clearly demonstrated the crucial 
role played by ICP34.5 in HSV-1 strain 17+» following intracerebral inoculation of mice. 
Previously, peptide antisera had been raised against 7 different regions of the predicted 
HSV-1 strain 17+ RL1 ORF, but none of these, until recently, had successfully identified 
ICP34.5 in HSV-1 strain 17+ infected cells. To demonstrate that the HSV-1 strain 17+ 
RL1 ORF was capable of expressing a protein, it was placed under the control of a strong 
T7 promoter and over-expressed in E.coli BL21(DE3) cells. A two-step process was 
developed for partial purification of the E.coli -expressed ICP34.5 which involved initial 
ammonium sulphate precipitation followed by anion-exchange chromatography. The 
partially purified protein was used as an immunogen for the production of a rabbit 
polyclonal anti-ICP34.5 serum. This antiserum successfully recognised ICP34.5 in HSV-1 
strain 17+ and HSV-1 F infected cell extracts and revealed that previous results which had 
indicated that ICP34.5 was underproduced in HSV-1 strain 17+ were inaccurate, and the 
protein was produced in similar quantities by both strains. Using this polyclonal antiserum, 
and 1771 as a negative control, ICP34.5 was specifically localised to the cytoplasm of 
HSV-1 strain 17+ infected cell extracts.
An antiserum, raised against a peptide corresponding to 10 copies of a Proline-Alanine- 
Threonine amino acid repeat predicted by the HSV-1 strain F RL1 ORF, had been 
previously shown to recognise a polypeptide of Mr 39K in HSV-1 strain F infected cell 
extracts, but only recently, following extensive optimization of our assay conditions has it 
specifically recognised ICP34.5 in HSV-1 strain 17+ infected cells. A strain F mutant, F ll ,  
with a deletion in RL1 was constructed to confirm the specifity of this antiserum, to use as 
a negative control in ICP34.5 localization studies, and to show that loss of ICP34.5 
expression specifically correlated with a loss of neurovirulence.
F l l  was shown to be totally non-neurovirulent following intracerebral inoculation of mice 
with a LD50 of >10? p.f.u./mouse, compared to <l(fi p.f.u./mouse for the parental wild- 
type HSV-1 strain F. Unlike the strain 17+ mutant 1716 (which has an identical deletion in 
its genome) F l l  was not significantly impaired , compared to the wild-type virus, in 
reactivating from latency. Using Western blot analysis we were able to demonstrate that
Summary
lack of synthesis of ICP34.5 correlated with a loss of neurovirulence. Using F l l  as a 
negative control, ICP34.5 was localised to the cytoplasm of HSV-1 strain F infected cells 
by immunofluorescence and cell fractionation studies.
During the analysis of single plaques from a transfection, a variant designated 1772, was 
isolated which had a large deletion in Us. It was observed that this variant had a small 
plaque morphology on BHK21/C13 cells which was indicative of a defect in cell-to-cell 
spread. This property had not previously been ascribed to any gene in Us, and for this 
reason initially, it was decided to further localize the deletion in 1772. Initial 
characterization demonstrated that 1772 had an extended lag phase following one-step but 
more noticably following multi-step growth analysis. Sequencing revealed that 1772 had a 
630bp deletion which removed the initiating methionine of US7, which encodes gl, and 
extended to the 3’ end of the gene. This was subsequently confirmed by 
immunoprecipitation, using a gl specific monoclonal antibody. 1772 was not impaired in 
adsorption or penetration onto BHK21/C13 cells, compared to the wild-type virus HSV-1 
strain 17+ However it was intermediate in neurovirulence following intracerebral 
inoculation of mice. Due to time constraints, further characterization of the defect in 1772 
was not possible.
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Chapter 1- INTRODUCTION
1.1. The herpesviruses
1.1.1. General properties of the herpesviruses
There are now more than 80 members of the herpesvirus group (Nahmias et al., 1972) 
which all conform to a set of basic morphological characteristics (Fenner, 1976). The virion 
(120-200nm in diameter) consists of 4 structural components; (a) a core made up of a
linear double-stranded DNA molecule of 120-240kbp is 
wrapped; (b) an icosahedral capsid 100-110nm in diameter composed of 162 capsomers; (c) 
an amorphous lipid-containing layer termed the tegument which surrounds the capsid- this is 
often distributed asymmetrically and may be variable in amount; (d) the envelope, a 
bilayered membrane which surrounds the tegument and has surface projections (Wildy et 
a l, 1960; Roizman and Furlong, 1974).
All members of the family possess a linear double-stranded genome with a molecular weight 
of approximately 80-150x106 (Roizman, 1982) and are readily separable using criteria such 
as base composition, genome structure, immunological cross-reactivity, biological 
properties and size. Classification of the Herpesviridiae in terms of biological properties 
(Roizman eta l, 1978; Mathews, 1982; Roizman, 1982) and genome structure (Honess and 
Watson, 1977; Roizman, 1982; Honess, 1984) is described below.
1.1.2. Classification according to biological characteristics
Members of the family Herpesviridiae are classified, primarily on the basis of biological 
behaviour, into 3 sub-groups, the Alpha-, Beta- and Gammaherpesviriniae (Roizman, 
1982). The differentiation between the Alpha- and Gamma- subfamilies is based on host- 
range and in vitro characteristics, while the differentiation between the Beta- subfamily and 
the others is based primarily on the length of the reproductive cycle and slow development 
of cytopathology in cell cultures.
The Alphaherpesviriniae are neurotropic and frequently, but not exclusively, become latent 
in neurons of the dorsal root ganglia of the peripheral nervous system (PNS). They are
1
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characterised by their short reproductive cycle and rapid spread of infection in cell culture 
resulting in mass destruction of susceptible cells. This subfamily can be further sub-divided 
into 2 genera; the Simplexvirus -the type virus of which is HSV-1- and the Varicellovirus 
whose members include VZV, EHV-1 and PRV.
In contrast the Betaherpesviriniae which comprise the Cytomegaloviruses have a relatively 
long reproductive cycle. In tissue culture they produce slowly progressing lytic foci and 
infected cells frequently become enlarged (cytomegalia) both in vitro and in vivo. Members 
of this group can establish latent infections in secretory glands, lymphoreticular tissue, 
kidneys and other tissues. They include HCMV and EHV-2.
The third family in this grouping are the Gammaherpesviriniae, which are lymphotropic and 
specifically infect B- and T- lymphocytes. In the lymphocyte, infection is frequently arrested 
either at a pre-lytic stage with persistence and minimal expression of the viral genome, or at 
a lytic stage, causing death without production of complete virions. EBV and HVA are 
members of this subfamily.
1.1.3. Classification on the basis of genome structure
Base composition, size of the genome and arrangement of reiterated sequences within the 
genome are 3 factors which can be considered when classifying the Herpesviridiae in terms 
of genome structure. As herpesviruses differ significantly in their overall base composition 
(32-75% G+C) and the size of their genome, the most useful characteristics for the 
classification of herpesviruses is the arrangement of reiterated sequences. On that basis the 
viral genomes fall into 5 classes (A through E). These are illustrated diagramatically in figure 
1. 1..
Group A: The genomes of members of this group have a single direct repeat at the termini 
which is in the same orientation at either end. The DNA exists in only one isomeric 
arrangement. CCV is a member of this group (Chousterman et al., 1979).
Group B: The DNA is present in only 1 isomeric arrangement. HVS is a member of this 
group. The genome is characterized by containing multiple copies of a sequence present as a
2
Figure 1.1. Genome structures of the herpesviruses.
Schematic diagram of the herpesvirus genomes. Solid lines represent unique sequences (Us 
and Ul )- Repeat sequences larger than lkb are shown in open boxes and those of small 
reiterated sequences are shown in shaded boxes. Letters (a)n and (b)n signify multiple 
tandem repeat sequences. Arrowheads above boxes indicate the orientation of the repeat 
sequences. An example of each group A-E2, is illustrated and the number of isomers 
indicated. In VZV, Us is in either orientation 50% of the time, while Ul  is in 1 orientation 
95% of the time.
a, b and c indicate repeat sequences with a’, b’ and c’ their complement respectively.
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direct repeat at each termini (Bomkamm et al, 1976; Albrecht et al., 1992).
Group C: EBV is a member of this group, the DNA of which is present again in only 1 
isomer (Raab-Traub et al, 1980). The termini of the DNA molecules are formed by several 
copies of a directly repeated sequence and internally, the genome carries another set of 
directly repeated elements. Both the terminal repeats and the major internal repeat families 
vary in copy number.
Group D: The viral DNA of this group is characterized by having two unique regions (U l 
and Us) with Us being flanked by inverted repeats (IRs and TR$) which allow inversion 
of Us, giving rise to 2 isomeric forms. PRV (Stevely, 1977) and EHV-1 (Chowdhury et 
a l, 1990; Yamanchili and O’Callaghan, 1990) are members of this group.
; Group E: This group has been further divided into 2 subgroups El and E2.
Subgroup El consists of viruses eg.VZV whose unique regions (Us and Ul ) are flanked
I!
| by inverted repeats (TRl /IRl , TRs /IRs )- Ul  is flanked by small inverted repeats and
i
inverts inefficiently, while Us is flanked by longer repeats and inverts to give equimolar 
amounts of both orientations of Us. In the case of VZV two of the isomers, representing 
one orientation of Ul  are about 20-fold more abundant than the other two (Davison, 1984). 
HSV-1 and HSV-2 belong to the subgroup E2. They have 2 unique segments (Ul  and Us) 
both of which are flanked by inverted repeats (TRl /IRl , TRs/IRs ) which share a short 
region of DNA directly repeated at the termini and indirectly repeated at the junction between 
the internal inverted repeats. Preparations of DNA contain equimolar amounts of 4 
sequence-orientation isomers.
The complete DNA sequences have been published of EBV (Baer et al., 1984), 
VZV(Davison and Scott, 1986a), HSV-1 (McGeoch et al., 1985,1986,1988a; Perry and 
McGeoch, 1988), HCMV (Chee et al., 1990), EHV-1 (Telford et al., 1992) HVS (Albrecht 
et al., 1992) CCV (Davison, 1992) and partial sequence data are available for many others. 
This information has enabled the re-evaluation of the original classification and has shown 
that although a virus may have the biological characteristics of one sub-family, it may be 
genetically related to a different family.
3
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In general, assessment of genetic relationships between individual viruses are based 
primarily on comparisons of predicted amino acid sequences and are in agreement with the 
biological classification, but there are exceptions. On the basis of morphology and biology 
CCV was classified as a member of the, Alphaherpesviriniae (Roizman, 1982). Sequence 
analysis of this virus (Davison, 1992) has shown that genetically, CCV should not be 
included in any of the recognised herpesvirus subfamilies, but should be classified as the 
sole member of a new subfamily, or possibly as a new virus family altogether.
HHV-6, being a lymphotrophic virus, would appear to belong in the Gammaherpesviriniae, 
but in fact its, sequence is closely related to HCMV, the prototype member of the 
Betaherpesviriniae. Similarly, two avian herpesviruses, MDV and the closely related 
herpesvirus of turkeys (HVT) had originally been assigned to the Gammaherpesviriniae 
because of their tropism for lymphocytes (Roizman, 1982), but comparison with other 
herpesviruses has indicated that they share greater homology to VZV (a member of the 
Alphaherpesviriniae) than to EBV (Buckmaster et al., 1988). Furthermore, it has been 
suggested that PRV and BHV-1, which have been classified with VZV in the Varicellovirus 
genus, should perhaps be considered along with HSV-1 as members of the Simplexvirus 
genus, on the basis of their similar mechanism of entry into cells (Spear, 1993).
1.1.4. The Human Herpesviruses
There are 7 herpesviruses known to infect man. These are HSV-1, HSV-2* VZV, EBV, 
HCMV, HHV-6 and HHV-7. A brief outline of the pathogenesis of each is given below.
HSV-1 and HSV-2 (reviewed by Whitley, 1990) usually cause cold sores and genital 
lesions respectively. At the time of primary infection, the virus replicates lytically in the 
peripheral tissues around the site of infection and enters sensory nerves at the termini of 
axons of sensory neurons. A lifelong latent infection is established in the neurons of the 
sensory ganglia and periodically, various stimuli including stress, exposure to ultraviolet 
light, hormonal changes and immune suppression induce reactivation and production of 
infectious virus. The reactivated virus then travels back to the tissues around the site of
4
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primary infection, where it may again replicate lytically, destroying cells and causing the 
formation of recurrent lesions.
VZV (reviewed by Gelb, 1990) produces two distinct clinical syndromes- chickenpox and 
shingles. Chickenpox (varicella) is a ubiquitous, highly contagious, generalized exanthem 
that spreads rapidly in a susceptible population. Herpes zoster, however appears to be a 
secondary reactivation of VZV that has remained latent since an earlier attack of varicella. It 
usually occurs in older and immunocompromised individuals.
EBV (reviewed by Miller, 1990) was first discovered in the lymphoblastoid cells of the 
tumour known as Burkitt’s lymphoma and was subsequently found to be the causative agent 
of infectious mononucleosis or ‘ glandular fever’; it has also been associated with the human 
malignancy nasopharyngeal carcinoma. Although EBV exists worldwide, nasopharyngeal 
carcinoma is endemic only in Southern China, and Burkitt’s lymphoma only in tropical 
Africa, suggesting the involvement of genetic or environmental factors in progression 
towards these diseases.
HCMV (reviewed by Alford and Britt, 1990). In immunocompetent individuals, HCMV 
infections are generally asymptomatic, however it is one of the most common opportunistic 
infections associated with people with AIDS. CMV recurrence is the major viral 
complication in bone marrow transplantation (Meyers et al., 1986) as well as in organ 
transplantation, including liver, kidney, heart and lung (Ho, 1991). It is established that 
recurrence from the transplant itself as well as within the transplant recipient both contribute 
to the overall risk of HCMV disease.
HCMV has been isolated from biopsies of cervical carcinoma, adenocarcinoma and 
Kaposi’s sarcoma, indicating that it may be associated with these cancers. However the 
ubiquitous distribution of the virus has made an aetiological association between HCMV 
infection and human cancer difficult to establish.
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HHV-6 was originally designated human B lymphotrophic virus, because it was first 
isolated in 1986 from peripheral blood leukocytes of AIDS patients and patients with 
lymphoproliferative disorders (Salahuddin et al, 1986). It is now thought that this virus can 
grow in B- and T- cell lineages (Downing et al, 1987; Lopez et al, 1988) and it has been 
renamed HHV-6. HHV-6 is the causative agent of exanthem subitum (roseola infantum), a 
common childhood disease characterized by high fever and skin rash. Using PCR, HHV-6 
DNA sequences have been detected in peripheral blood and saliva samples from the majority 
of healthy individuals (Gopal et al, 1990; Jarret et al, 1990), and it is likely that saliva is an 
important vehicle for transmission of HHV-6.
HHV-7 was first isolated in 1990 from CD4+ T-cells purified from peripheral blood 
mononuclear cells of a healthy individual (Frenkel et al, 1990) but little is known about this 
virus. Berneman et a l (1992) independently isolated HHV-7 from peripheral blood 
mononuclear cells of a patient with chronic fatigue syndrome. Using the serum of a patient 
infected with HHV-7 they demonstrated by immunofluoresence that HHV-7 has a tropism 
for primary human T-lymphocytes and for at least one immature T-cell line. Although HHV- 
6 and HHV-7 were found to be molecularly and immunologically related, the molecular 
divergence between HHV-6 and HHV-7 is enough for HHV-7 to be considered another 
herpesvirus rather than a ‘sub-type’ of HHV-6.
1.1.5. Morphological structure of the herpesviruses
Herpesviruses consist of 4 morphologically distinct structures: core, capsid, tegument and 
envelope. Previously, the core was thought to have the form of a cylindrical protein plug 
j around which the DNA was wound ( Nazerian, 1974; Irmiere and Gibson, 1983) but this has 
recently been shown to be incorrect (F. Rixon, personal communication).
In the case of HS V, the cylindrical protein plug appears to be largely composed of the single 
protein VP21 (Gibson and Roizman, 1972). The cylinder provides a mechanical support for 
the orderly winding of the virus DNA, which in HSV is spooled around the cylinder- with a 
spacing of 4-5nm generating a toroid arrangement of DNA in the core (Furlong et al,
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1972).
The herpesvirus capsid is approximately lOOnm in diameter and surrounds the core. It 
exhibits 2-, 3- and 5- fold symmetry and is composed of 162 capsomeres, of which 150 are 
hexameric and 12 are pentameric (Wildy et al., 1960) arranged in the form of 
an icosahedron. It is composed of 7 proteins: VP5 (UL19), VP19C (UL38), VP22a 
(UL26.5), VP21 (UL26 C-terminal), VP23 (UL18), VP24 (UL26 N-terminal) and VP26 
(UL35) (Gibson and Roizman, 1972; Cohen et al, 1980).
VP5, encoded by the UL19 gene (Costa et a l , 1984; McGeoch et al, 1988a) is the major 
capsid protein. It has a Mr of 155,000 and forms the main component of the hexameric and 
probably the pentameric capsomeres (Newcomb and Brown, 1989,1991). VP19C and 
VP23 are located near the capsid surface (Newcomb and Brown, 1989) and may be 
components of the trimeric structures linking adjacent capsomeres. VP22a is a highly 
processed protein, comprising many forms with apparent Mrs in the region of 40,000, 
several of which are phosphorylated (Gibson and Roizman, 1974; Preston et a l, 1983). 
VP26 is a component of the capsid interior, whereas VP21 and VP24 are core proteins 
(Newcomb and Brown, 1989).
An amorphous layer known as the tegument surrounds the capsid (Roizman and Furlong, 
1974). VP1-3 (Gibson and Roizman, 1972) the products of the UL36 gene (McGeoch et al, 
1988a), and the 65K virion trans-activating factor are amongst several proteins believed to 
reside within the tegument and intercalate with the capsid and envelope (Batterson and 
Roizman, 1983; Campbell eta l, 1984). Although the size of the capsid is well conserved 
between herpesviruses, the dimensions of the tegument vary and appear to be determined at 
least in part by the virus (Nazerian and Witter, 1970; McCombs et al, 1971).
The tegument is completely enclosed in a trilaminar membrane described as the envelope 
(Wildy et al, 1960; Darlington and Moss, 1968). The envelope has a mean diameter of 
180nm and exhibits spikes 8-10nm long spaced 5nm apart over the surface (Wildy et a l, 
1960). The use of monoclonal antibodies coupled to immunogold labelling identified some 
of these spikes as being HSV encoded glycoproteins (Stannard et al., 1987). There are at 
least 8 distinct HSV-1 glycoproteins in the virion envelope: gB(UL27), gC (UL44), gD
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(US6), (Spear, 1976), gE (US8), (Baucke and Spear, 1979), gG (US4), (McGeoch et al., 
1985; Frame e ta l,  1986), gH (UL22), ( Buckmaster. et al., 1984), gl (US7), (Sullivan and 
Smith, 1988) and gM (UL10), (Baines and Roizman, 1993). No direct evidence is yet 
available for gK (UL53), (Hutchinson et al., 1992b; Ramasway and Holland, 1992) or gL 
(UL1), (Hutchinson et al, 1992a). In addition to HSV encoded glycoproteins, the envelope 
is believed to contain cell lipids (Asher et al, 1969) deduced from the sensitivity of virions 
to lipid solvents and detergents, and spermidine (Gibson and Roizman, 1971).
1.1.6. Light-particle production
Ficoll gradient purification of HSV-1 strain 17+ virus particles has demonstrated the 
existence of a non-infectious particle termed ‘light-particle’. As well as normal virions, light 
particles are generated during HSV-1 infection (Szilagyi and Cunningham, 1991). These 
particles lack capsids and viral DNA and consist predominantly of tegument and envelope 
proteins. They contain at least 5 phosphoproteins not normally observed in virion profiles. 
The UL26 mutant ts 1201 (Preston et al, 1983) which does not package DNA at the non- 
permissive temperature, has been used to demonstrate that L-particle formation is 
independent of virion formation (Rixon e ta l,  1992). Other HSV-1 strains (eg. HSV-1 
strain F) and other Alphaherpesviruses including HSV-2, PRV, BHV and EHV-1 also 
produce ‘light-particles’ (McLaughlan and Rixon, 1992; Dr.D. Dargan, personal 
communication). The role of these light particles in the HSV life-cycle is currently being 
determined (Dr.D. Dargan, personal communication).
It is possible that ‘light-particles’ could be used for the production of a non-infectious sub­
unit vaccine. Initial experiments have shown that vaccination with HSV-1 strain 17+ light 
particles protects against subsequent challenge both with wild-type HSV-1 strain 17+ in a 
mouse model and with wild-type HSV-2 in a guinea-pig model; while in a therapeutic 
model, innoculation with HSV-1 strain 17+ light particles reduces the severity of 
recrudescent disease symptoms from a previously established latent HSV-2 infection in a 
guinea pig model (Dr.A.R. MacLean, personal communication).
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Table 1.1. The HSV-1 genes identified to date.
The status of genes known to be essential for virus growth in culture cells is marked ‘e \  
and non-essential ‘n e \ e? indicates that data regarding status is not conclusive, e/ne, 
necessity depends on culture conditions or temperature. Immediate early proteins are 
termed ‘IE’. The absence of information regarding status is indicated by a dash. 
References are omitted because of space constraints; recent referenced lists of HSV-1 
functions are published by McGeoch et a l , 1988a and McGeoch and Schaffer, 1993. 
Adapted with permission from Dr. D.J. McGeoch from McGeoch eta l, 1993.
HSV-1 gene Protein / function
RL1
RL2
UL1
UL2
UL3
UL4
UL5
UL6
UL7
UL8
UL9
UL10
UL11
UL12
UL13
UL14
UL15
UL16
UL17
UL18
UL19
UL20
UL21
UL22
UL23
UL24
UL25
UL26
UL26.5
UL27
UL28
UL29
UL30
UL31
Neurovirulence factor (ICP34.5)
IE protein; transcriptional regulator (VmwllO)
Glycoprotein L
Uracil-DNA glycosylase
Function unknown
Function unknown
Component of DNA helicase-primase
Role in virion morphogenesis
Function unknown
Component of DNA helicase primase
Ori-binding protein essential for DNA replication
Function unknown; probable integral membrane protein
Myristylated tegument protein; role in envelopment
and transport of nascent virions
Deoxyribonuclease; role in maturation/ packaging of
nascent DNA
Tegument protein; probable protein kinase 
Function unknown
Function unknown; possible NTP-binding motifs 
Function unknown 
Function unknown 
Capsid protein (VP23)
Major capsid protein (VP5)
Integral membrane protein; role in egress of nascent virions 
Function unknown
Virion surface glycoprotein H; role in virus entry 
Thymidine kinase 
Function unknown 
Virion protein
Proteinase, acts in virion maturation; N-terminal portion 
is capsid protein VP24; C-terminal is VP21 
Internal protein of immature capsids (VP22a); processed by 
UL26 proteinase
Virion surface glycoprotein B; role in cell entry 
Role in capsid maturation/ DNA packaging 
ssDNA binding protein; essential for DNA replication 
Catalytic subunit of replicative DNA polymerase 
Function unknown
Status
ne
ne
e?
ne
ne
ne
e
e
e
e
ne
ne
e
ne
e?
ne
e?
e
e/ne
e
ne
ne
e
e
e?
e
e
e
e
Table 1.1 continued.
HSV-1 gene Protein / function______________________________ Status
UL32 Function unknown
UL33 Role in capsid maturation/ DNA packaging e
UL34 Membrane associated phosphoprotein
UL35 Capsid protein (VP26) e
UL36 Very large tegument protein (VP 1-3) e
UL37 Function unknown; may have DNA-binding role
UL38 Capsid protein (VP19C) e
UL39 Ribonucleotide reductase large subunit (Rl) e/ne
UL40 Ribonucleotide reductase small subunit (R2) e/ne
UL41 Virion protein; host shutoff factor ne
UL42 Subunit of replicative DNA polymerase; increases processivity e
UL43 Function unknown; probable integral membrane protein ne
UL44 Virion surface glycoprotein C; role in cell entry ne
UL45 Virion protein ne
UL46 Modulates IE gene transactivation by UL48 gene ne
UL47 Tegument protein; modulates EE gene transactivation by UL48
protein ne
UL48 Major tegument protein; transactivates IE genes (VP16,
Vmw65, aTIF) e
UL49 Tegument protein (VP22)
UL49A Possible membrane protein e?
UL50 Deoxyuridine triphosphatase ne
UL51 Function unknown
UL52 Component of DNA helicase-primase e
UL53 Glycoprotein K e?
UL54 IE protein; post-translational regulator of gene expression
(ICP27, Vmw63) e
UL55 Function unknown ne
UL56 Function unknown ne
LAT Family of transcripts expressed during latency; function unknown
protein-coding capacity uncertain ne
RSI IE protein; transcriptional regulator (ICP4, | Vmwl75) e
US1 IE protein; function unknown (ICP22, Vmw68) e/ne
US2 Function unknown ne
US3 Protein kinase ne
US4 Virion surface glycoprotein G ne
US5 Virion surface glycoprotein J ? ne
US6 Virion surface glycoprotein D; role in entry e
Table 1.1 continued.
HSV-1 gene_______Protein / function_________ :___________________ Status
US7 Virion surface glycoprotein I ne
US8 Virion surface glycoprotein E ne
US8.5 Function unknown ne
US9 Virion protein ne
US 10 Virion protein ne
US 11 Virion protein; ribosome associated in infected cells ne
US 12 IE protein; function unknown (ICP47, Vmwl2) ne
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1.2. The HSV-1 genome
The sequence of the HSV-1 strain 17+ genome published in 1988, contains 152,260 
residues in each strand (McGeoch e ta l, 1985,1986,1988a; Perry and McGeoch, 1988). As 
with all herpesvirus genomes studied in detail, the existence of variation means that this 
number is not fixed.
The complete sequence of HSV-1 strain 17+ was predicted to contain 70 distinct genes 
(McGeoch et al, 1988a). Determination of the coding potential was based on critical 
sequence interpretation with gene designations requiring evidence beyond the presence of an 
open-reading frame (ORF) starting with a methionine, of which many existed other than 
those considered genuinely functional. Specifically, the protein-coding potential of ORFs 
was evaluated on the basis of codon-usage triplet periodicity in base frequencies compatible 
with the high G+C content of the genome and size of ORF (>Mr 9K). The number of ORFs 
was a conservative estimate and at the time, it was expected that extra genes (especially small 
genes) would be discovered. In HSV-1 strain F, the region upstream of IE1 has been shown 
to encode the gene RL1 (Chou and Roizman, 1986; Ackermann et a l, 1986). A 
homologous gene was subsequently identified in HSV-1 strain 17+ (Dolan et al, 1992) and 
HSV-2 strain HG52 (McGeoch e ta l ,  1991). Three additional genes have since been 
identified, namely UL26.5 (Liu and Roizman, 1991a)| UL49A (Barker and Roizman, 1992; 
Barnett et al, 1992) and US8.5 (Georgopoulou et al, 1993; Dr. B. Barnett, personal 
communication). The HSV-1 genes identified to date are listed in Table 1.1..
1.2.1. Comparison of the HSV-1 genome with other alphaherpesvirus 
genom es.
Comparisons of genome organization between five alphaherpesviruses, HSV-1, HSV-2, 
VZV, PRV and EHV-1 has shown extensive genome colinearity between the viruses 
(Davison and Wilkie, 1983b). In contrast, when the genome organizations of VZV and the 
gammaherpesvirus EBV are compared, three regions containing conserved genes are 
observed. Although the genes are generally colinear within these regions, the three are 
arranged differently in the two genomes (Davison and Taylor, 1987).
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HSV;1 and VZV differ substantially in terms of genome size, and organization of repeat 
elements, but they have largely corresponding sets and layout of genes. Like HSV-1, VZV 
has elements equivalent to U l, RS and Us, however in VZV R l  is only 88bp (Davison,
1984). VZV has an overall base composition of 46% G+C, compared witl}68.3%G+C of 
HSV-1. Although the sequence of VZV U l  is grossly colinear with that of HSV-1 the S 
region varies to a much greater extent, with VZV lacking counterparts of 6 genes found in 
HSV-1 (Davison and McGeoch, 1986); namely US2, US4 (gG), US5, US6 (gD), US11 
(virion protein) and US 12 (Vmwl2).
With more sequencing data becoming available, it has now become possible not only to 
determine the genome organization of different herpesvirus but to compare the amino acid 
sequences of individual genes. It has been found that in general, the S component is the 
most variable region in alphaherpesviruses, ranging in size from 19,87lbp in VZV to 
37,289bp in EHV-1. Genes corresponding to HSV-1 RSI (IE175), USl|(Vmw68), US3 
(protein kinase), US7 (gl) and US9 (tegument protein) are conserved in VZV, HSV-1, PRV 
and EHV-1 (Telford etal., 1992), although the relative positions of some genes differ. 
Davison and McGeoch (1986) concluded that differences in gene layout between the S 
components of HSV-1 and VZV have resulted from expansion and contraction of IRs/TRS 
during evolution, and this is perhaps true for all members of the alphaherpesviriniae.
EHV-1 and HSV-1 share a common gene arrangement as demonstrated by the mapping of 
several EHV-1 genes including the glycoproteins gC (Allen and Coogle, 1988), gB 
(Whalley et al., 1989), gD (Audonnet et al, 1990; Whalley et a l, 1991), gl and gE 
(Audonnet etal., 1990), the transcriptional regulator IE110 (Grundy e ta l ,  1989) and 
thymidine kinase (Robertson and Whalley, 1988). The complete DNA sequence of the Ab4 
strain of|EHV-l has recently been published (Telford e ta l,  1992). The EHV-1 genome 
contains 76 distinct genes and the transcript pattern of the genome, as predicted from the 
position of potential polyadenylation sites is largely similar to those proposed for VZV 
(Davison and Scott, 1986a) and HSV-1 (McGeoch e ta l,  1988a). Only 3 EHV-1 genes 
were found to lack positional and sequence counterparts in VZV and HSV-1, while 4 EHV-
1 0
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1 genes lack amino acid homologues in VZV and HSV-1 but have positional counterparts in 
VZV or HSV-1 to which they are probably related evolutionarily.
HSV-1 and HSV-2 have a very similar G+C content| (68.3% and 69% respectively) and share 
extensive homology in 50% of their sequences (Kieff et al., 1972). Coding sequences of 
corresponding genes in general show 7-0-80% identities, with gG being the most highly 
divergent gene identified so far (McGeoch et al., 1987) while non-coding regions, in 
particular the major repeats typically show greater differences and in some cases have 
become highly diverged (Davison and Wilkie, 1981; Whitton and Clements, 1984).
The entire HSV-2 strain HG52 genome is currently being sequenced (Dr. B. Barnett, 
personal communication). Comparison of the genetic content of R l  and the adjacent parts of 
U l  with the equivalent region in HSV-1 has revealed that their genetic content is very 
similar (Perry and McGeoch, 1988; McGeoch et a l., 1991). At the left-hand end of U l, 
HSV-2 has coding regions of genes with counterparts to HSV-1 genes UL1 to UL4 and part 
of UL5. At the right-hand end, counterparts to HSV-1 genes UL54 to UL56 and part of 
UL53 are found. In HSV-2 R l  sequences were identified corresponding to HSV-1 genes 
encoding ICP34.5 and IE110 (RL1 and RL2 respectively). In HSV-2 RL1 contains an 
intron which is not present in the HSV-1 RL1 ORF. The most highly conserved region in 
the 2 proteins is near the C-terminus in which 63 amino acids in each are aligned without 
introduction of gaps, and show 83% homology. Homologues of this protein are not found 
in other herpesviruses (Dr. B. Barnett, personal communication). In HSV-2 the R l
sequence encoding the LATs was found to be dissimilar to that of HSV-1, however the 
proposed promoter regions of both were found to be similar. The two parts of HSVj-2 Ul
sequenced are closely similar to, and colinear with the corresponding parts of HSV-1 Ul , 
whereas the Rl  sequences are generally more divergent.
Certain herpesvirus genes show conservation in their encoded amino acid sequence to 
nonherpesvirus genes; these include the .genes for ribonucleotide reductase (Gibson et al.,
1984), DNA polymerase (Wong et al., 1988), and helicase (Hodgman, 1988). It is possible 
that these genes have been acquired either directly or indirectly from a cellular genome
1 1
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during evolution.
1.2.2. Organization of the HSV-1 genome
Herpes simplex virus DNA consists of 2 unique segments, the long unique (U l) and short 
unique (Us), each bounded by a set of internal (Ir) and terminal (T r) inverted repeats, 
IR l/T R l and IRs/TRs respectively (Sheldrick and Berthelot, 1974; Delius and Clements, 
1976). A short sequence, known as the ‘a’ sequence is present as a direct repeat at the 
termini and in an inverted orientation at the L-S junction (Sheldrick and Berthelot, 1974; 
Wadsworth et al, 1976; Davison and Wilkie, 1981). Us and U l  can invert relative to one 
another resulting in 4 possible isomeric arrangements (Clements e ta l,  1976; Wilkie and 
Cortini, 1976; Roizman, 1979). These isomers occur in equimolar amounts and are termed 
P (prototype), I I  (inversion of the long segment), Is (inversion of the short segment) and 
ISL (inversion of both the long and short segments).The gross organization of the HSV-1 
genome is illustrated in fig. 1.2..
Because the HSV-1 DNA molecule exists in 4 equimolar isomers, restriction enzyme 
analysis of the DNA yields 3 classes of fragment (Skare and Summers, 1977; Clements et 
al, 1976) which occur at different frequencies. Fragments derived entirely from the unique 
regions of the molecule (Us and U l) appear in 1M quantities relative to the molarity of 
intact viral DNA (Skare and Summers, 1977; Wilkie, 1976; Wilkie and Cortini, 1976). 
Since each terminus is present in only 2 of the 4 isomers, terminal sequence fragments are 
present in 0.5M quantities whereas fragments which consist of the L-S joint sequences are 
present in only 1 of the 4 isomers so they are found in 0.25M quantities.
1.2.3. The ‘a’ sequence
The ‘a’ sequence is a direct repeat found at the termini and the L-S junction of the HSV-1 
genome, and varies in size from 250-550bp. This variation is seen both within (Wagner and 
Summers, 1978) and between strains (Locker and Frenkel, 1979).
Tandem reiterations of the ‘a’ sequence may be found at the L terminus and joint region of 
the genome, but only a single copy is found at the S terminus (Wilkie, 1976; Wagner and
12
Figure 1.2. Structure of the HSV-1 genome
The HSV genome is shown, with unique sequences as solid lines (Us and Ul ). The repeats 
TRL, IRl , IRS and TRs are illustrated as boxes with their component parts a, b, c and a’, 
b’, c’ designated. Below the genome representation, the isomerisation of the HSV-1 genome 
is illustrated. The 4 isomers are: P (prototype), I I  (L inverted with respect to P), Is (S 
inverted with respect to P) and ISL (S and L inverted with respect to P).
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Summers, 1978).
Several important functions are mediated by the ‘a’ sequence, including circularization of the 
genome following infection, site specific recombination and cleavage/packaging of HSV 
DNA (Davison and Wilkie, 1983a; Poffenberger and Roizman, 1985). It can be divided into 
several structural regions (Mocarski and Roizmar\1981) which consist of both unique (U) 
and directly repeated regions (DR); the difference in size between different ‘a’ sequences 
being due to variation in the copy number of these direct repeats. In HSV-1 strain F 
(Mocarski and Roizman, 1981), the L-S junction ‘a’ sequence can be represented as DRi_ 
Ub-(DR2) l9-(DR4 )3-Uc-DRi (see fig.1.3.), where DRi is a 20bp sequence present at both 
ends, Ub and Uc are unique sequences of 58bp and 65bp respectively and are named by 
virtue of their proximity to the b’ and c’ repeated regions respectively; DR2 is a 12bp 
sequence present in 19-22 tandem copies and DR4  is a 37bp sequence present in 3 tandem 
copies.
Chou and Roizman (1985) demonstrated that deletion of the Ub or Uc domains does not 
affect the ability of the ‘a’ sequence to mediate inversion, whereas deletion of DR4 
drastically reduces inversion and deletion of both DR2 and DR4 completely abolishes 
inversion.
1.2.4. Cleavage /packaging of DNA
Following replication of the HSV-1 genome, the large concatemeric DNA molecules (section
1.5.) are processed into unit length genomic molecules and packaged into viral capsids. 
Cleavage of these concatemers occurs within terminally reiterated ‘a’ sequences situated at 
the junctions between adjacent viral genomes (Vlazny and Frenkel, 1981; Mocarski and 
Roizman, 1982; Stow et al., 1983). The distal DRlb and DR1C elements in the ba and ac 
termini respectively, together constitute a complete DRI sequence. Thus in HSV-1 strain F 
(Mocarski and Roizman, 1982), the ba terminus was reported to contain 18.5bp (ie.l8bp 
plus one 3’ overhang) of the DRI sequence, whereas the ac terminus contained the 
remaining 1.5bp. Mocarski and Roizman (1982) proposed a model whereby a baac junction 
is cleaved within the shared DRI element to generate the ba and ac termini.
Figure 1.3. Structure of the HSV-1 ‘a’ sequence
A. The HSV-1 genome.
B. An expansion of the IRiTIRs junction showing the structure of the ‘a’ sequence. The ‘a’ 
sequence consists of unique and directly repeated elements (the information given concerns 
the HSV-1 strain F ‘a’ sequence [Mocarski and Roizman,1981,1982]).
Ub- a unique region located towards the b’ region of the genome.
Uc- a unique region located towards the c’ region of the genome.
DRlb and DR1C - 20bp elements present as direct repeats at the edge of the ‘a’ sequence 
DR2- a directly repeated 12bp element present in 19-22 copies 
DR4- a directly repeated 37bp sequence present in 2-3 copies.
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Although the nucleotide sequence of the ‘a’ sequence varies between different virus strains, 
two highly conserved regions termed pac-1 and pac-2 -are present in Ub and Uc respectively 
and appear to be essential for the cleavage/packaging process (Varmuza and Smiley, 1985; 
Deiss et al, 1986).
1.2.5. Promoter activity of the ‘a* sequence
The feature of the ‘a’ sequence most relevant to this study is its promoter activity. Chou and 
Roizman (1986) reported that in HSV-1 strain F, the ‘a’ sequence contains the promoter- 
regulatory domain and the transcription initiation sites of a gene located in the ‘b’ region of 
the genome. By fusing the ‘a’ sequence to a promoterless thymidine kinase gene, they found 
that when the ‘a’ sequence was orientated with Ub adjacent to the thymidine kinase gene, 
expression of thymidine kinase occurred, whereas when the ‘a’ sequence was in the 
opposite orientation (with Uc adjacent to the thymidine kinase gene) no expression occurred. 
Sequence analysis of the region between IE110 and the ‘a’ sequence predicted a protein of 
358 amino acids in size which was designated ICP34.5. A peptide antiserum raised against a 
Proline-Alanine-Threonine repeat sequence found 10 times in the strain F sequence detected 
a protein of 43,500K in HSV-1 strain F infected cell extracts (Ackermann et al, 1986). This 
protein will be dealt with in greater detail in a later chapter.
1.3. HSV latent infection
The basis of most clinical disease arising from HSV infection is the ability of the virus to 
preferentially and specifically interact with components of the peripheral nervous system 
(PNS). HSV has evolved a complex interaction with the neurons of the PNS whereby it can 
survive throughout the life of the infected individual in a latent state and thus evade the hosts 
immune response. Following primary infection and active replication at peripheral sites, 
virus attaches to the sensory nerve terminals (Vahlne et al, 1978), enters them and travels 
centripetally via axons to neuronal cell bodies within the sensory ganglia (Cook and 
Stevens, 1973; McLennan and Darby, 1980). In the case of HSV-1 these are mainly
14
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trigeminal ganglia (Bastian et al, 1972; Baringer and Swoveland, 1973; Efstathiou et al, 
1986) and in the case of HSV-2 dorsal root ganglia (DRG) including sacral, lumbral and 
thoracic (Baringer, 1974; Galloway et al., 1979, 1982). Latent virus has also been 
recovered from cells of peripheral tissues eg. corneas of humans (Schimeld et a l, 1982; 
Cook, 1988), and experimentally infected rabbits (Cook et al, 1987), and mice (Openshaw, 
1983), and footpads of experimentally infected mice (Al-Saadi et a l, 1983). Latency in 
peripheral tissues is thought to be a secondary sequelae to primary HSV infection (Hill,
1985).
As a working hypothesis in the laboratory, latency is defined as the ability to isolate 
infectious virus from explant cultures (of sensory ganglia) after a period of time in culture, 
where there has been failure to isolate virus from the explant tissue homogenate immediately 
post explantation. The phases of a latent infection are broadly divided into 3 main 
components- establishment, maintenance and reactivation. The phenomenon of latency has 
been the subject of extensive research over many decades and an outline of this is presented 
below.
1.3.1. Animal models of latency
A number of animal models have been developed in which HSV latency has been studied. 
By far, the most common is the mouse (Stevens and Cook, 1971; Walz.gr a/.,1974; Al- 
Saadi et a l, 1983; Clements and Subak-Sharpe, 1983, 1988). Additional experimental 
systems have been provided by rabbits (Nesbum, 1967, 1977), guinea pigs (Scriba, 1975, 
1976) and monkeys (Reeves et al, 1976, 1981). Peripheral inoculation sites of footpad 
(Stevens and Cook, 1971; Scriba, 1975), eye (Nesbum et al, 1967), ear pinnae (Hill et al, 
1975, 1978, 1980) , flank (Underwood and Weed, 1974; Whitby et a l, 1987) and vagina 
(Scriba, 1976) have been used. Inevitably none of these models of HSV infection fully 
mimic the pathogenesis of HSV infection in humans in terms of eg. innoculation site, dose 
of input virus, reactivation triggers or immune response. They have however provided 
invaluable information on the three basic components of latency although none provide the 
ideal system to study establishment, maintenance and reactivation in a single host.
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The first demonstration that HSV could establish a latent infection in sensory ganglia was 
provided following footpad inoculation of mice and the subsequent explantation of DRG 
which released infectious virus after a period of time in culture (Stevens and Cook, 1971). 
This fundamental study provided the basic model of in vitro reactivation as a measure of 
latent infection. It was consequently demonstrated by explantation following post mortem 
dissection that HSV resides in a latent state in human sensory ganglia (Warren et al, 1978). 
The footpad model has been used extensively (Stevens and Cook, 1971; Walz eta l, 1974; 
Al-Saadi et a l, 1983; Clements and Subak-Sharpe, 1983, 1988) and has allowed the 
demonstration that HSV can also establish a latent infection within cell populations within 
the footpad skin (Al-Saadi et al, 1983, 1988). Infection by the footpad route does not 
provide a system to study reactivation in vivo as recurrences neither occur spontaneously, 
nor can they be induced (Hill, 1985).
Another model which is widely used, is that of peripheral inoculation of the eye of both 
mouse (Knotts et al, 1974; Walz et al, 1974) and rabbit (Nesbum et a l, 1967; Stevens et 
al, 1972). In the mouse spontaneous or induced reactivation is not reproducible (Harbour et 
a l, 1983; Shimeld et a l, 1990) and hence only factors affecting establishment and 
maintenance in vivo can be addressed. The rabbit on the other hand, provides a system 
where reactivation can be induced “on demand” by iontophoresis of adrenalin into the eye 
(Nesburn et al, 1977). Frequent spontaneous recurrent shedding also takes place (Nesbum 
eta l, 1977) and this makes interpretation of factors influencing reactivation difficult.
Both ear pinnae and flank inoculation of mice have facilitated the study of reactivation as 
virus recrudesence can be induced by mild trauma such as cellophane stripping (Hill et. al, 
1978), U.V. irradiation (Blyth eta l, 1976) or treatment with chemicals, (Harbour et al,
1983) at the site of inoculation.
A novel model of HSV latency has recently been described (Sawtell and Thompson, 1992a) 
which is based on the strong correlation between fever and HSV reactivation in humans 
(Boak et al, 1934; Roizman and Sears, 1990). Latently infected mice are briefly immersed 
in hot water to induce mild hyperthermia, with the rate of rise in core temperature being 
controlled by the depth of immersion of the animal. Using this method virus could be
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isolated from the trigeminal ganglia of mice within 14hrs post-induction; the approximate 
time required for 1 round of viral replication in culture. It is not clear if virus is shed at the 
appropriate peripheral site.
HSV-2 latency has historically been studied following intravaginal inoculation of guinea 
pigs which results in vaginal recurrences (Scriba, 1976). This system has been hampered by 
the high incidence of viral persistence in the cells of the vagina (Stanberry et al, 1985).
The use of mutants in early stages of gene transcription has suggested replication is not 
required for the establishment of a latent infection (Clements and Stow, 1989; Coen et al, 
1989; Efstathiou et al, 1989; Leib et al, 1989a; Steiner et a l, 1990). Null mutants with 
lesions in Vmw63 and Vmwl75 do not replicate in the eye or ganglia and fail to establish 
reactivable latent infection (Leib et al, 1989a); since both Vmw63 and Vmwl75 are 
essential for virus replication, it is possible that input virus leads to latent viral DNA below 
the level of detection.
Thymidine kinase mutant viruses can establish latent infection in neurons of mouse 
trigeminal ganglia but do not replicate productively in these cells (Coen e ta l ,  1989; 
Efstathiou et a l, 1989). During the early stages of establishment of latency by these 
mutants, expression of viral lytic genes is drastically reduced or undetectable as assayed by 
in situ hybridization (Kosz-Vnenchak et al, 1990), suggesting that the block to productive 
replication during establishment of latent infection by HSV occurs before or early during the 
expression of a  genes.
It has been shown that the vast majority of latent HSV genomes are in a linear non-integrated 
and possibly episomal state in vivo (Rock and Fraser, 1983; Efstathiou et a l, 1986), and a 
similar situation has been reported in vitro (Section 1.3.2.).
1.3.2. In vitro models of HSV latency.
Animal models by their very nature have intrinsic problems which make them inefficient as a 
system to study latency, especially at the molecular level. Tissue culture systems have 
therefore been developed in which latency can be mimicked and manipulated. As with
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animal models, any tissue culture system can never be fully satisfactory but they can provide 
information which may facilitate the design of more meaningful in vivo experiments. 
Various tissue culture systems have been studied as models of “ in vitro latency”. Cells of 
both neuronal and non-neuronal origin have been used eg. rat and human sensory neurons 
(Wigdahl etal., 1983, 1984a,b; Wilcox and Johnson, 1987, 1988, 1990), corneal cells 
(Cook and Brown, 1987) and HFL cells (Russell and Preston, 1986; Harris and Preston, 
1991). The systems have for the most part relied on the inhibition of genome replication by 
the use of inhibitors eg. AraC, acycloguanosine and/or the use of elevated temperatures 
generally >40°C. The cultures have been assessed as containing HSV genomes in a “latent” 
state by the criteria of ability to reactivate infectious virus following manipulations such as 
temperature reduction (Russell and Preston, 1986), superinfection with HSV or other 
herpesviruses (Colberg-Poley et al., 1979; Russell and Preston, 1986; Russell etal., 1987) 
and BVDU/ IFN a  treatment (Wigdahl et al., 1983).
The question arises whether repressed equals latent ? In this Institute a system has been 
developed which does not rely on the use of inhibitors. Use of HSV-2 at very low m.o.i., 
elevated temperature of 42°C and HFL cells has produced a working system which is 
reproducible and demonstrates some of the features of in vivo latency (Russell and Preston,
1986). It has led to an understanding of the role of the HSV gene IE1 in reactivation from 
latency (Russell et al., 1987; Harris et al., 1989; Zhu et a l, 1990) and Vmw65 tXTIF 
(Harris and Preston, 1991) in the establishment of latency. Modification using the HSV-1 
Vmw65 ocTIF mutant (in 1814) has allowed higher levels of latency to be established. This 
has provided information on the episomal nature of the latent genome (Preston and Russell, 
1991) and its relationship with chromatin (Dr D.R.S. Jamieson, personal communication). 
Unfortunately the system falls down in that there is no evidence of latency associated 
transcript expression (Section 1.3.3.) during the “latent” state.
1.3.3. Transcription during latency- latency associated transcripts (LATs).
Until recently there had been no convincing evidence of transcription from the latent HSV 
genome. In 1987, both Stevens et al., and Spivak and Fraser discovered that a region of the
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HSV-1 genome is transcribed during latency to preduce LATs. These have subsequently 
been demonstrated in human sensory ganglia (Krause et al, 1988). Their discovery has led 
to inumerable investigations into their organization, relevance and role in latency. They are 
transcribed in an antisense direction from a genomic region adjacent to and partially 
overlapping the IE1 gene (Rock eta l, 1987; Spivak and Fraser, 1987; Stevens e ta l, 1987; 
Krause et al, 1988). Transcripts of size-2 , and 1.2-1.5 kb have been identified in various 
systems (Rock et al, 1987; Spivak and Fraser, 1987; Krause et al, 1988) and are thought 
to be the stable intron products of an 8kb primary transcript (Zwaagstra et al, 1990). The 
location and organization of the LATs is shown diagramatically in Fig 1.4..
Although no protein products have been found or reported, with the exception of one 
unrepeated in vitro experiment!(Doerig et.al., 1991) there are ORFs within the LATs. Many 
hypothesis regarding their role, especially in suppressing IE1 transcription, have been put 
forward (Stevens e ta l, 1987). Various mutants in the LATs and LAT promoter regions 
have been constructed (Ho and Mocarski, 1989; Leib et al, 1989b; Steiner et al., 1989; 
Block et a l, 1990; Natarajan et al, 1991; Trousdale et al, 1991). The mutants appear to 
establish latency efficiently but the efficiency of and temporal control of reactivation both in 
vitro and in vivo is affected (Leib et a l, 1989b; Steiner et al, 1989; Trousdale et al., 
1991). However a recent experiment suggests that LAT mutants may be impaired in 
establishing latency (Sawtell and Thompson, 1992b). The role of LATs is therefore still 
open to question.
Peripheral nervous system sensory neurons are undoubtly privileged sites for the 
establishment of HSV latent infections (Baringer and Swoveland, 1973; Warren et al., 1978; 
Krause et a l, 1988). Despite the important discovery of LATs, a comprehensive 
understanding of the factors controlling this particular virus/host interaction has not been 
achieved. It may be pertinent in the future to investigate (i) the strategic importance of the 
juxtaposition of three ORFs whose products have defined roles in HSV/neuronal 
interactions ie. LATs, VmwllO (Harris etal., 1989; Zhu et al, 1990) and ICP34.5 (Chou 
and Roizman, 1991; MacLean, A., et al., 1991a; Dr S.M. Brown, personal
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Figure 1.4. The LAT region of HSV-1
(A) The HSV-1 genome is shown. The LATs are encoded by a diploid gene that maps to the 
repeat regions. (B) The LAT region. LAT is overlapped by transcripts expressed during a 
lytic infection. (C) LAT promoter features. The putative LAT promoter maps to a TATA 
element between two PstI sites at nucleotide 118,773 (McGeoch e ta l, 1988a). Within this 
region are several transcription factor binding sites, which probably play a role in LAT 
regulation. (D) Possible LAT transcripts. From the LAT promoter, an approximately 8-kb 
long primary transcript is proposed to be transcribed during latency. Stable 2-, 1.5- and 
1.45-kb RNA species which map towards the 5’ end of LAT have been identified in tissue 
culture and accumulate to high levels in latently infected tissue. The 6.0-kb LAT which 
would result from splicing, if the 2.0-kb transcript is an intron has not been detected. (E) 
2.0-kb LAT open-reading frames. Within the 2-kb RNA, there are two open-reading frames 
that are conserved within several HSV-1 strains but not in HSV-2 strain HG52 (McGeoch et 
a l, 1991). However, no convincing evidence for expression of any viral polypeptide during 
in vivo latency exists (Adapted from Fraser et a l, 1992).
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communication) (ii) whether other cellular factors which may or may not be present in 
neurons, make a contribution to the latency process such as has been demonstrated for Oct 2 
(Lillycrop et a l, 1991), and (iii) whether control is exercised in the form of differential 
transcriptional splicing of defined genes in cells of neuronal and non-neuronal origin.
1.4. The HSV-1 lytic cycle
1.4.1. Adsorption (attachment of HSV to the cell surface).
Entry of HSV-1 into cells requires a cascade of events that occur at the cell surface 
(reviewed by Spear, 1993). Adsorption is mediated, at least in part, by the binding of virions 
to heparin sulphate moieties. There are several lines of evidence to support this: (i) HSV 
does not bind to surfaces stripped of heparin sulphate by enzymatic treatment with 
heparinase or hepartinase, or to mutant cells that fail to synthesize heparin sulphate 
(WuDunn and Spear, 1989), (ii) HSV virions can bind to immobilized heparin and soluble 
heparin can block the binding of HSV to cells (WuDunn and Spear, 1989) and (iii) Heparin- 
binding proteins can inhibit HSV adsorption and plaque formation (WuDunn and Spear, 
1989; Kaner et a l, 1990), probably by competing with virus for receptor sites associated 
with cell-surface heparin sulphate.
Shieh et a l (1992) used CHO cell mutants, defective in various aspects of heparin sulphate 
synthesis to provide genetic evidence that heparin sulphate serves as a cell surface receptor 
for HSV. Binding of virus to heparin sulphate-deficient mutant cells was severely impaired 
and mutant cells were resistant to HSV infection.
Glycoprotein C (gC) appears to be the glycoprotein principally involved in adsorption of 
HSV-1 to the cell surface (Kuhn e ta l,  1990; Herold et a l, 1991), but gD and gB also 
probably play a role in adsorption as monoclonal antibodies against these glycoproteins can 
inhibit virion binding to cellular surface components (Kuhn et al, 1990). Virions lacking gC 
bind to significantly fewer cells than wild-type virus under conditions approaching 
saturation of available sites on the cell surface (Herold eta l, 1991). In PRV (Robbins et al, 
1986b; Mettenleiter, 1989) and BHV-1 (Liang et a l, 1991) homologues of gC have been
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reported to play a similar role in mediating stable attachment of virions to the cell surface.
1.4.2. Penetration (entry of bound virus into the cell).
At least 5 viral glycoproteins, gD, gB, gH, gK and gL (Fuller and Spear, 1987; Cai et a l, 
1988; Ligas and Johnson, 1988; Fuller et al, 1989; Fuller e ta l, 1989; Hutchinson et a l, 
1992a, 1992b; Roop et al, 1993) are involved in virus entry into cultured cells. Several 
results suggest that gD in virions interacts with a cellular receptor after virion attachment to 
heparin sulphate proteoglycans. Cell lines which express large amounts of gD are resistent 
to infection (Campadelli-Fiume e ta l,  1988; Johnson and Spear, 1989), suggesting that 
intracellular gD sequesters a receptor. Infection can be prevented by prior exposure to U.V.- 
inactivated wild-type virus but not gD minus virus (Ligas and Johnson, 1988). The 
interactions of gD with its receptor are required for virus entry into cells but not for 
adsorption, which occurs whether or not the critical gD receptors are blocked (Johnson and 
Ligas, 1988; Ligas and Johnson, 1988). In addition, HSV-1 and HSV-2 plaque production 
can be inhibited by treatment of cells with soluble forms of gD (Johnson et a l, 1990). 
Binding of soluble gD was inhibited by treatment of cells with certain proteases, but not by 
enzymatic treatment to remove cell surface heparin sulphate glucosaminoglycans or when 
binding was carried out in the presence of heparin. This suggests that gD binds to proteins, 
or to structures dependent on proteins on the cell surface following initial adsorption of gC 
to heparin sulphate moieties.
Kaner et al (1990) suggested that fibroblast growth factor receptor (bFGFR) was a portal of 
entry for HSV-1 as they found that Chinese Hamster Ovary (CHO) cells expressing a 
transfected receptor for bFGF bound and internalized greater amounts of radiolabelled HSV 
than did the bFGF deficient parental cells or control cells. Binding was inhibited by bFGF. 
The drawback with this study was that only one cell line- bovine arterial smooth muscle- 
was used and several groups (Shieh and Spear, 1991; Muggeridge et a l, 1992) have since 
shown that inhibition by bFGF is restricted to a minority of cell types. Muggeridge et a l 
(1992) tested several cell lines, but only one showed comparable inhibition by bFGF. 
Furthermore, they could not find a correlation between the amount of bFGF receptor and the
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ability of bFGF to block infection, as cell lines expressing low levels of bFGF receptor were 
permissive for HSV. FGF receptor- positive and FGF receptor-negative rat myoblasts do 
not differ in susceptibility to HSV infection (Mirda et al, 1992) and soluble forms of FGF 
fail to inhibit HSV infection whereas they inhibit basic FGF binding and biological activity. 
Taken together, these results suggest that different cell types harbour different receptors for 
HSV.
Productive entry of HSV-1 can also occur through pH-independent direct fusion of the 
virion envelope with the plasma membrane that leads to disassembly of the virion and 
initiation of gene expression (Fuller and Spear, 1987). Neither the molecular interactions 
which mediate this entry nor the specific roles which the essential glycoproteins play in 
penetration have been defined. Fuller and Lee (1992) proposed a model for pH-independent 
entry of HSV-1 into cells with separate roles for gD and gH. gD was shown to play a role in 
the early stage of virus penetration, contributing to a stable virion attachment and close 
association of the virion envelope and cell membrane, while gH neutralized virus proceeded 
to events post-attachment but did not completely disassemble or fuse with the cell 
membrane. It appears that HSV-1 entry into cells is mediated by a cascade of virus-cell 
interactions in which each glycoprotein plays a specific role in triggering or signalling 
changes in the virion which result in membrane fusion and nucleocapsid uncoating.
1.4.3. Additional functions of the HSV-1 glycoproteins 
Cell fusion
The HSV-1 glycoprotein gK (Hutchinson e ta l , 1992b) is the product of the UL53 gene 
(DebRoy et al, 1985; McGeoch et a l, 1988a). It was detected using a peptide antiserum 
raised against the hydrophilic region of the predicted protein. gK is thought to play an 
important role in regulating membrane fusion and the majority of well characterized syncytial 
mutations map to this gene (Ruyechan e ta l,  1979; Bond and Person, 1984; Pogue-Geile 
and Spear, 1987). The EHV-1 UL4 gene codes for a protein homologous to HSV-1 gK 
(Telford eta l, 1992; Zhao e ta l, 1992).
Mutations affecting the cytoplasmic C-terminal domain of gB also induce a syncytial
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phenotype (DeLuca et al., 1982; Bzik et al, 1984; Cai e ta l,  1988). gB-negative virus 
cannot enter cells, but its infectivity is increased by treatment with polyethylene glycol 
(PEG) to promote cell fusion (Cai et al, 1988). It appears likely that gB is directly involved 
in cell fusion.
The glycoproteins gH and gD also play a role in virus entry into cells, and although 
mutations in these genes do not give rise to a syncytial phenotype, there is evidence that both 
may be involved in cell fusion. gH-negative virions bind to cells, but do not enter them 
unless treated with PEG (Forrester etal,. 1992). Similarly anti-gD mAbs can neutralize HSV 
infectivity by blocking penetration of the virus at the cell surface, (Fuller and Spear, 1987) 
apparently by blocking fusion between the virion envelope and plasma membrane. 
Neutralized virus binds to cells and accumulates on the surface with reversal of the effect of 
neutralizing antibody again being achieved by treatment with PEG.
Other syncytial mutations have been mapped to non-glycoprotein encoding regions of the 
HSV-1 genome including UL24 (Sanders et al, 1982; Jacobson et al., 1989a) and the Syn 
6 locus (Romanelli et al., 1991) which maps between the 5’ end of IE110 and the 3’ end of 
RL1. Deletion of the UL20 gene also appears to give rise to a syncytial phenotype (Baines et 
al., 1991). Previous marker rescue experiments had erroneously suggested that a syn 
mutation mapped to the UL1 gene (Little and Schaffer, 1981; McGeoch e ta l, 1988a), which 
was recently shown to encode gL (Hutchinson et al., 1992a), but more recently this 
mutation was found to map to the UL53 gene (Roop et al, 1993).
Fc receptor
Receptors which have affinity for the Fc domain of immunoglobulin G (IgG) are expressed 
on the surface of HSV-1 infected cells and on virion envelopes (McTaggart et a l, 1978; 
Westmoreland and Watkins, 1974). In 1979, Bauke and Spear identified a group of 
electrophoretically similar HSV-1 polypeptides which bound with high affinity to IgG 
columns. These proteins were all thought to be derived by post-translational modification of 
gE (Cross et al, 1987). Johnson and Feenestra (1987) subsequently detected a novel HSV- 
1 induced polypeptide which was structurally distinct from gE and was provisionally named
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g70. It could be detected on the surfaces of infected cells and was co-precipitated using 
rabbit or human IgG or anti-gE antibody.
Johnson et a l (1988) used a monoclonal antibody (MAb 3104) to further characterize g70. 
Using extracts from pulse-labelled cells, a polypeptide was precipitated with MAb 3104, 
which had an electrophoretic mobility identical to the smaller polypeptide precipitated with 
rabbit IgG. This polypeptide was the mature form of a protein with an electrophoretic 
mobility very similar to the immature form of gE. Insertional mutagenesis and antipeptide 
sera were used to map g70 to the US7 open reading frame and gl (Johnson et al., 1988; 
McGeoch et al, 1988a). US7 had previously been shown to be non-essential (Longnecker 
e ta l,  1987).
Expression of gE alone is sufficient for induction of Fc activity, whereas gl alone gives no 
detectable Fc binding (Bell e ta l, 1990; Dublin e ta l,  1990). Coexpression of gl and gE 
gives better binding than expression of gE alone, suggesting that HSV-1 has the potential to 
induce 2 Fc receptors- one a low affinity receptor composed of gE alone and a high affinity 
receptor composed of gE + gl. gE appears to be the Fc receptor for IgG complex, while gE 
and gl form the Fc receptor for monomeric IgG (Dublin et al, 1990).
C3b binding
Mammalian cells in culture which are infected with HSV-1 express receptors for the C3b 
component of complement (Cines e ta l, 1982). These receptors are not present following 
HSV-2 infection. Friedman et al (1984) demonstrated that gC-1 but not gC-2, when 
expressed on cells, functions as a C3b receptor. Sequence analysis has shown that gC-1 
relative to gC-2 has a 28 amino acid insert (Frink e ta l, 1983; Swain et a l ,1985) which 
may explain the functional differences between these 2 polypeptides.
Purified gC-1 has been found to demonstrate dose-dependent acceleration of decay in the 
activity of C3 convertase of the alternative pathway and, by this mechanism, can block the 
effects of complement (Fries e ta l, 1986). gC-1 can thus protect against complement 
mediated cytolysis by inhibition of the alternative pathway (Harris et al, 1990) The presence 
of gC-1 or gC-2 in virions appears to provide protection against complement mediated
2 4
Introduction
neutralization (McNeamey eta l, 1987).
1.4.4. Effects on host cell macromolecular synthesis
A characteristic of herpesvirus-infected, cells is the rapid shut-off of host macromolecular 
metabolism early in infection (reviewed by Fenwick, 1984). In the host cell, DNA synthesis 
is shut-off, protein synthesis declines, RNA synthesis is reduced and glycosylation of host 
proteins ceases.
HSV host shut off occurs in two stages, one (early shut-off, or vhs ) is due to the action of a 
constituent of the infecting virus particle and does not require de novo protein synthesis 
(Fenwick and Walker, 1978; Kwong and Frenkel, 1987; Kwong e ta l,  1988), whereas the 
other (delayed shut-off) requires virus gene expression (Read and Frenkel, 1983; Fenwick 
and Clark, 1982).
The viral component responsible for vhs activity has been mapped to the UL41 open 
reading frame of the HSV-1 genome (Kwong e ta l, 1988). It is predicted to encode a 489 
amino acid protein of 58K (Frink e ta l,  1981; McGeoch et a l, 1988a). which is a virion 
component (Fenwick and Everett, 1990a) that is phosphorylated in infected cells (Smibert et 
al, 1992). vhs activity is not essential for virus replication. The level of vhs activity varies 
markedly between different HSV strains and is particularly weak in HSV-1 strain 17+ 
(Fenwick and Everett, 1990b). Several conserved regions have been identified by protein 
sequence alignment with various alphaherpesviruses (HSV-1, HSV-2, VZV and EHV-1) 
counterparts (Berthomme eta l, 1993).
1.4.5. Virion assembly
Very little is known about how the virus particle is formed but the available evidence 
supports a model in which the viral genome is inserted into a pre-formed capsid (Preston et 
al, 1983). One protein involved in virion assembly is VP22a (ICP35) which is present in 
large amounts in intermediate capsids which lack virion DNA but is only found in trace 
amounts in empty capsids devoid of any internal structure, in DNA-containing capsids and 
in mature virions (Rixon et a l, 1988; Sherman and Bachenheimer, 1988). The precise
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function of VP22a is unclear, but its ability to self-assemble into defined structures (toroids) 
in vitro (Newcomb and Brown, 1991), in the absence of preformed capsids raises the 
possibility that its in vivo function may be to form a scaffold or jig around which other 
proteins (VP5, VP 19 and VP23) could condense to form the capsid shell.
VP22a was initially identified as the product of HSV-1 gene UL26 from the genome location 
of the lesion in the mutant & 1201 which has a defect in the N-terminal part of UL26 and is 
defective in processing VP22a (Preston et al, 1983). This region has since been shown to 
encompass 2 genes designated UL26 and|UL26.5(Liu and Roizman, 1991a) which encode 2 
related proteins specified by overlapping transcripts with a unique 5’ end but common 3’ 
ends (see fig 1.5). The inability of ts 1201 to process VP22a at non-permissive temperatures 
was explained by the recent discovery that UL26 has proteolytic activity which is 
responsible for cleaving;UL26.5to produce VP22a (Liu and Roizman, 1991b, 1992; Preston 
et a l, 1992). The protease undergoes self cleavage at 2 sites; one near the C terminus and 
the other at a second position upstream from the|UL26.5 sequence to release 2 large 
fragments VP21 and VP24. These have recently been identified as capsid components 
(Davison e ta l, 1992).
Recently infection of cells with baculovirus expressing all the capsid genes has allowed 
reconstitution of virus capsids (J. Tatman, personal communication).
1.4.6. Envelopment and Egress
HSV capsids acquire a tegument and envelope en route from the nucleus to the oustide of 
the cell. The precise details of events are still unclear, but it is apparent that capsids leave the 
nucleus by budding through the inner membrane into the space between the inner and outer 
membrane (Darlington and Moss, 1968; Nii e ta l,  1968). Johnson and Spear (1982) 
proposed a model for HSV-1 envelopment and viral egress by which virions were first 
enveloped at the inner membrane where they acquired viral glycoproteins lacking golgi 
modifications. Subsequently these “immature” virions are transported to the Golgi 
apparatus, where precursor glycoproteins are modified as the enveloped particles move 
through the Golgi stacks. It was concluded that complete processing of viral glycoproteins is
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Figure 1.5. Organization of the HSV-1 genes UL26 and UL26.5
The two 3’ co-terminal mRNAs are shown as rightward orientated arrows. These are 
overlaid by boxes indicating the positions of the open reading frames specifying the protease 
(UL26) and VP22a (UL26.5). Proteolytic cleavage sites (a and b) are indicated by vertical 
lines. Cleavage of the protease at site a releases the capsid proteins VP21 and VP24 
(adapted from Rixon,1993).
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not essential for virion morphogenesis or infectivity but is associated with egress of virions 
The first evidence that a viral gene product was involved in egress of the virus was provided 
by Baines et al. (1991). They demonstrated that deletion of the UL20 gene (McGeoch et al, 
1988a) resulted in accumulation of enveloped and unenveloped capsids in the cytoplasm. 
The product of the UL20 gene was required in some cell lines although not in Vero cells, 
possibly indicating the presence of a cellular gene product which can complement the UL20 
deletion.
It is suspected that the product of the UL11 gene- a myristylated virion protein- also plays a 
role in virus assembly, envelopment or release (MacLean et al, 1989,1992)
1.5. HSV-1 DNA replication
HSV-1 DNA replication is first detected 3 hours post-infection at 37°C, peaks by about 9- 
11 hours and is virtually complete by 16 hours post-infection (Wilkie, 1973). The majority 
of the progeny viral DNA are large concatemeric molecules (Jacob et al, 1979) and hence, it 
has been hypothesized that viral DNA replication occurs by a rolling-circle mechanism 
(Roizman, 1979).
Initially, synthesis is localised within the nucleus to discrete sites , which grow and coalesce 
as infection proceeds, until the entire nucleus is filled with replicating viral DNA (Rixon et 
al, 1983). The initial sites of viral DNA replication appear to be virus specific structures 
induced by infection, and have been called “replication compartments” (Quinlan et a l,
1984).
1.5.1. HSV-1 origins of replication
Herpes simplex virus has been shown to contain 3 origins of DNA replication. These 
sequences were originally identified as those required for replication of defective genomic 
DNA in infected cells (Frenkel et al, 1976; Schroder et al, 1975). The first HSV origin of 
replication, oriS was identified using a plasmid based system (Stow, 1982). Fragments of 
DNA from the S region of the wild-type HSV-1 genome were cloned into plasmids and
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analysed for their ability to enable amplification of the linked plasmid vector sequences, 
when helper functions were provided by superinfecting virus. An origin was mapped within 
a 955bp fragment contained entirely within the short repeat genome segment, and was thus 
present in 2 copies. Deletion analysis of this oriS fragment defined a 90bp region containing 
all the necessary cis -acting signals required for the initiation of HSV DNA replication 
(Stow, 1982; Stow and McMonagle, 1983).
The other HSV-1 origin of DNA replication, oriL, is located at map units 0.4 in the unique 
sequences of the L component of the HSV-1 genome (Gray and Kaemer, 1984; Weller et 
a l , 1985). The sequences of oriS and oriL are closely related (Weller eta l, 1985; Murchie 
and McGeoch, 1982). Both contain an extensive inverted repeat sequence, the central 18bp 
of which are exclusively AT base pairs. The inverted repeat region of oriL is considerably 
longer than that of oriS. For this reason plasmids containing oriL, but not oriS are highly 
unstable in E.coli and analysis of this region has proved difficult.
Weller etal. (1985) successfully cloned the sequences between 0.398 and 0.413 map units 
in the HSV-1 genome, which contain oriL, into a yeast cloning vector in an undeleted form. 
Sequence analysis of a 425bp region revealed a 144bp perfect palindrome with striking 
homology to oriS. The minimum sequences required for the function of oriS correspond 
well to the region of highest similarity with oriL (Lockshon and Galloway, 1988) indicating 
that they are functionally equivalent.
1.5.2.Gene products required for HSV-1 replication
The complete set of viral genes that are required for HSV-1 DNA replication were identified 
by means of a transient complementation assay in which cloned segments of HSV-1 DNA 
were tested for the ability to support the replication of co-transfected plasmids containing 
oriL or oriS. Seven genes (UL5, UL8, UL9, UL29, UL30, UL42 and UL52) were found 
to be both necessary and sufficient for origin dependent DNA replication (McGeoch et al., 
1988b; Wu et al., 1988). Similar results were obtained in insect cells transfected with an 
oriS-containing plasmid and superinfected with a mixture of 7 baculovirus recombinants 
expressing the HSV-1 DNA replication proteins (Stow, 1992). These genes are all essential
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for virus replication and DNA synthesis in tissue culture (Weller, 1991). A brief outline of 
each is given below and their positions on the HSV-1 genome are illustrated in figure 1.6. 
(for review, see Challberg, 1991).
UL9
The initial event in the activation of a HSV-1 origin of replication is likely to be the sequence 
specific binding of an origin binding protein (OBP) to oriL or oriS.
Olivio etal. (1988) expressed the UL9 gene using a baculovirus expression system and 
using an immunoassay for protein-DNA interaction, they demonstrated that the UL9 protein 
binds specifically to the HSV origins of replication. Two pieces of evidence suggested that 
origin-binding is an intrinsic property of UL9; protein DNA complexes containing oriS and 
an origin specific binding activity from HSV-1 infected cells were immunoprecipitated with 
UL9 antiserum, and extracts from insect cells infected with recombinants expressing UL9 
also contain an HSV-1 origin binding activity. Again, this binding activity can be 
precipitated with UL9 antiserum. DNase I footprinting analysis showed that UL9 interacts 
with 2 related high affinity sites (site I and site II) on oriS. As had previously been shown 
(Stow et al., 1983), site I occurs within a region of hyphenated dyad symmetry, whereas 
site n  is located in a region homologous to site I on the other side of the dyad axis.
It has subsequently been demonstrated that oriS contains a third UL9 binding site (site III) 
which is of much lower affinity (Elias et al., 1990; Dabrowski and Schaffer, 1991). 
Analysis of sites I and II has identified an llbp  sequence-CGTTCGCACTT- which is 
specifically recognised by UL9 (Koff and Teghnmeyer, 1988; Elias et al, 1990). Mutations 
in site I or site II which abolish UL9 binding eliminate or greatly reduce DNA replication, 
whereas mutations in site HI reduce replication efficiency by a factor of around 5 (Weir and 
Stow, 1990; Hernandez et al, 1991).
The sequence of events which follow UL9 binding are unclear. The two parental strands 
must be unwound before replication is initiated. This is consistent with the finding that UL9 
has intrinsic helicase activity (Bruckner et al., 1991). When cells expressing truncated forms 
of OBP are infected with HSV-1 they do not replicate the DNA efficiently (Stow, 1992;
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Figure 1.6. Locations of the genes determining DNA replication functions 
on the herpes simplex virus genome.
The HSV-1 genome is shown schematically in the prototype orientation with the unique 
regions drawn as thin lines and the inverted repeats flanking the long and short unique 
regions as closed and open boxes respectively. The positions and orientations of the ORF’s 
encoding the seven proteins essential for viral DNA replication are shown by arrows. The 
positions of the origins of replication, oriL and oriS are also indicated (adapted from 
Arbuckle, 1993).
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Perry et al., 1993; Stow et al., 1993). The transdominant phenotype of truncated forms of 
OBP is probably^due to a loss of helicase activity, but retention of binding capacity; hence 
the truncated forms bind to one or both high-affinity sites in a replication origin, thereby 
blocking that origin’s participation in a productive replication complex. This shows that 
DNA binding alone is insufficient for UL9 function and that helicase activity is also required 
(Stow,1992).
UL42 /  Pol(UL30)
The HSV-1 DNA polymerase (UL30) co-purifies from infected cells in a heterodimeric form 
with its accessory protein UL42 (Gallo et al., 1988; Crute et al., 1988). One known 
function of UL42 is to increase the ability of Pol to synthesize longer DNA products 
(Gottlieb et a l , 1990; Hernandez and Lehman, 1990) through an increase in processivity. 
The DNA polymerase has intrinsic 3’-5’ exonuclease activity which probably serves a 
proof-reading function to increase the fidelity of DNA replication (O’Donnell et al., 1987; 
Purifoy and Powell, 1977) and a 5’-3’ exonuclease/RNase activity similar to E.coli Pol I 
(Crute and Leihman, 1989). This activity may play a role in the removal of the RNA primers 
present on the 5’ end of Okazaki fragments which are made on the lagging strand during 
semi-discontinuous synthesis.
As UL42 and Pol are essential for virus growth (Aron et al., 1975; Marchetti et a l, 1988; 
Marcy et al., 1990; Johnson et al, 1991) this would indicate that the interaction between the 
2 polypeptides is also essential (|Gottlieb^ al, 1990; Digard and Coen, 1990) making it a 
valid target for antiviral agents.
Owsianka et al. (1993) attempted to identify the regions of UL42 which affect DNA 
polymerase activity.
They synthesized overlapping decapeptides spanning the entire 488 amino acids of 
the UL42 protein and tested their ability to inhibit polymerase activity on a defined template 
primer in the presence or absence of UL42. Peptides from 5 separate regions were found to 
interfere with HSV polymerase activity, but there was no evidence that these peptides acted 
by disruption of the Pol/UL42 interaction. Two other groups (Digard et al, 1993; Tenney et
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a l, 1993) used combinations of deletion and insertion mutagenesis to demonstrate that 
sequences mapping in the carboxyterminal 40 amino-acids of DNA polymerase are crucial 
for the stability of UL42 binding. In addition, a region which is highly conserved in several 
other Alphaherpesviruses (HSV-2, EHV-1 and VZV), between amino acids 1176 and 1195 
of UL30, was found to be crucial for a productive interaction with UL42| (Tenney et al., 1993).
UL5/UL8/UL52 (helicase-primase)
Crute e ta l  (1988), identified a DNA-dependent ATPase, present specifically in HSV-1 
infected cells. Partial purification of this activity and SDS-polyacrylamide gel electrophoresis 
of the fractions obtained by Superose 12 gel-filtration showed that 3 major polypeptides 
with masses of 130, 97 and 70 kDa coincided with the peak of DNA dependent ATPase 
activity.
These proteins were purified to homogeneity (Crute et al, 1989) and immunochemical 
analysis revealed that they were the products of the UL52, UL5 and UL8 open-reading 
frames (Wu e ta l, 1988; McGeoch eta l, 1988b). In addition, analysis of DEAE-sephadex 
fractions for DNA primase activity showed that the primase co-eluted perfectly with the 
herpes-induced DNA-dependent ATPase. The association of these 2 activities enables close 
coordination of the priming of the lagging strand DNA with unwinding of the replication 
fork.
The precise role which each subunit plays in these activities is unclear, but a complex 
consisting of only the UL5 and UL52 subunits in vitro exibits all the known activities of the 
3 component complex (Calder and Stow, 1990; Dodson and Lehman, 1991). The predicted 
UL5 amino acid sequence contains 6 sequence motifs which are characteristic of helicases 
(Hodgman,1988; McGeoch et al, 1988b). However purified UL5 has not been 
demonstrated to act as a helicase in the absence of UL52 (Calder and Stow, 1990; Dodson 
and Lehman, 1991).
Calder et a l (1992) used immunofluoresence to demonstrate that the UL8 protein is 
important for efficient nuclear uptake of the helicase-primase complex. In addition, UL8 acts 
to increase the efficiency of primer utilization by stabilizing the association between nascent
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oligoribonucleotide primers and template DNA (Sherman et al, 1992). UL8 has recently 
been expressed in insect cells (Parry et al, 1993), but no binding of the purified protein to 
ssDNA, dsDNA or to a DNA/RNA hybrid was observed, suggesting that UL5 and UL52 
are required for binding of UL8 to nucleic acid.
U L29
The major ssDNA-binding protein (mDBP) was first recognised as an abundant HSV 
induced protein of about 130kDa (Honess and Roizman, 1973; Powell and Courtney, 1975) 
which binds more tightly to ssDNA columns than to dsDNA columns (Bayliss et al., 1975; 
Purifoy and Powell, 1976) based on DNA cellulose chromatography of infected cell extracts. 
Analysis of ts mutants (Conley e ta l,  1981; Powell e ta l ,  1981; Weller e ta l ,  1983; 
Holland et al, 1984) later demonstrated that the mDBP (also known as ICP8) is the product 
of the UL29 gene.
UL29 has many characteristics of a helix destabilizing protein. It not only binds 
preferentially and co-operatively to ssDNA templates with no detectable sequence specificity 
(Ruyechan, 1983; Ruyechan and Weir, 1984) but it can also enhance the denaturation of a 
polydeoxyadenylic acid-polydeoxythymidylic acid duplex (Powell et al, 1981). It is likely 
that the HSV-1 mDBP has a function analogous to that of the E.coli ssDNA binding 
protein, which binds to and stabilizes regions of ssDNA at the replication fork (Powell et 
al, 1981; Ruyechan, 1983; Ruyechan and Weir, 1984).
UL29 is known to form intracellular complexes with viral DNA (Lee and Knipe, 1983). It 
accumulates at specific regions within the cell nucleus by 4-5hrs post-infection (Quinlan et 
al, 1984) and under certain conditions where DNA synthesis is permitted UL29 is found at 
discrete pre-replicative sites throughout the nucleus where it plays a role in organizing DNA 
replication proteins (deBruyn Kops and Knipe, 1988; Bush e ta l, 1991).
There is evidence to suggest that UL29 may interact specifically with other replication 
proteins. Bush et a l (1991) used immunofluoresence to examine the intracellular localization 
of HSV-1 Pol in infected cells. Pol was found to localize to the nucleus in the absence of 
any other replication proteins, but functional mDBP was required for localization of Pol to
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the pre-replicative sites. In cells infected with mutant viruses encoding defective Pol 
molecules, mDBP localizes to pre-replicative sites, indicating that Pol is not required for 
formation of pre-replicative sites or the localization of mDBP to these structures. Although 
several studies have supported a possible direct interaction between Pol and mDBP 
(Hernandez and Lehman, 1990; Ruyechan and Weir,l 984; Chiou et al., 1985; O’Donnell et 
al, 1987) no direct biochemical evidence for an interaction has been presented.
Several laboratories (Weller et al, 1983; Leinbach et al, 1984; Leinbach and Heath, 1988; 
Gao and Knipe, 1989) have attempted to identify functional domains of UL29. It appears 
that the carboxyterminal region of the gene contains the ssDNA binding site (Leinbach and 
Heath, 1988; Gao and Knipe, 1989) while the amino-terminus contributes to the ssDNA 
binding activity of the intact protein by maintaining the carboxyterminus in an active 
configuration (Leinbach and Heath, 1988).
1.5.3. Enzymes required for DNA replication
HSV-1 specifies a large array of enzymes which are involved in nucleic acid metabolism. 
With the exception of the alkaline DNase (Weller et al, 1990) these are generally dispensible 
for growth in tissue culture.
The HSV-1 UL2 ORF encodes a uracil DNA glycosylase (Cardonna and Cheung, 1981; 
McGeoch et a l, 1988a) which plays a role in DNA repair and proof-reading. The function 
of uracil-DNA glycosylase is in the removal of uracil residues from DNA created from either 
the deamination of cytosine or the incorporation of dUMP into DNA; the extremely high 
G+C content of HSV-1 DNA makes this an important element of error correction in HSV-1 
DNA. This gene is non-essential for growth in tissue culture (Mullaney et al, 1989).
A HSV encoded dUTPase has been identified (Caradonna and Cheung, 1981) which maps 
to the UL50 open reading frame (Preston and Fischer, 1984; McGeoch et a l, 1988a). 
dUTPases act to hydrolyse dUTP to dUMP, providing both a mechanism to prevent 
incorporation of dUTP into DNA and a pool of dUMP for conversion to dTMP by 
thymidylate synthetase.
The HSV ribonucleotide reductase (RR) functions to reduce ribonucleotides to
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deoxyribonucleotides creating a pool of substrates for DNA synthesis (Bacchetti et al, 
1986, 1986; Ingemarson and Lankinen, 1987). In HSV-1 the enzyme consists of a large 
subunit R l, and a small sub-unit R2, which have Mr values of 136K and 38K respectively 
(Frame et al, 1985; Bacchetti et al, 1986; Darling e ta l,  1988). The subunits consist of a 
tight complex in an a2 f2  structure similar to the RR enzymes of E.coli and mammalian 
cells (Ingemarson and Lankinen, 1987); The large sub-unit, designated ICP6 (Honess and 
Roizman ,1973, 1974), is encoded by the UL39 gene; the small subimit, designated ICP38, 
is encoded by the UL40 gene (McGeoch et al, 1988a). These genes map between 0.562 
and 0.597 m.u. on the viral genome and are translated from 3’-coterminal RNAs of 5.0 and 
1.3kb respectively (Anderson et al, 1981; Swain and Galloway, 1986; McLauchlan and 
Clements, 1983). A synthetic nonapeptide (YAGAVVNDL), corresponding to the carboxy- 
terminal 9 amino acids of the small subunit specifically inhibits the HSV-1 enzyme (Dutia et 
a l, 1986; Cohen et al, 1986) by dissociation of the 2 subunits (McClements et al, 1988). 
HSV-1 thymidine kinase phosphorylates thymidine (Kit and Dubbs, 1963; Dubbs and Kit, 
1964), deoxycytidine (Jamieson and Subak-Sharpe, 1974) and thymidylate (Chen and 
jPrusoff, 1978).
A virus specific topoisomerase has also been reported (Muller et al, 1985) but has not been 
shown to be virally encoded (Bapat et al, 1987).
These enzymes will be discussed more fully in a later section in relation to their role in HSV 
pathogenicity.
1.6. Regulation of transcription of viral genes by HSV-1
The expression of viral genes during infection of tissue culture cells by HSV-1 can be 
divided into 3 broad classes termed a , P and y (Honess and Roizman, 1974, 1975) or 
immediate-early (IE), early (E) and late (L), (Clements et a l, 1977) based on their kinetics 
of appearance and requirements for either de novo protein or DNA synthesis. This “cascade” 
pattern is however, more complex than a simple 3-fold one (Wagner, 1985). The late genes 
can be subclassed into leaky-late (Py, yl) which require 3 to 5hrs of protein synthesis before
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expression, or true-late (y2) which require in addition the onset of viral DNA replication 
(Weinheimer and McKnight, 1987; Jones and Roizman, 1979; Harris-Hamilton and 
Bachenheimer, 1985; Clements et a l, 1977). In general, the IE genes code for 
transcriptional regulatory proteins, E genes are involved in DNA replication and L genes are 
structural and assembly proteins.
In the presence of inhibitors of protein synthesis, mRNAs from the 5 IE genes accumulate in 
relatively large quantities. The IE genes are defined as those genes which can be transcribed 
in the absence of de novo protein synthesis. Following separation by gel electrophoresis, 
IE-mRNAs labelled with 32p were used to locate the IE genes on the viral genome and in 
vitro translation was used to define their products (Watson et al., 1979).
1.6.1. Transcriptional control of IE genes by Vmw65
The regulatory regions of the IE gene promoters of HSV-1 contain 1 or more copies of a 
conserved DNA sequence element which has a minimum consensus TAATGARAT (where 
R=purine) (Mackem and Roizman, 1982; Whitton and Clements, 1984),which is required 
for response of the promoter to transactivation by a major component of the virus particle 
Vmw65 (Batterson and Roizman., 1983; Campbell e ta l, 1984; Marsden etal., 1987) the 
product of the gene UL48 (Dalrymple et al., 1985; Parris et al., 1988). Fragments or short 
oligonucleotides containing this consensus sequence can confer Vmw65 inducibility upon 
otherwise non-responsive promoters (Cordingley et al., 1983; Preston and Tannahill, 1985; 
Preston et al, 1984). Vmw65 does not bind DNA by itself (Marsden et al., 1987) but its 
effect is to induce transcription of the IE genes by cellular RNA polymerase II (Post et al., 
1981; Batterson and Roizman, 1983, Campbell et al., 1984).
Kristie and Roizman (1987), first demonstrated the binding of a host protein to each of the 
IE gene upstream regulatory regions and this was later confirmed by several other 
j laboratories (O’Hare and Goding, 1988; Preston et al, 1988). This factor was subsequently 
identified as Oct-1 (Stem et a l, 1989) a transcriptional factor already implicated in the 
regulation of a number of cellular genes. Subsequent results obtained on the binding of 
TAATGARAT by Oct-1 (O’Hare and Goding, 1988) demonstrated that Vmw65 is recruited
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onto the TAATGARAT element in a manner that is dependent on Oct-1 binding. Mutational 
analysis of Vmw65 (Triezenberg et al, 1988; Greaves and O’Hare, 1989; Haigh et al,
1990) showed that it contains 2 separable domains. One of these domains, which is located 
at the amino terminus interacts with Oct-1 to form the IE complex which binds to 
TAATGARAT.
A second cellular factor also appears to be required for the regulation of HSV-1 IE genes by 
Vmw65 (Gerster and Roeder,1988; Kristie eta l, 1989).This factor interacts directly with 
Vmw65 in the absence of other components of the transactivation complex.(Kristie and 
Sharp , 1990; Katan eta l, 1990). Therefore it is likely that it interacts with Vmw65 to form 
a stable protein complex that subsequently recognises the DNA-bound Oct-1. This factor has 
been purified from HeLa cell nuclear extracts (Kristie and Sharp, 1993; Wilson et al, 
1993), and is composed of several polypeptides which appear to be post-translational 
products of a larger 300kDa protein (Wilson et al, 1993).
IE gene transinduction by Vmw65 is not essential for virus growth at high m.o.i. but plays a 
critical role in determining plaquing efficiency and thus whether infection is lytic or non­
productive (Ace et al, 1988,1989). Vmw65 is also important for the virulence of HSV-1 in 
mice (Ace et al, 1989).
VZV ORF10 encodes a protein homologous to HSV-1 Vmw65 (Davison and Scott, 1986b), 
but it is 80 amino acids shorter and lacks sequences similar to that of the Vmw65 acidic 
carboxy-terminal tail (Cohen et al, 1993). Furthermore, VZV ORF10 does not form IE 
complexes with the TAATGARAT sequence element and cellular proteins (McKee et al,
1990) so it was not thought to have gene regulatory activity. Mouriuchi et a l  (1993) have 
shown however, that VZV ORF10 can transactivate both the VZV IE gene ORF62 and 
HSV-1 VmwllO and Vmwl75 promoters. This indicates that ORF10 is a transactivating 
protein despite the absence of the acidic carboxyterminus, which activates transcription in 
Vmw65. At present it is not known if VZV ORF10 transregulatory activity is mediated 
through binding to cellular factors.
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1.6.2. The HSV-1 IE gene products
Several nomenclatures exist for the IE genes and their products. The most commonly used 
are listed below.
The IE genes of HSV-1 and their products.
Glasgow nomenclature Chicago nomenclature
G en e* G ene** Product Gene Product
IE-1 RL2 VmwllO otO ICPO
IE-2 UL54 Vmw63 a l l  ICP27
IE-3 RSI Vmwl75 a4 ICP4
IE-4 US1 Vmw68 a22 ICP22
IE-5____________ US 12_____________Vmwl2_________ oc47 ICP47
* Original designation (Clements et al.,1919)
0 Later designation in complete HSV-1 sequence (McGeoch e ta l,  1988a; McGeoch et al, 
1991).
V m w l l O
VmwllO has a size of Mr 11 OK by SDS-PAGE and is encoded by the diploid gene RL2, 
contained within R l. VmwllO encodes one of the few spliced transcripts in the HSV-1 
genome; its protein coding regions are contained within 3 exons (Perry e ta l ,  1986). 
VmwllO is not absolutely essential for virus growth in tissue culture (Stow and Stow, 
1986; Sacks and Schaffer, 1987) but at low m.o.i. viruses with a deletion in VwmllO show 
a defect in growth which is overcome at high m.o.i.. Viruses which lack VmwllO are 
unable to stimulate latent viral genomes to reactivate in an in vitro latency system (Russell et 
al, 1987), while expression of VmwllO also causes reactivation in this system (Harris et 
al, 1989). However, in vivo, the role of VmwllO in reactivation is less clear as virus 
lacking Vmwl 10 can reactivate from explanted latently infected mice ganglia, albeit more 
slowly than the wild-type virus.
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VmwllO can activate the expression of a large number of HSV-1 and non-HSV-1 
promoters both by itself and in a synergistic manner with Vmwl75 (O’Hare and Hayward, 
1985; Quinlan and Knipe, 1985; Everett, 1986). The production of VmwllO itself is 
regulated by Vmwl75 (Resnick eta l, 1989). Although the efficiency of promoter activation 
by VmwllO alone and its degree of synergy with Vmwl75 vary depending on the 
experimental conditions (Everett, 1988b), some of the regions that are involved in its 
intrinsic and synergistic activation events have been defined (Everett, 1987; 1988a).
The major determinant of transactivation maps to a cysteine rich region in the second exon 
(Everett et al, 1987, 1988a; Chen e ta l, 1991). This region is highly conserved in the 
VmwllO homologues of other herpesviruses (Perry e ta l ,  1986; Cheung, 1991; van 
Santen, 1991). Other regions of the protein contribute to its function, but this is dependent 
on the promoter examined and the cell type in which the assays are performed (Chen et a l, 
1991). VmwllO is thought to mediate transactivation by interaction with an unknown 
cellular factor. Recent results (Weber and Wigdahl, 1992) indicate that the domain of 
Vmwl 10 which interacts with the putative cellular factor is encoded by the first two exons.
Vmw63
Vmw63 is encoded by the gene UL54 and migrates as a Mr 63K polypeptide on SDS- 
PAGE. Evidence from transfection studies has shown that in the presence of VmwllO and 
Vmwl75, Vmw63 can repress expression of some target plasmids containing HSV-1 early 
promoters and enhance expression of targets containing late promoters (Everett, 1986; Rice 
and Knipe, 1988; Su and Knipe, 1989; McMahan and Schaffer, 1990).
Studies with Vmw63 ts and deletion mutants have demonstrated that the gene plays an 
essential role in viral growth, is involved in the negative regulation of IE and some E genes, 
does not appear to be absolutely essential for DNA synthesis and is required for the 
expression of later classes of genes (Sacks et al, 1985; McCarthy et a l , 1989; Rice and 
Knipe, 1990).
Data presented by McCarthy et a l (1989) suggested that Vmw63 mediates its effect on late 
gene expression transcriptionally. In contrast however Smith e ta l  (1992) found that while
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the synthesis of new transcripts continued when Vmw63 was defective, the accumulation of 
late mRNAs and their translation into protein was reduced. The converse was found for IE 
products suggesting that Vmw63 was acting partly post transcriptionally to regulate the 
expression of IE and L gene products.
VmwI75
RSI, the gene encoding Vmwl75 (McGeoch et al, 1988a) is located in the short repeat 
genome segment and is therefore present twice. The encoded polypeptide migrates as a Mr 
175K species on SDS-PAGE gels (Courtney and Benyesh-Melnick, 1974). However, the 
size of the primary translation product as predicted by the DNA sequence is only 132,835 
daltons. Vmw 175 is a phosphoprotein which appears as several closely migrating species 
following SDS-PAGE (Wilcox eta l, 1980). One of the phosphorylated species is stable 
throughout the course of infection, whereas phosphate cycles on and off at least two other 
species. The Vmw 175 sequence can be divided into 5 regions on the basis of similarity to 
the corresponding proteins produced by other alphaherpesviruses (McGeoch etal., 1986; 
Vleek et al, 1989; Grundy etal., 1989).
Vmwl75 is an essential polypeptide *(Preston, 1979; Sacks et al., 1985) and a critical 
transactivator of most HSV genes. Of the 5 IE gene products, Vmw 175 is perhaps the most 
important, since its inactivation results in failure to transcribe early or late genes and an 
apparent over-expression of the IE genes (DeLuca et al, 1985). Thus, Vmwl75 is required 
directly or indirectly for the normal regulation of HSV-1 genes.
Vmw 175 is a phosphorylated nuclear protein which binds to DNA in crude cell extracts and 
is associated with chromatin (Hay and Hay, 1980; Wilcox et al, 1980). It is known to bind 
specifically to DNA sequences (Tedder et al., 1989; Imbalzano etal., 1990; Pizer et al, 
1991) many (but not all) of which contain the motif ATCGTC.
The DNA binding domain of Vmwl75 is well defined (Everett et al., 1990,1991; Wu and 
Wilcox, 1990; Pizer et al, 1991) and consists of the entire highly conserved region 2 of the 
polypeptide and also the distal part of the less well conserved region 1. The precise 
relationship between DNA binding and Vmwl75 function is unclear, as a virus with
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mutations in the Vmwl75 binding domain which reduces the ability of the protein to bind 
DNA still grows normally in tissue culture (Sheperd and deLuca, 1991a,b).
Vmw68
Vmw68 is encoded by the gene US1 and migrates as a Mr 68K species on SDS-PAGE. 
Vmw68 and Vmw 12 are derived from identical promoters in the repeat sequences which 
bound the short unique region of the genome. The splice donor site used in IE-4 and IE-5 
RNAs is also in Rs while their entire coding regions differ, being located at either end of 
Us (Watson etal., 1981, Rixon and Clements, 1982).
Post and Roizman (1981) constructed a virus lacking the carboxyterminal third of Vmw68. 
This virus grew normally in Vero cells, but later analysis using different cell lines showed 
that in some cases the virus grew poorly (Sears et al., 1985) and the activity of at least 1 true 
late promoter was substantially reduced. This virus was non-neurovirulent in mice but could 
establish a latent infection. Since the majority of the ORF in the mutant used was left intact, 
these studies did not give a clear answer to the role of Vmw68 but it appears to play a role in 
determining host-range.
V m w l 2
Vmw 12 is encoded by the gene US 12 and has a size of Mr 12K on SDS-PAGE. Its function 
is unknown, but Marsden etal. (1982), suggested that its cytoplasmic location and the 
observation that it is the only nonphosphorylated IE polypeptide may point to a different role 
from other IE polypeptides. Viable deletion mutants have been isolated which lack the whole 
of this gene, indicating that it does not play an obvious or essential role during infection of 
tissue culture (Longnecker and Roizman, 1986; Umene, 1986; Brown and Harland, 1987).
1.6.3. Expression of HSV-1 early and late genes.
The mechanisms of activation of HSV-1 E and L promoters remain unclear. E and L 
promoters do not contain obviously conserved class-specific sequences analogous to 
TAATGARAT. The E promoters that have been examined consist of a near upstream region
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composed of binding sites for cellular transcription factors linked to a TATA box/ cap site 
(McKnight and Kingsbury, 1982; Everett, 1984; McKnight and Tjian, 1986).
HSV-1 true late promoters appear to have a simpler structure than E promoters. A TATA 
element is the only consensus element identified in the upstream regulatory region of viral 
late promoters (Wagner, 1985) and deletion studies have indicated that little sequence 
information upstream from this element is required for efficient expression (Homa et al., 
1986; Homa etal., 1988). However, Kibler etal. (1991) demonstrated that sequences 
downstream of the US11 TATA box play an active role in specifying true L temporal 
expression.
Steffy and Weir (1991) constructed linker-scanning mutations in the gC and gH promoters 
to help define the promoter elements common amongst HSV-1 late promoters. Their 
analysis identified 3 sequence elements in each promoter: a TATA element, an element that 
overlapped the start of transcription and an element downstream from the start of 
transcription. The TATA element or initiation sequence appear to be important for normal 
transcription initiation.
Analysis of expression from hybrid gE/gC (ylly2) promoters (Sethna and Weir, 1993) 
revealed that the initiation elements of these 2 promoters were interchangable. The gE 
promoter is active to a degree before the onset of viral DNA replication, and this appears to 
be controlled by a separate regulatory element upstream from the TATA element.
1.7. Pathogenicity of HSV
HSV-1 and HSV-2 are important human pathogens that cause a variety of diseases ranging 
from benign superficial cutaneous lesions to life-threatening encephalitis (Whitley, 1985). 
Identification of the genes that control pathogenic properties and elucidation of their function 
are of fundamental importance if we are to understand the basic mechanisms by which 
disease is initiated.
Various animal models such as mice, guinea pigs, rabbits, rats and monkeys have been used 
to study HSV pathogenicity. Several host factors controlling pathogenicity have been
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identified; namely, humoral immunity (McKendall etal., 1979), cytotoxic immunity (Nash 
etal., 1985), interferons (Lopez, 1985), state of skin and mucous membrane, age of host 
and route of inoculation (Sprecher and Becker, 1986, 1987). Within the same host the 
degree of pathogencity is affected by virus strain, serial passage of the virus in vivo 
(Kaerner etal., 1983), in vitro (Goodman and Stevens, 1986) and body temperature of the 
host (Thompson and Stevens, 1983a). As HSV is a natural pathogen of man, the question 
arises whether a direct extrapolation can be made between animals and man in defining 
genetic loci responsible for differences in pathogenicity.
As HSV-1 glycoproteins play an important role at the early stages of the virus life-cycle (ie. 
adsorption and penetration) it might be expected that they would also be relevant in vivo. 
Very little has been published on the pathogenicity of HSV-1 glycoprotein mutants. gC is 
not a virulence determinant in the mouse model as gC" mutants of both HSV-1 and HSV-2 
remain highly virulent following intravaginal (Johnson et al., 1986), intracerebral and 
footpad inoculation (Dix etal., 1983; Sunstrum etal., 1988). Similarly monoclonal antibody 
resistent (mar ~) gD or gB mutants have no significant affect on pathogenicity (Kumel etal., 
1985). Using engineered Us mutants, Meigner et al. (1988) demonstrated that a gE" mutant 
was not significantly impaired in neurovirulence following intracerebral inoculation of mice, 
with a LD50 less than 100-fold higher than that of the parental virus.
Both HSV-1 Ang and HSV-1 KOS are completely non-neurovirulent following inoculation 
on the mouse footpad (Kumel et al., 1983; Kaerner et al., 1983; Thompson et al., 1986) 
although both are neurovirulent following intracranial inoculation. Following passage in the 
mouse brain, variants of HSV-1 Ang arise (Ang path) which are capable of causing lethal 
neurologic disease following footpad inoculation. This increase in neuroinvasiveness (as 
defined by the ability of the virus to spread to the CNS following peripheral inoculation) is 
associated with a single base change in the gD ORF (Izumi and Stevens, 1990). In HSV-1 
KOS, 2 loci are required for complete restoration of a neuroinvasive phenotype (Yuhaz and 
Stevens, 1993); one within a region of the genome encoding the genes UL10, UL11, UL12, 
UL13 and parts of UL9 and UL15 has not yet been fully characterized, whereas the other is 
localized to gB; as with HSV-1 Ang, a single base change in a glycoprotein greatly affects
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neuroinvasiveness. As gB and gD play a role in virus adsorption and penetration 
respectively, the decrease in neuroinvasiveness associated with these amino acid 
substitutions could be due to a decreased affinity of the mutant glycoproteins for their 
cellular receptors, leading to less efficient spread throughout the nervous system. Two 
amino acid substitutions in the C-terminal portion of gB have been shown to result in a virus 
which is still virulent following footpad inoculation but produces unusual clinical symptoms 
(Goodman and Engel, 1991; Engel et al., 1993). Unlike inoculation with the wild-type virus 
HSV-1 strain 17+, an acute inflammatory response occurs in inoculated footpads with 
subsequent death of the inoculated animal without hind limb paralysis. It is possible that in 
this case the alterations in gB may alter antigen presentation, thus affecting the host response 
to infection.
In addition to gE (US8), Meigner et a l (1988) examined the biological properties of 5 other 
genes in US namely US1, US2, US3, US4 (gG) and US11. Deletion of any of these genes 
was claimed to greatly reduce intracerebral neurovirulence. However, the pathogenicity of 
variants with single mutations in gG (US4) and US2 was not determined. In both cases the 
protein kinase gene (US3) (which was shown to be very important for neurovirulence) was 
also deleted. Deletion of US9, US10, US11 or US12 has no effect on pathogenicity (Taha, 
1990; Nishiyama et al, 1993). The affect of a US7 deletion on neurovirulence has not been 
described.
Any alteration in a virus gene which impairs replication in vitro will also affect the 
performance of the virus in vivo and so all essential genes could be considered ‘virulence’ 
genes. It is now clear however, that the virus possesses genes whose expression is not 
required for multiplication in tissue culture, but are required for a wild-type phenotype in 
vivo. In HSV-1 several genes are required for maximum demonstration of neurovirulence in 
various animal models; some of these are described below.
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1.7.1. DNA polymerase
HSV-1 mutants which are resistant to antiviral drugs arise in the laboratory at a frequency of 
about 10"3 (Coen et al., 1982). Certain acyclovir (ACV)-resistant mutants and all known 
vidarabine (araC)-resistant mutants owe their resistance to mutations in the viral DNA 
polymerase gene (Crumpacker et al, 1980; Coen et al, 1982). Several early studies using 
HSV-1 drug resistant mutants (Darby et al, 1984; Field and Darby, 1980) implicated a role 
for the DNA polymerase gene in pathogenicity for mice. Field and Coen (1986) looked at 
the pathogenicity of 3 distinct DNA polymerase mutants in a mouse ear model. These 
mutants exhibited no significant difference in replication kinetics compared to the wild-type 
virus at the periphery (ear pinna). No clinical signs suggesting neurological involvement 
were noted in any mice inoculated at the pinnae. Following intracerebral inoculation pol 
mutant viruses were found to be highly attenuated for pathogenicity. In a mouse flank 
model (Larder et al, 1986) DNA polymerase mutants were also found to be greatly reduced 
in neurovirulence.
HSV-2 strain 186 grows poorly in the eyes and sensory ganglia of mice, indicating that it is 
non-neuroinvasive following ocular infection (Oakes et al, 1986). Marker rescue of the 
lesion to restore the wild-type phenotype (Day et al, 1987) showed that a mutation in the 
DNA polymerase gene was responsible for the loss of neuroinvasiveness. Recently, Lausch 
et a l  (1990) reported the failure of similar strains to grow in human lymphocytes indicating 
that the gene for HS V DNA polymerase may have an important role during infection of man. 
However, the significance of growth in lymphocytes, which are not likely to be infected by 
HSV-1 during a natural infection is questionable.
It is possible that the decrease in neuropathogenicity of DNA polymerase mutants is due to 
decreased affinities of mutant polypeptides for deoxynucleoside triphosphates which are
; presumed to be in lower concentrations in the nondividing cells of nervous tissues than in
i
i  peripheral tissues.
1.7.2. Thymidine kinase
HSV-1 mutants that lack the ability to produce thymidine kinase (tk) have been studied in a
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number of laboratories. Field and Wildy (1978), reported that tk' mutants of HSV-1 and 
HSV-2, selected by treatment of infected cells with bromodeoxyuridene (BUdr) were less 
virulent than the parental tk+ virus. Tenser et a l (1979,1981) demonstrated that tk" mutants 
do not replicate in the trigeminal ganglia.
Although tk" mutants do not replicate in murine sensory ganglia, they do establish a latent 
infection (Coen et al, 1989; Efstathiou et al, 1989; Leist et al., 1989; Tenser et al, 1989 ). 
Efstathiou et a l (1989) demonstrated the reactivation of tk" virus from latency following 
superinfection with wild-type virus, despite the inability to. detect DNA from this virus in 
nervous tissue during acute or latent infection, or reactivate virus from explanted ganglia. 
This result confirmed an earlier study (Field and Wildy, 1978) which had shown that a tk" 
variant produced a transient increase in titre 1 day after inoculation into the mouse ear pinnae 
with little infectious virus being found thereafter. Virus could not be isolated from the 
ganglia during acute infection, but was found to establish and reactivate from a latent 
infection following explant of ganglia.
Coen et a l (1989) similarly demonstrated the reactivation of tk" virus from latency following 
superinfection with wild-type virus, although they were also unable to reactivate tk" virus 
from explanted ganglia. Southern blotting of reactivated virus demonstrated in vivo 
complementation of the mutant virus with wild-type virus. Using in situ hybridization, they 
detected LAT in only ~2 to 5-fold higher frequencies in wild-type infected ganglia than in tk" 
virus infected ganglia. These results confirmed the ability of tk" virus to enter the PNS and 
establish a latent infection, and indicated that tk was specifically required for reactivation 
from latency.
1.7.3. Ribonucleotide reductase
Ribonucleotide reductase (RR) is a key enzyme in DNA biosynthesis of eukaryotic and 
prokaryotic organisms. By reducing ribonucleotides to their corresponding 
deoxyribonucleotides, the enzyme provides a major pathway in the formation of DNA 
precursors. HSV-1, like other herpesviruses, encodes its own RR (Dutia, 1983).
The existence of a ts mutant, ts 1207 with a lesion in RR suggested that this enzyme was
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essential for virus replication (Preston et al, 1984). In a mouse model, ts 1207 shows a 
reduction in neurovirulence of >10^-fold compared to the wild-type virus following 
intracerebral or intraperitoneal injection (Cameron et a l, 1988). At the non-permissive 
temperature this mutant fails to induce reductase activity, and shows a reduction in yield of 
-10^ with respect to that at the permissive temperature following growth on BHK21/C13 
cells. However, several reports indicated that RR was not absolutely required for virus 
growth in tissue culture. Concentrations of hydroxyurea that inhibited RR activity to 
undetectable levels in proliferating cells infected with HSV-2 reduced virus yield by only 6- 
fold (Nutter et al, 1985), and an HSV-1 insertion mutant lacking most of R1 induces no 
detectable RR activity and produces only a 4- to 5-fold lower yield of progeny virus in 
exponentially growing tissue culture cells than does the parental virus (Goldstein and 
Weller, 1988a). However, in serum starved cells this mutant had an extremely small plaque 
size compared to the wild-type virus, and one-cycle growth analysis indicated a 30- to 40- 
fold reduction in yield of the mutant virus in these cells. A deletion variant, ICP6A, lacking 
90% of the R1 coding sequences was found to have similar growth characteristics to ts 1207 
: in Vero cells at both the permissive and non-permissive temperature (Goldstein and Weller, 
1988b) indicating that the temperature sensitivity of ts 1207 may not be due to the 
thermoliability of the viral RR at higher growth temperatures, but more likely is due to the 
| inability of the host pathways to complement the defect at elevated temperatures. The 
i  absence of alternate pathways for obtaining deoxyribonucleotides in non-dividing cells 
explains the defect in serum starved cells.
In a mouse ocular model (Jacobson et al, 1989), ICP6A showed reduced ability to replicate 
| following peripheral inoculation, and was impaired in reactivation from latency. At 38°C 
ICP6A was impaired in growth in mouse cells relative to growth in Vero cells indicating that 
a mouse factor (eg. cellular RR) required for HSV growth in the absence of viral RR, is
I
| more sensitive to temperature than the corresponding factor in Vero cells. The extreme
I
impairment of the RR mutant in the mouse eye is probably a result of the impairment of this 
mutant in mouse cells. The mutant replicated poorly in the cornea and unlike the wild-type 
virus KOS, and the wild-type rescuant it did not cause severe ocular disease (Brandt et al,
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1991). It also grew poorly in human primary corneal fibroblasts, suggesting that RR may be 
required for virulence in human infections.
1.7.4. dUTPase
A HSV-1 neurovirulence locus has been mapped to the genomic region which encodes the 
viral dUTPase (Thompson and Wagner,-1988). This gene is located between 0.69 and 0.70 
m.u. on the viral genome (Preston and Fisher, 1984), corresponding to the UL50 ORF 
(McGeoch et al., 1988a). In tissue culture, HSV-1 dUTPase is not required for viral 
replication, suggesting that a cellular counterpart is present in sufficient quantity and can be 
utilized by HSV-1 (Fisher and Preston, 1986; Williams, 1988; Barker and Roizman, 1990). 
Pyles et al. (1992) demonstrated that dUTPase negative mutants are approximately a 10-fold 
reduction in neurovirulence following intracerebral inoculation compared to the wild-type 
virus. In this study, the neuroinvasiveness of these mutants was assessed through 
determination of their ability to|invade the CNS following peripheral (footpad) inoculation. 
The average LD50 value of HSV-1 strain 17+ was 2.9x10^ following peripheral 
inoculation, whereas dUTPase mutants were at least 3 orders of magnitude less 
neuroinvasive using this assay. dUTPase mutants replicated with wild-type kinetics in 
nonneural tissue (footpad) and PNS, but were defective in entry or replication in the CNS. 
They reactivated from latency following jexplantation of ganglia at a frequency half that of the 
wild-type virus by day 7 post explantation (by day 7 100% of all wild-type infected ganglia 
had reactivated) but were more severely impaired in reactivation following hyperthermia 
induction (10% and 21% of ganglia infected with dUTPase mutant reactivating compared to 
82% of wild-type virus infected ganglia).
Therefore the HSV-1 dUTPase is an important determinant of HSV-1 virulence, 
establishment and/ or reactivation from latency.
1.7.5. UL56
The HFEM strain of HSV-1 has a deletion of 4.1kb ( compared to HSV-1 strain F) in its 
genome which completely abolishes its pathogenicity in tree-shrews by the intraperitoneal
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route (Rosen and Darai, 1985). In vivo marker rescue of the deletion with a restriction 
enzyme fragment (np 113322-np 123464) from HSV-1 strain F which is highly pathogenic 
for tree shrews by the intraperitoneal route led to the isolation of a recombinant which 
regained intraperitoneal virulence for tree shrews (Rosen et al, 1986). A 1.5kb RNA 
hybridizing to the DNA sequences of the HSV-1 strain F genome at npl 16659-116951 was 
found to be missing in cells infected with HSV-1 HFEM and other apathogenic HSV-1 
strains (Rosen-Wolff et al., 1988). The corresponding ORF in the HSV-1 genome was 
found to be the UL56 gene (Rosen-Wolff and Darai, 1991). In the HSV-1 HFEM genome, 
the promoter region of UL56, including the TATA box is deleted (Koch et a l, 1987) 
accounting for the absence of the 1.5kb transcript. At present the role of the UL56 gene in 
viral replication is unknown, but there is evidence that sequences in the deleted region of 
HFEM determine the suppression of humoral antibody formation by herpes simplex virus 
(Wollert et al, 1991). Viruses deleted in UL56 of HSV-1 (strain 17+) exhibit no impairment 
in pathogenicity by the footpad or intracerebral route in B ALB/c mice and no impairment in 
reactivation from latency (Sinclair, 1992).
1.7.6. UL10
The HSV-1 UL10 gene is predicted to encode a membrane protein with eight potential 
transmembrane domains (McGeoch et al, 1988a). It is a virion component which becomes 
associated with infected-cell membranes (Baines and Roizman, 1993; MacLean etal., 1993) 
and is modified by N-linked glycosylation. Recently, the product of the UL10 gene has been 
somewhat inappropriately designated gM (Baines and Roizman, 1993); unlike other HSV-1 
glycoproteins which have previously been described, the UL10 gene product is a type HI 
membrane protein and spans the membrane more than once.
The UL10 gene product is non-essential for growth in tissue culture, but inactivation of the 
gene causes an impairment in growth (Baines and Roizman, 1991; MacLean, C., et al, 
1991, 1993). In vivo characterization of a UL10 deletion variant (MacLean et al, 1993) 
demonstrated that the UL10 gene product is required both for growth at the periphery and 
subsequent spread to the nervous system. Although still capable of establishing a latent
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infection, its reactivation kinetics were impaired compared to the wild-type virus. Following 
intracerebral inoculation, the UL10 deletion variant was slightly less neurovirulent than the 
wild-type revertant. Although UL10 is not absolutely required for neurovirulence in vivo, it 
is apparently required for optimum virus growth and spread reflecting its impairment in 
tissue culture, rather than a specific in vivo defect.
1.7.7. ICP34.5
The existence of a neuro virulence locus in the long repeat region of the HSV-1 genome was 
first demonstrated by Thompson et al. (1983). They noted that the HSV-1 x HSV-2 
intertypic recombinant, RE6, was completely non-neurovirulent following intracerebral 
inoculation of mice, with a LD50 of 3.2x10^ p.f.u./mouse, compared to a lethal dose of 10 
p.f.u. for either HSV-1 strain 17+ or HSV-2 strain HG52, the wild-type parental strains of 
this recombinant (Thompson and Stevens, 1983b). Restriction enzyme analysis and 
Southern blotting revealed that HSV-1 information from 0.71 to 0.83 m.u. had been 
incorporated into the RE6 genome (Thompson eta l, 1983) and was specifically associated 
with the decrease in the neurovirulence of this virus (Thompson et al, 1985). Sequences 
mapping between 0.698 and 0.721 m.u. could partially rescue the non-neurovirulent 
phenotype of RE6 (Thompson and Wagner, 1988). However a cloned HSV-1 fragment 
spanning the region of the HSV-1 genome from 0.82 to 0.832 m.u. restored the virulence of 
RE6 to near wild-type levels (Thompson et al, 1989).
At around the same time that this work was published, a non-neurovirulent variant of HSV- 
2 strain HG52 was described. This variant, JH2604, has previously been shown to have RL 
sequences spanning 0.00 to 0.002 m.u. and 0.81 to 0.83 m.u. in the viral genome deleted 
(Harland and Brown, 1985). The neurovirulent phenotype of JH2604 could be restored by 
recombination with HSV-2 sequences between 0.7 and 0.91 m.u. (Taha et a l, 1989a). 
Further analysis of this variant (Taha et a l, 1989b) revealed a 1488bp deletion which 
removes 1 complete copy of the 17bp DR1 element of the ‘a’ sequence and terminates 522bp 
upstream of the 5’ end of IE-1. JH2604 was unable to replicate within neuronal cells of the 
CNS or produce necrotizing encephalitis in mouse brain following intracerebral inoculation
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(Taha et al, 1990).
In our laboratory, a non-neurovirulent variant of HSV-1 strain 17+ has recently been 
described (MacLean, A., e ta l,  1991a). This variant, 1716, has a 759bp deletion which 
removes 1 complete 18bp DR1 element of the ‘a’ sequence and terminates 1105bp upstream 
of the 5’ end of IE-1. 1716 grows identically to the wild-type virus in vitro, but is non- 
neurovirulent following intracerebral inoculation of mouse brain with a LD50 of 7x10^ 
p.f.u./mouse. This absence of neurovirulence is due to an inability to replicate in mouse 
brain.
When the work described in this thesis began, the HSV-2 strain HG52 genome had not been 
sequenced and in HSV-1 strain 17+» the region between IE-1 and the ‘a’ sequence was 
apparently non-protein coding (McGeoch etal., 1988a). Initial sequencing data of the HSV- 
2 strain HG52 genome (Dr.D.J. McGeoch, personal communication) revealed a 63 amino 
acid coding sequence in this region of high homology, between HSV-1 strain 17+ and 
HSV-2 strain HG52. In 1986, Chou and Roizman demonstrated that in HSV-1 strain F, the 
region between the ‘a’ sequence and IE1 is protein coding. Using a peptide antiserum which 
had been raised against a Pro-Ala-Thr trimer repeat found 10 times in the strain F sequence, 
Ackermann et al. (1986) detected a protein of 43.5K in HSV-1 strain F infected cell extracts. 
This protein had not previously been detected among electrophoretically separated proteins 
of HSV-1 and overlaps in part with the bands formed by ICP35. The promoter of the gene 
encoding ICP34.5 has several unusual features: it lies within the ‘a’ sequence which is G-C 
rich and contains numerous repeats and features, including a canonical TATA box 
characteristic of HSV promoters, are not present. The ORF ascribed to HSV-1 strain F 
ICP34.5 was not present in the published sequence of HSV-1 strain 17+ (McGeoch et al., 
1988a). However, in 1990, when Chou and Roizman republished their sequence of HSV-1 
strain F ICP34.5, they now predicted a protein of only 263 amino acids in size, but more 
importantly their revised sequence was now almost identical (with the exception of 1 
frameshift) to the published sequence of the relevant region in HSV-1 strain 17+.
Chou et al. (1990), confirmed the importance of HSV-1 strain F ICP34.5 in neurovirulence 
following intracerebral inoculation through the construction of 4 recombinant viruses. These
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were (i) a virus in which both copies of the gene encoding ICP34.5 were deleted (ii) a virus 
into which a 6-frame stop-codon had been inserted in both copies of the gene (iii) a virus, 
containing after the first codon, an insert encoding a 16-amino acid epitope known to react 
with a specific monoclonal antibody and (iv) a wild-type rescuant. Both HSV-1 strain F and 
the wild-type rescuant were neurovirulent following intracerebral inoculation. The virus 
which contained the 6- amino acid epitope insert was only slightly reduced in neurovirulence 
compared to the wild-type virus, whereas the variants in which the gene encoding ICP34.5 
had been deleted or truncated by insertion of a 6-frame stop codon were completely non- 
neurovirulent following intracerebral inoculation. These results implied that ICP34.5 plays a 
crucial role in neurovirulence following intracerebral inoculation of mice and indicated that 
homologous proteins must be present in HSV-1 strain 17+ and HSV-2 strain HG52. 
Resequencing of HSV-1 strain 17+ confirmed the presence of the homologue (Dolan eta l,
1992) and an equivalent ORF was also identified in HSV-2 strain HG52 (McGeoch et al,
1991).
1.8. Virulence determinants in non-herpesviruses
A major focus for the study of virus-host interactions has been pathogenesis and the ability 
of viruses to cause disease. Viruses can initiate and cause disease by several means such as, 
(i) infection of susceptible cells causing molecular alterations which eventually lead to cell 
death, (ii) immunopathobiology eg. recognition and killing of virus infected cells and (iii) 
persistence and alteration of cellular function perhaps leading to oncogenesis. In HSV-1 
virulence is multifactorial and several genes have been shown to be required for maximal 
display of neurovirulence in diverse animal models. In some other viruses however, the 
alterations in the viral genome which abolish pathogenicity have been well characterised; 
some of these are described below.
1.8.1. Poliovirus
Poliovirus, a human enterovirus belonging to the Picornaviridae family, is the causative
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agent of poliomyelitis. It replicates in the human digestive tract and may induce paralysis by 
infecting and destroying motor neurons (Couderec et al, 1989). Over the past 30 years, the 
disease has been controlled by the use of the Sabin live-attenuated vaccine (Assaad and 
Coburn, 1982). This vaccine is based on attenuated strains of poliovirus which were 
empirically derived by passage of wild-type viruses in monkey tissue in vivo and in vitro 
(Sabin, 1965; Sabin and Boulger, 1973). Although the Sabin vaccine against poliomyelitis 
is one of the safest and most effective in current use, in a very low percentage of recipients 
(less than 1 case per million recipients) poliomyelitis may occur as a consequence of 
vaccination (Minor, 1980; Minor, 1982; Notlay etal., 1981).
The ability to clone and rapidly sequence the 7431 nucleotides of poliovirus has enabled the 
research groups headed by Jeffrey Almond of Leicester and Geoffrey Schild of London to 
determine what changes in sequence correlate with the acquisition of virulence.
Comparison of the complete nucleotide sequences of the genomes of the Sabin type 3 
vaccine strain P3/Leon/12aib and its neurovirulent progenitor P3/Leon/37 indicates that they 
differ by just 10 point mutations (Stanway et al, 1984). Sequence analysis of revertant 
strains, vaccine virus (Cann etal,  1984; Stanway eta l,  1984; Almond e ta l ,  1985; Evans 
et al, 1985) and neuro virulence testing of recombinant viruses derived from infectious 
cDNAs of the Sabin vaccine strain P3/Leon/12aib and its neurovirulent progenitor (Westrop 
et al, 1989) revealed that the attenuated phenotype of the poliovirus vaccine strain is the 
product of 2 point mutations which act additively. These mutations are at positions 472 (C- 
to-U) and 2034 (C-to-U) change in the virus structural protein VP3. The mutation at 472 in 
the 5’ non-translated leader appears to contribute to the attenuation of Sabin type 3 
poliovirus vaccine by decreasing the translation efficiency of the viral genome (Svitkin et al, 
1990) although the mechanism by which this occurs is unclear.
1.8.2. Coxsackie B4 virus
Coxsackieviruses are members of the enterovirus genus of the family Picornaviridae. 
Coxsackieviruses of the B group have been implicated in diseases such as pancreatitis, 
myocarditis, myositis and type 1 insulin-dependent diabetes mellitis (Grist e ta l ,  1978;
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Melnick, 1985). Of the group B viruses, variants exist within a single serotype thereby 
contributing to the variability in pathogenicity of coxsackieviruses.
Coxsackieviruses have structural features common to all picornaviruses, namely a capsid 
comprised of 4 virus-encoded proteins (VP1 to VP4) enclosing a single-stranded positive 
sense RNA genome of approximately 7,500 nucleotides. The RNA is polyadenylated at the 
3’ terminus and has a small protein VPg,-covalently attached to the 5’ terminus. The primary 
translation product of picomavirus RNA is a single large polyprotein which is processed by 
virus encoded proteases to yield the mature viral proteins (reviewed by Rueckert, 1986). 
Comparison of nonneurovirulent and highly neurovirulent coxsackie B4 virus recombinants 
in a mouse model (Ramsingh et al, 1989; Ramsingh et al, 1990) revealed that the virulence 
phenotype mapped to the PI region of the genome. This region comprises the 5’ 
untranslated region (UTR) and the genes encoding the structural proteins VP1, VP2, VP3 
and VP4.
Comparison of the corresponding cDNA sqeuences of virulent and nonneurovirulent virus 
(Jenkins et al, 1987; Ramsingh et al, 1992) identified 13 nucleotide substitutions, 4 in the 
non-coding region, 4 silent and 5 resulting in amino acid substitutions in VP1, VP2 and 
VP4. Analysis of individual mutations in both VP1 and VP2 (Caggana et al, 1993) revealed 
that a single residue (Thr-129 of VP1) determined the virulence phenotype. In contrast to 
other picornaviruses including poliomyelitis and Theiler’s murine encephalomyelitis virus 
(Fu e ta l ,  1990; Westrop e ta l  , 1989) the 5’ UTR does not appear to contribute 
significantly to neurovirulence.
Sequence and structure alignment (Caggana et al, 1993) positions Thr-129 of coxsackie B4 
on the DE loop of VP1 in a similar position to lie-143 of poliovirus, an amino acid which 
has been shown to be of importance in attenuation of poliovirus type 2 (Ren et a l, 1991). 
Hence, the molecular mechanisms underlying virulence in both of these viruses may share 
common features mediated by the DE loop of the VP 1 capsid proteins.
1.8.3. Louping ill virus
Louping ill (LI) virus, a tick-transmitted member of the Flaviviridae (Westaway et al,
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1985), causes an encephalitic or encephalomyelitic disease of sheep and grouse. The 
flaviviruses are ssRNA viruses with a positive-sense genome about 10.4kb in length. The 
viral proteins are encoded in one open reading frame and the entire gene order of both the 
structural and nonstructural (NS) proteins is core, pre-membrane (prM), membrane (M ), 
envelope (E), NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5 (Bell etal., 1985; Castle et 
al, 1985; Speight e ta l,  1988). From the biological standpoint, the viral E protein is 
considered particularly important because it agglutinates erythrocytes, induces antigenically 
cross-reactive neutralizing and protective antibodies in infected animals and probably defines 
the tropism of flaviviruses for their target cell, thus defining virus virulence ( reviewed by 
Gould eta l, 1990; Heinz e ta l, 1990).
To analyse the regions of the E protein which determines the virulent phenotype, Jiang et a l 
(1993) produced 7 LI virus immunological escape mutants. The nucleotide sequence of the 
E protein of each of these mutants was determined and the deduced amino acid sequence 
compared to that of the wild-type virus. A change from the amino acid aspartate to 
asparagine at position 308, which represented a potential glycosylation site was found to be 
the most effective at reducing neurovirulence. It is possible that this amino acid change 
affects the protein folding and hence the ability of the E protein to bind to its receptor. 
Antibody-resistant escape mutants in the E protein of both tick-borne encephalitis and 
Japanese encephalitis virus have previously been shown to exhibit reduced neurovirulence in 
mice (Holzmann et al, 1990; Cecilia and Gould, 1991).
1.8.4. Lymphocytic choriomeningitis virus
Lymphocytic choriomeningitis virus (LCMV) is the prototype member of the Arenaviridae . 
The ssRNA genome consists of 2 segments L and S which give rise to a total of 5 structural 
proteins; an RNA polymerase (L), a nucleocapsid protein (NP), 2 structural proteins, GP-1 
and GP-2 which are derived by cleavage of the precursor GP-C and a zinc-finger protein 
(Romanowski eta l, 1985; Salvato eta l, 1989; Salvato and Shimomaye, 1989).
In a normal host, LCMV introduced by a peripheral route is eradicated and the host is 
immune to subsequent challenge. However, in an immunocompromised host, the virus is
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not cleared and establishes a life-long persistent infection. It has been clearly demonstrated 
that the outcome is dictated by the CTL response (reviewed by Buchmeier, 1980; Byrne and 
Oldstone, 1984). Adoptive transfer of CD8+ lymphocytes from an LCMV-immune mouse 
to a persistently infected animal results in clearance of the virus (Jamieson etal., 1987; 
Oldstone et a l, 1986), while abolition of virus-specific CTL responses during acute 
infection changes the outcome from clearance to persistence (Gilden et al, 1972). 
Spontaneous variants have been isolated which cause a persistent infection in 
immunocompetent mice by suppression of the CTL response (Ahmed et al, 1984). Early 
results (Ahmed et al, 1988; Salvato et al, 1988) indicated that the immunosuppressive 
phenotype mapped to the L RNA segment, but more recent analysis has demonstrated that 
this is not the case. Reassortment analysis with homologous LCMV strains implicated the S 
RNA segment as the major locus for the immunosuppressive phenotype (Matloubian et al, 
1990).
By sequencing oligo-primed DNA Salvato et a l (1991) demonstrated that a change in GP
amino acid 260, located on the S RNA, was consistently associated with the
immunosuppressive phenotype. It is most likely that the GP 260 mutation influences CTL
induction by affecting early stages of viral replication ie. by altering virus entry or GP
processing and stability. This mutation was found to be necessary, but not sufficient to
cause the immunosuppressive phenotype with secondary mutations in the polymerase or
transcriptional control regions on the L RNA also believed to be involved (Salvato et al,
\ 1991).
|
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11.9. Aims of project
i
j The work presented in this thesis had several aims; (i) to show that the HSV-1 strain 17+ 
; genome encodes an HSV-1 strain F ICP34.5 homologue, (ii) to demonstrate that in HSV-1 
strain 17+, this protein plays a crucial role in neurovirulence following intracerebral 
inoculation of mice, and (iii) to produce an ICP34.5 polyclonal antiserum which would 
specifically detect ICP34.5 in HSV-1 strain 17+ infected cells and which might also detect
Introduction
the semi-conserved protein in HSV-2 strain HG52.
The preliminary characterization of a Us deletion variant which was isolated during the 
course of this work is also described.
Chapter 2- Materials and methods
Materials and methods
2.1. Materials
2.1.1. Cells
Baby hamster kidney 21 clone 13 (BHK21/C13) cells were used throughout this study 
(MacPherson and Stoker, 1964).
2.1.2. Viruses
The wild-type parental viruses used in this study were HSV-1 strain 17+ (Brown et al., 
1973) and HSV-1 strain F (Ejercito et.al., 1968).
The HSV-1 strain 17+ deletion variant 1716 was frequently utilized as an ICP34.5 
negative control (MacLean, A., et al, 1991).
2.1.3. Cell culture media
BHK21/C13 cells were grown in Eagle's medium (Gibco) supplemented with 10% 
newborn calf serum (Gibco) and 10% (v/v) tryptose phosphate broth (Busby et.al., 1964). 
This will be referred to subsequently as ETC 10.
Variations on the basic growth media were:
PIC Phosphate-free Eagle's medium containing 1% newborn calf serum
Emet/5C2 Eagle's medium containing one-fifth the normal concentration
of methionine and 2% calf-serum.
EMC 10% Eagle's medium containing 1.5% methyl cellulose and 10%
newborn calf serum.
2.1.4. Bacterial strains
The bacterial strains used for cloning were JM109 [supE, thi, (lac-proAB), (F'traD36, 
proAB, lacl92 M15)] (Yanisch-Perron etal., 1985) and NM522 [supE,thi, (lac-proAB), 
hsd5(r_, m-), (F' proAB, lacl92 M15)], (Gough and Murray, 1983). For expression of 
ICP34.5 BL21(DE3) [F-ompT- rbm 'b] (Studier and Moffat, 1986) was used.
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2.1.5. Bacterial growth media
The media used for bacterial growth were L-broth (170mM NaCl, 10g/l Difco 
bactotryptone, 5g/l yeast extract) and 2xYT (85mM NaCl, 16g/l Difco bactotryptone, 5g/l 
yeast extract).
Bacteria from glycerol stocks was generally plated out onto L-broth agar (L-Broth 
containing 1.5% w/v agar) plates.
Top agar - 1% (w/v) agar in water was used in the preparation of template DNA for 
sequencing.
2.1.6. Oligonucleotides
Synthetic oligonucleotides were synthesised in the department by Dr J.McLauchlan, using 
a model 8600 Biosearch multiple column DNA synthesiser.
2.1.7. Radioisotopes
All radioisotopes were supplied by Amersham International pic.. They had the following 
specific activities:
[35s]-methionine >1000Ci/mmol
[32p]-orthophosphate 3000Ci/mmol
5' [ a  -32P] dNTPs ~3000Ci/mmol
[ 35s] dATP ~5000Ci/mmol
2.1.8. Chemicals
The chemicals used were of analytical grade and most of these were supplied by either 
BDH chemicals UK or Sigma Chemical Co.. Exceptions were:
APS and Temed - Bio-Rad Laboratories
Ampicillin (Penbritin) - Beecham Research
Caesium Chloride - Koch Light Ltd. (Suffolk, England).
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2.1.9. Enzymes
Restriction enzymes were obtained from either Bethesda Research Laboratories (BRL) or 
New England Biolabs. T4 DNA ligase and T4 polynucleotide kinase were obtained from 
Boehringer Mannheim Corporation.
Lysozyme, Ribonuclease A and Deoxyribonuclease 1 were obtained from Sigma 
Chemical Co..
2.1.10. Plasmids
The starting plasmid used for the construction of the ICP34.5 expression vector was 
pET8c (Studier et al, 1990). This was kindly provided by Dr. Judy Furlong. For the 
construction of HSV-1 recombinant plasmids pGEM 3zf(-) (Promega) was used. 
Wild-type HSV-1 strain 17+ fragments cloned into pAT153 (ie. BamHIj^and BamHI £) 
were kindly provided by Dr. A. Davison.
2.1.11. Commonly used buffers and solutions
Acrylamide gel tank buffer: 53mM glycine, 3.5mM SDS, 52mM Tris
This is a 24:1 mixture of chloroform and isoamylalcohol 
600mM NaCl, 200mM NaOH 
600mM NaCl, 1M Tris-HCl, adjusted to 
pH8.0 with HC1
7% SDS, 0.5M NaP (NaH2PC>4; Na2HPC>4),pH7.4. 
lOOmM DTT, ImM EDTA, lOOmM MgCl2, 
lOmM spermidine, 0.5M Tris-HCl, pH 7.6 
200mM DTT, lOOmM MgCl2, 0.5M Tris- 
HCl, pH 7.8
1M Tris-HCl, pH 7.6, 1M MgCl2, 1M DTT 
This is a 1:1 mixture of phenol and chloroform 
170mM NaCl, 3.4mM KC1, lOmM 
Na2HP0 4 ,1.8mM KH2PO4 , pH7.2
Chloroform: isoamylalcohol: 
Gel soak 1:
Gel soak 2:
Hybridization buffer:
Kinase buffer (10X):
Ligase buffer (10X):
T4 polymerase buffer (10X): 
Phenol chloroform (1:1): 
PBS A:
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PBS complete:
PBS /calf:
RE stop:
Saturated phenol:
lxSSC:
TBE:
Tris-saline:
Trypsin:
Trypsin-Versene:
Versene:
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PBS A plus 6.8mM CaCl2, 4.9mM MgCl2
PBS complete containing 5% newborn calf serum 
lOOmM EDTA, 10% (w/v) Ficoll 400, 0.25% (w/v) 
bromophenol blue, 0.1% (w/v) xylene cyanol, 5xTBE 
Phenol saturated by mixing 2:1 with phenol saturation 
buffer; (lOmM Tris-HCl, pH7.5, lOmM EDTA, lOOmM 
NaCl)
15mM trisodium citrate, 150mM NaCl
2mM EDTA, 89mM boric acid, 89mM Tris-HCl pH8.0
140mM NaCl, 30mM KC1, 280mM Na2HP04, lmg/ml
glucose, 0.0015% (w/v) phenol red, 25mM Tris-HCl 
(pH7.4), 100 units/ml penicillin, 0. lmg/ml streptomycin 
0.25% (w/v) Difco trypsin dissolved in Tris- 
saline
1 volume trypsin + 4 volumes versene
0.6mM EDTA dissolved in PBS containing 0.002%
(w/v) phenol red.
2.1.12. Antisera
For the detection of ICP34.5 in HSV-1 infected cell extracts a peptide antiserum, 78, 
which had been raised against a ten times repeat of the Pro-Ala-Thr (PAT) sequence 
present in the published sequence of RL1 was utilized. The characterization of this 
antiserum has been previously described (MacKay et a l, 1993)).
Two other peptide antisera against ICP34.5 were provided by Dr.C. MacLean. These had 
been raised against peptides which corresponded to sequences within the 63 amino acid 
region of homology between HSV-1 and HSV-2 RL1 and were synthesized by Dr.A. 
Owsianka. These will be described more fully in a later section (Section 3.2.1.).
The monoclonal antibodies, 3104 and ZLF11 which recognise gl and 65KDBP 
respectively, were kindly provided by Dr.A.Cross.
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Specific polyclonal antisera against 2 IK and VmwllO were provided by Dr. Howard 
Marsden..
2.1.13. Miscellaneous
Phenyl sepharose 
S-sepharose 
Repelcote 
XS-1 film 
XK 16 column 
Giemsa stain 
Neutralizing antibodies 
(human serum)
2.2. Methods
2.2.1. Growth of cells
BHK21/C13 cells were grown in 80oz roller bottles within a humidified atmosphere of 
95% air and 5% CO2 at 37°C for 3 days. The yield from a confluent roller bottle is
approximately 1x10** cells.
Cells were harvested by washing the monolayers twice with 25mls of trypsin- versene, 
and resuspending the detached cells in 20mls of ETC 10. Cells from 1 roller bottle could 
be used to seed a further 10 roller bottles. For some experiments cells were plated on 
50mm or 30mm petri dishes or Linbro wells at a density of 4x10^, 2x10^ and 5x10^ cells 
per plate respectively.
2.2.2. Growth and harvest of HSV
Confluent roller bottles were infected with 0.003 p.f.u./cell of HSV in 20mls of ETC 10, 
assuming that there were 1x10** cells per roller bottle. These were incubated at 31°C for 
3-4 days, until c.p.e. was complete, when the cells were shaken into the medium. The cells
Pharmacia
Pharmacia
BDH Chemicals
Kodak
Pharmacia
BDH
Gibco
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were pelleted in 250ml plastic falcon tubes by spinning at 2K for 10 minutes at 4°C in a 
Fison's Coolspin. The supernatant and cell pellet were separated and two individual virus 
stocks prepared:
Supernatant stock: The supernatant was poured into 250ml centrifuge bottles and spun at 
12K for 2hr (4°C) in a Sorvall GSA rotor. The supernatant was discarded, and the virus 
pellet resuspended in 1ml ETC 10 or PBS/calf per roller bottle. The pellet was sonicated 
until homogeneous, before aliquoting into 2ml amounts and storing at -70°C.
Cell- associated stock: The cell pellet was resuspended in 0.5ml medium/ roller bottle 
and thoroughly sonicated before spinning at 2K for 10 minutes at 4°C in a Fison's 
Coolspin centrifuge. The supernatant was kept on ice while the process was repeated. The 
two supernatants were combined to give the cell-associated virus stock. This was 
aliquoted and stored as above.
2.2.3. Titration of virus stocks
Virus stocks were serially diluted 10-fold in PBS/calf. 0.1ml aliquots were added to 75% 
confluent monolayers of BHK21/C13 cells on 50mm petri dishes from which the medium
i
had been removed. The plates were incubated at 37°C for 45min- lhr, to allow absorption 
I of the virus to the cells, before overlaying with 4ml EMC 10%. Plates were incubated at 
37°C or 38.5°C for 2 days, or for 3 days at 31°C. Monolayers were fixed and stained with 
Giemsa at RT for lhr. After washing, plaques were counted on a dissection microscope 
and virus titres were calculated as p.f.u./ml.
2.2.4. Virus adsorption onto cells.
70% confluent monolayers of BHK21/C13 cells on 50mm plates were precooled to 4°C 
for 30-60 minutes, before infection with 400 p.f.u. virus/plate in 500ul ETC 10. From 0, 
15, 30, 45, 60, 80, 100, 120 and 240 minutes post-infection, unadsorbed virus was 
removed by washing the monolayers twice with PBS/calf. Plates were overlaid with 4ml 
EMC 10%, incubated at 37°C for 2 days and stained. The number of plaques on each plate 
was counted and each time-point calculated as a percentage of the virus adsorbed at
62
Materials and methods
T=240. The percentage virus bound at each timepoint was calculated as the mean of the 
plaque count from 3 plates.
2.2.5. Virus penetration into cells.
70% confluent monolayers of BHK21/C13 cells on 50mm plates were pre-cooled to 4<>c 
for 30-60 minutes before infection with'400 p.f.u. virus/plate in 500ul ETC 10. Following 
adsorption at 4°C for lhr, unadsorbed virus was removed by washing the monolayers 
twice with PBS/calf. Plates were overlaid with 4ml ETC 10 and transferred to 37°C (T=0). 
At 0, 5, 10, 20, 30, 45 and 60 minutes post-adsorption, medium was removed from the 
plates and 1ml citrate buffer (40mM citric acid, lOmM KC1, 135mM NaCl, pH 2.5) 
added. Plates were incubated at RT for 5 minutes, washed twice with PBS/calf and 
overlaid with 4ml EMC 10%. In a control experiment, plates were incubated with 1ml 
PBS/calf at RT for 5 minutes, washed twice with PBS/calf and overlaid with 4ml 
EMC 10%.
Following incubation at 37°C for 2 days, plates were stained and the number of plaques 
on each counted. Percentage virus bound at each timepoint represents the mean of the 
plaque count from 3 plates and was calculated as a percentage of the virus penetrated at 
; T= 60.
2.2.6. Sterility checks on virus stocks.
Brain heart infusion agar (BHI) plates and BHI plates containing 10% horse blood (BHI 
blood agar) were obtained from the Cytology department.
To check for fungal contamination of stocks, a small aliquot was streaked onto BHI plates 
in duplicate, which were sealed with parafilm and incubated at RT. Yeast or bacterial 
contamination was detected by plating onto BHI blood agar and incubating at 37°C. If no 
i  colonies were visible after 7 days incubation, the stocks were considered sterile.
i
I
!i
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2.2.7. Preparation of HSV DNA.
To prepare a large scale HSV DNA stock, 10 roller bottles containing almost confluent 
monolayers of BHK21/C13 cells were infected with virus at a m.o.i. of 0.003 p.f.u./cell. 
The infection was continued at 31°C until c.p.e. was extensive (3-4 days). The cells were 
shaken into the medium and spun at 2K for 10 minutes in a Fison's Coolspin. The 
supernatant was kept on ice while the nuclei were extracted from the cell pellet by 
treatment with 0.5% (w/v) NP40 in RSB (lOmM KC1, 1.5mM MgCl2, lOmM Tris-HCl, 
pH 7.5) followed by centrifugation (2K for 10 minutes as before) to pellet the cell debris 
and nuclei. This was repeated before pooling the supernatants and spinning to pellet the 
virus at 12K for 2hr in a Sorvall SS34 rotor.
The virus pellet, containing cell released and cytoplasmic virus was resuspended in NTE 
buffer (lOmM Tris-HCl, pH7.5, lOmM NaCl, ImM EDTA) before adding EDTA and 
SDS to a final concentration of lOmM and 2% (w/v) respectively to cause lysis of the 
virus. Viral DNA was extracted 3-4 times with saturated phenol and once with 
chloroform: isoamylalcohol, prior to precipitating with 2 volumes of ethanol at RT for 5 
I minutes. DNA was pelleted at 2K for 10 minutes, washed with 70% ethanol, dried at
I 37°C and resuspended in a minimal volume of H2O+ RNase A (50ug/ml).
2.2.8. Transformation of E.coli.
Ten ml of 2xYT broth was inoculated with 15ul of a glycerol stock of bacteria and 
incubated with shaking at 37°C overnight to produce a saturated culture.
One ml of this culture was used to inoculate 100ml of 2xYT broth which was shaken at 
37°C for 2.5-3hr (when the bacteria should be in mid-log phase). The bacterial cells were 
pelleted by spinning at 2K for 10 minutes, in a Fison's Coolspin and resuspended in l/10th 
volume of transformation and storage buffer (lOmM MgCl2, lOmM Mg(SO)4, 10%(w/v) 
PEG 3,500, 5% (v/v) dimethyl sulphoxide). After 10 minutes on ice, the bacteria were 
considered competent for transformation.
Typically, lul and lOul of a ligation mix or plasmid preparation were incubated for 30 
minutes on ice with lOOul of competent E.coli. One ml of L-broth was added to the
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transformation mix and incubation was continued for a further hour at 37°C. If the 
bacteria had been transformed with a plasmid which conferred a particular trait eg. 
antibiotic resistance, the lhr incubation at 37°C allowed plasmid gene expression to 
occur.
One hundred ul of the transformed bacteria were plated onto L-broth agar plates 
containing, if appropriate lOOug/ml ampicillin. Plates were allowed to dry at room 
temperature, before incubating in an inverted position at 37°C overnight.
2.2.9. Small scale plasmid preparation.
Single, transformed, bacterial colonies were picked into 5ml of L-broth containing 
lOOug/ml ampicillin, and shaken at 37°C for 8-16hr. 1.5ml aliquots of each culture were 
spun at low speed (6500g) in a microfuge, the supernatant discarded and the cells 
resuspended in lOOul of solution I (50mM glucose, 25mM Tris-Cl, pH8.0, lOmM EDTA, 
5mg/ml lysozyme added just prior to use). Following 5 minutes incubation at RT, 200ul of 
solution II was added (0.2M NaOH, 1% (w/v) SDS), and the cultures shaken vigorously. 
After a further 5 minutes at room temperature 150ul of solution III was added [5M KAc, 
pH4.8]. Following 5 minutes incubation at RT a white precipitate consisting of the cell 
debris was pelleted at high speed (13000g) in a microfuge .
Plasmid DNA was extracted from the supernatant using an equal volume of phenol: 
chloroform followed by ethanol precipitation at RT for 1 minute. The DNA was pelleted 
by spinning at 13,000g for 5 minutes in a microfuge, washed in 70% ethanol, dried in a 
Speedivac and resuspended in lOOul H2O+ RNase A (50ug/ml).
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2.2.10. Large scale plasmid preparation.
The method used was essentially as described by Birnboim and Doly (1979), and 
modified by Manniatis et.al (1982). Single transformed bacterial colonies from a L-broth 
agar plate were inoculated into 5ml of L-broth containing the appropriate antibiotic and 
shaken at 37°C for 8-16hr. The culture was transferred into 500ml L-broth containing the 
appropriate antibiotic in a.2 litre dimpled flask and shaken at 37°C overnight.
The bacteria were pelleted by centrifugation at 8K for 10 minutes in a Sorvall GSA rotor, 
the pellet resuspended in 7ml solution I (see section 2.2.9.) and incubated at RT for 10 
minutes. Freshly made solution II (14ml) was added and incubation continued for a 
further 10 minutes on ice. Ice-cold solution III (10.5ml) was added, incubation continued 
on ice for 10 minutes and the bacterial debris pelleted by centrifugation at 12K for 10 
minutes in a Sorvall SS34 rotor. DNA was extracted twice with an equal volume of 
phenolichloroform and once with an equal volume of chloroform. The DNA was 
precipitated by the addition of 2 volumes of ethanol, centrifuged at 12K for 30 minutes in 
a Sorvall SS34 rotor at RT, washed in 70% ethanol, pelleted as before, dried in the 
incubator and dissolved in water containing 50ug/ml RNase A.
In some instances, to remove residual host DNA and RNA, the DNA was further purified 
by isopycnic banding on caesium chloride gradients. In this case, the DNA was only 
extracted once with phenolichloroform. Caesium chloride was added until the buoyant 
density was 1.56g/cm^ and ethidium bromide was added to a final concentration of 0.5 
ug/ml. The mixture was pipetted into Oakridge tubes, which were capped, sealed and 
centrifuged at 45,000 r.p.m. overnight in Sorvall Ti50 rotor. The DNA was visualised on a 
long wave U.V. light box and the lower band which contained the supercoiled plasmid 
DNA was removed using a needle and syringe. After extracting at least 3 times with 
isoamyl alcohol, the DNA was ethanol precipitated as described above. The DNA 
concentration was quantitated by running a small quantity on an agarose gel alongside 
standards of known concentrations.
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2.2.11 Restriction enzyme digestion of DNA
The manufacturer's recommended buffers and conditions were generally used for each 
individual restriction enzyme. To achieve complete digestion, lug samples of HSV or 
plasmid DNA were digested with 2-5 units of restriction enzyme for 4hr at the appropriate 
temperature. If the digested DNA was to be run on an agarose gel, 1/5- 1/6 volume of RE 
stop was added prior to loading, otherwise the digested DNA was recovered as described 
in section 2.2.13..
2.2.12. Recovery of DNA from agarose gels using DEAE-sephacel.
Generally the DNA to be recovered had been digested with restriction enzymes before 
running on an agarose gel. In order to cause the minimum possible damage to the DNA, it 
was visualised using a long wave (300-360nm) U.V. lamp and a gel slice containing the 
desired fragment cut out with a sharp scalpel.
This slice was placed in a length of dialysis tubing containing lxTBE and the DNA was 
eluted at 100V for 2-3hr, using lxTBE as a running buffer. Following this, the polarity of 
the current was reversed for 2 minutes to release any DNA which had attached to the inner 
wall of the dialysis tubing. The buffer surrounding the gel slice was carefully removed and 
the dialysis tubing was washed out with a small quantity of lxTBE.
Disposocolumns (Bio-Rad) were packed with 0.6ml of DEAE-sephacel (sufficient to bind 
20ug of DNA) which had been equilibrated with lOmM Tris-Cl, pH7.6, ImM EDTA and 
60mM NaCl. The packed columns were washed with 1.5ml of NTE (1mm EDTA, 
lOOmM NaCl, 10mm Tris-HCl, pH7.4) before applying the sample to the top of the 
column. The eluate was collected, and reapplied to the top of the column, in case any 
DNA had not bound the first time. Bound DNA was washed with 2.5ml of NTE, before 
elution with 2x250ul aliquots of TE (lOmM Tris-Cl, pH7.6, ImM EDTA) + 1M NaCl. 
The DNA was extracted first with phenol and then chloroform, ethanol precipitated and 
washed with 70% ethanol. After drying in the incubator, the DNA was resuspended in 20- 
25ul of H2O.
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2.2.13. Phenol-chloroform extraction of DNA from restriction enzyme digestion 
mixtures.
If the digestion mixture was not at least lOOul, it was increased to this volume using 
dH20. An equal volume of phenol:chloroform was added, the mixture shaken, and spun at
13000g for 2 minutes in a microfuge. The top aqueous layer was removed into a separate 
eppendorf tube and the bottom layer was back extracted with an equal volume of dH2 0 .
To this 1 volume of chloroform was added and the mixture shaken and spun at 13000g for 
2 minutes in a microfuge. The top layer was removed and the sample was back extracted 
as before.
To precipitate the DNA, 2 volumes of ethanol and 0.1 volumes of 3M sodium acetate 
were added. Following 10 minutes incubation on dry ice, the DNA was pelleted at 13000g 
for 5 minutes, washed with 70% ethanol and dried in a Speedivac, before resuspending in 
an appropriate volume of dH2 0 .
2.2.14. Ligation.
Both vector and insert, were cut with the appropriate restriction enzymes. If the vector 
was cut with a blunt-cutting enzyme its digestion was usually carried out in the presence 
of 1 unit calf intestinal phosphatase to prevent recircularization during ligation. The vector 
was purified as described in section 2.2.13. and the fragment as described in section 
2.2.12.. Three types of fragment ends could be generated:
i) Blunt or compatible ends: In this case various quantities of fragment were ligated to 
lOOng of vector DNA at 14°C overnight. Ligation was carried out in lx  ligation buffer 
(lOx ligation buffer contains 200mM DTT, lOOmM MgCl2, 0.5M Tris-HCl, pH 7.6) in 
the presence of 2 units of ligase.
ii) 5’ overhangs: In the absence of a compatible site in the vector: if the fragment to be 
cloned had 5' overhangs these had to be filled in before cloning into the vector which had 
been cut with a blunt-cutting enzyme eg. Sma I. Prior to running on a gel, 0.1 volume of 
2.5mM dNTPs and lunit of Klenow was added to the digestion mixture. Following 
incubation at 37°C for 30 minutes, the digest was run on a gel. The appropriate fragment
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was purified as described in section 2.2.12. and ligated to the vector as described in (i) 
above.
iii) 3’ overhangs: In the absence of a compatible site in the vector: if the fragment to be 
cloned into the vector had 3' overhangs, these had to be exonucleased. The digestion 
mixture was purified as described in section 2.2.13. and redissolved in an appropriate 
volume of dH20. To this was added 1 unit T4 DNA polymerase which has a strong 3'-5' 
exonuclease activity and 0.1 volume of T4 polymerase buffer. Following incubation at 
37°C for lhr, purification and ligation of the fragment was carried out as in (i) above.
2.2.15. Mini-gel electrophoresis.
This method was generally used to quantitate small volumes of fragment and vector DNA 
prior to ligation. Gels were prepared by boiling the appropriate concentration of agarose in 
50ml lxTBE. When cool, 0.5ug/ml ethidium bromide was added and the agarose was 
poured directly into the mini-gel kit (Bio-Rad). Once set, the comb was removed and 
50ml lxTBE was added to the kit. Samples (generally 5-7ul) were run at 50V for 1-2 hrs 
and visualised using a long wave U.V. lamp. A lkb marker of known Concentration was 
| run alongside the fragments to enable confirmation of the vector/fragment size and 
quantitation of the concentration of each sample.
2.2.16. Purification of a synthetic oligonucleotide
Eighty ml of 6% acrylamide,lxTBE, 9M Urea sequencing gel mix was polymerized with 
160ul of 25% (w/v) APS and 60ul TEMED. This was then poured between two 20x22cm 
glass plates separated by 1.5mm spacers and a 10 tooth comb inserted at the top.
The oligonucleotides were synthesized on a Biosearch 8600 DNA synthesiser, 
subsequently deprotected at 65°C for 5-6hr, frozen on dry ice and dried in the speedivac 
overnight. The oligonucleotide was resuspended in 50ul H2O by vortexing. Fifty ul of
sample buffer was added before boiling for 10 minutes and loading immediately onto the 
gel. Two ul of formamide dye mix was loaded in a separate well to act as a molecular 
weight marker and the gel was run at 10mA for 3-4hr in lxTBE.
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To visualise the DNA, the gel was removed, wrapped in cling-film and viewed against a 
white chromatographic plate by angled long-wave U.V. light. If the synthesis had been 
succesful, then a predominant band, with possibly a few lower molecular weight bands , 
was observed. The top band was cut out with a scalpel, mashed with a glass rod, and 
incubated at 42°C for 16hr in 1ml elution buffer (0.5M ammonium acetate, ImM EDTA, 
0.5% (w/v) SDS). This was filtered through glass wool to remove the acrylamide, phenol: 
chloroform extracted, ethanol precipitated, washed in 70% ethanol, dried and redissolved 
in dH20. To quantitate the DNA, the OD26O was reac* and the conversion factor: 10D
unit= 20ug/ml used.
2.2.17. Transfection of DNA into cells using the CaP04 technique.
This method is a modification of that described by Stow and Wilkie (1976). Four hundred 
ul HEBS, pH7.05, (130mM NaCl, 4.9mM KC1, 1.6mM Na2HPC>4 , 5.5mM D-glucose,
2ImM HEPES) containing lOug/ml calf thymus DNA , 0.2-2ug intact virus DNA, 1- lOug 
plasmid DNA and 130mM CaCl2 , were added to semi- confluent monolayers of
BHK21/C13 cells on 50mm petri dishes, from which the medium had been removed. 
Following incubation at 37°C for 45-60 minutes, cells were overlaid with 4ml ETC 10. 
Four to eight hr later the media was removed from the plates and they were washed twice 
with ETC 10. 1ml 25% (v/v) DMSO in HEBS was added and the plates incubated at RT 
for 4 minutes. The DMSO was removed and the plates washed twice and overlaid with, 
4ml ETC 10. Incubation was continued at 37°C until c.p.e. was complete.
2.2.18. Isolation of single plaques from transfection.
Once c.p.e. was complete, the cells were scraped into the growth media, transferred into a 
black-cap vial and sonicated until homogeneous. Serial 10-fold dilutions of each 
transfection were made in PBS/calf and the 10'3 to 10‘7 dilutions from each plated onto 
70% confluent BHK21/C13 cells. After absorption at 37°C for lhr, the plates were 
overlaid with 4ml EMC 10% and incubation continued at 37°C for a further 48hr. The 
plates were washed twice and overlaid with a few ml of PBS/calf. To prepare plate stocks,
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single plaques were isolated and grown in Linbro wells containing BHK21/C13 cells . 
Plates were incubated for 3-4 days at 37°C, then stored at -70°C.
2.2.19. Preparation of 32p labelled viral DNA.
This is a modification of the method described by Lonsdale (1979). Confluent monolayers 
of BHK21/C13 cells in Linbro wells were infected with either lOOul of a plate stock or 
2x1 ()6 p.f.u. of a virus stock. After absorption for 45 minutes at 37°C, the virus was 
removed and the cells washed with and maintained in PIC for 2hr at 31°C. One uCi of 
orthophosphate ( 32p) jn 50ul PIC was added per well and incubation continued at 31°C 
for 2-5 days.
Following incubation at 31°C for 2-5 days, 0.5ml of 5% (w/v) SDS was added to each 
well. Trays were incubated at 37°C for 5-10 minutes, before scraping the cells off the 
wells using a blue tip and adding them to 1ml of phenol. The samples were inverted and 
incubated at RT for 10 minutes, with a further inversion after 5 minutes. They were 
centrifuged at 2K for 10 minutes (RT) in a Fison's Coolspin before removing the top layer 
into 2 volumes (2ml) of ethanol. After gently inverting the tubes, they were spun as 
i before. The ethanol was poured off and the DNA dried for 10 minutes at 37°C with the 
i test-tubes in an inverted position. Two hundred ul of 50ug/ml RNAse A was added to 
each sample and the DNA left to dissolve for 2hr at 37°C. The DNA was then ready for 
; digestion with the appropriate enzyme(s).
2.2.20. In vitro *^P labelling of DNA.
Plasmid or gel purified fragments of virion DNA were P labelled using the method of 
random priming. 10-100ng of DNA was boiled for 10 minutes before labelling. Five times 
random prime buffer comprises 3 solutions A, B, and C at a ratio of 10:25:15 respectively. 
Solution A: 1ml 1.25M Tris-HCl, pH 7.8, 0.125M MgCl2
i 18ul 2-mercaptoethanol
5ul lOOmM dGTP
!
[
5ul lOOmM dATP
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5ul lOOmM dTTP 
Solution B: 2M HEPES, pH 7.6
Solution C: Hexadeoxyribonucleotides (Pharmacia) resuspended in TE at 90 OD units/ml. 
The boiled DNA is added to 5ul of 5x random prime buffer, with lul of 1% BSA, 20uCi 
32p dCTP, 1 unit.Klenow polymerase and made up to 25ul with water. The mixture was 
incubated at 37°C for 30 minutes and boiled, prior to use for Southern blotting.
2.2.21. Southern blotting.
Purified virus, infected cell DNA or plasmid DNA was digested with the appropriate 
restriction enzyme(s) before running on an agarose gel. The gel was visualised under 
short-wave U.V. light to confirm DNA digestion and to partially fragment larger DNA 
fragments and so aid their transfer to membranes.
The gel was placed in 500ml Gel Soak I (see section 2.1.11.) for lhr, rinsed with 
deionised water and transferred to Gel Soak II for lhr. After rinsing as before, it was 
transferred to 500ml lOxSSC for a further lhr. The gel was now ready for blotting onto 
i either 1 sheet or 2 sheets simultaneously of Hybond N nylon membrane (Amersham). For 
each transfer 1 sheet of nylon membrane and 5 sheets of Whatmann 3MM paper, all cut to 
the exact size of the gel were required.
A bundle of 'Hi-Dry' towels was placed on the bench followed by 3 sheets of dry then 2 
sheets of lOxSSC soaked 3MM filter paper. The sheet of nylon membrane, soaked in 
lOxSSC was placed on top of the filter paper followed by the gel, thus ensuring that there 
were no air bubbles between the gel and the nylon membrane. A glass plate and heavy 
weight were placed on top and left for at least 4hr during which time the DNA was drawn 
out of the gel and onto the adjacent side of the nitrocellulose. To transfer DNA to two 
membranes this procedure was repeated on top of the gel.
The DNA was cross-linked to the nylon membrane using a U.V. Stratalinker, and 
hybridized to the labelled probe in a sealed bag containing 20ml hybridization buffer. 
Hybridization was generally carried out overnight at 65°C. The nylon membrane was
72
Materials and methods
washed for 3x30 min with 1 litre 2xSSC, 0.1%(w/v)SDS before drying and setting up for 
autoradiography against Kodak XS-1 film.
2.2.22. Construction of M13 recombinant plasmids
M Bmp 18 and mpl9 double-stranded DNA was commercially available from Pharmacia. 
Typically lOug DNA was digested with the appropriate restriction enzyme. Following 
extraction as described previously (section 2.2.13.) the DNA was resuspended in lOul 
H2O. One ug aliquots of M13 and a wide range of fragment amounts (0.1-10ug) were
generally used in each ligation mix. Standard cloning methods were employed (Manniatis 
et.al.1982).
2.2.23. Transformation of E.coli cells with M13
E.coli strain JM109 were prepared as described in section 2.2.8.. Typically lul and lOul 
of ligation mix was added to 200ul of competent cells and incubated on ice for 30 
 ^ minutes. Three ml melted top agar at 42°C, containing 25ul of 25mg/ml IPTG in water 
and 25ul of 25mg/ml 5-chloro-4-bromo-3-indoyl-2-D-galactoside (X-gal) in dimethyl 
formamide was added and the mixture poured onto 90mm L-broth agar plates and 
incubated at 37 °C overnight.
2.2.24. Preparation of M13 single stranded DNA.
Single, colourless, transformed M13 colonies were used to inoculate 3ml 2xYT broth 
containing 1/100 dilution of an overnight saturated bacterial culture. Following 4.5-6hr 
incubation with shaking at 37°C, 1.5ml culture was spun at 13,000g in a microfuge to 
pellet the bacteria. The supernatant, which contained the M 13 bacteriophage, was retained 
and respun to ensure no bacterial contamination. M13 was precipitated by the addition of 
200ul of a solution containing 2.5% (w/v) PEG 6000 and 3M ammonium acetate. 
Following incubation at RT for 10 minutes, bacteriophage were pelleted by centrifugation 
at 13,000g in a microfuge. The supernatant was discarded and the pellet respun before 
removing any excess liquid with an eppendorf tip. After resuspending the pellet in 200ul
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H2O, the DNA was extracted once with an equal volume of phenol-chloroform, before 
precipitating with 2 volumes of ethanol and 0.1 volumes of 3M sodium acetate on dry-ice 
for 10 minutes. The DNA was pelleted by centrifugation at 13,000g for 5 minutes in a 
microfuge, washed with 70% ethanol, dried and resuspended in 15ul H2O containing
50ug/ml RNase A.
2.2.25. Sequence analysis of recombinant M13 clones.
To facilitate the sequencing of regions of DNA with a high G-C content a Sequenase 
Version 2.0 kit (Amersham), was used in accordance with the manufacturer’s instructions, 
otherwise the following protocol was used.
Five ul of each single-stranded DNA template was annealed to 3ng of commercial 
oligonucleotide primer (Pharmacia) (which hybridizes upstream of the multicloning site 
and is known as the universal sequencing primer) in a buffer containing 40mM Tris.HCl, 
pH7.5, lOmM MgCl2 and 50mM NaCl in a total volume of lOul, by first heating to 55°C
for 5 minutes in a 1.5ml eppendorf tube, then allowing to cool to room temperature over a 
period of 15-30 minutes. The templates were briefly chilled on ice, before being labelled 
and extended using a buffer which contained 0.19uM dCTP, 0.19uM dGTP, 0.19uM 
dTTP, lOuCi 35S dATP, 6mM DTT and 2 units of Klenow polymerase in a total volume 
of 16ul and labelling carried out at RT for 2-5 minutes. Each template was extended and 
terminated by addition of 3ul of labelled template to 2.5ul of each of the 4 ddNTP 
termination mixes in microtitre wells, which had been pre-warmed to 37°C. Each ddNTP 
termination mix contained one ddNTP at a concentration of ddATP: 300uM, ddCTP: 
lOOuM, ddGTP: 150uM, ddTTP: 500uM. The dNTPs were at a concentration of 250uM 
except for the one corresponding to the ddNTP where the concentration was 25uM. The 
plate contents were mixed by centrifugation in a Beckman benchtop centrifuge and the 
reactions carried out at 37°C for 10-30 minutes. Three ul formamide dye mix (95% 
formamide, 20mM EDTA, 0.5% (w/v) bromophenol blue, 0.5%(w/v) xylene cyanol) was 
added to each sample. The samples were boiled for 5 minutes before loading onto a gel for 
electrophoresis.
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2.2.26. Electrophoresis and autoradiography of sequencing gels.
Electrophesis was carried out at 70W through vertical gels 42x34x0.04 cm in size. Gels 
consisted of 6% acrylamide (cross-linked with 5%(w/v) N,N'-methylbisacrylamide) and 
9M urea in lxTBE. Polymerization was achieved by addition of 0.05%(w/v) APS and 
0.1%(v/v) TEMED. Spacers and gel combs were supplied by Gibco-BRL. Both plates 
were treated with repelcote enabling the gel to. be transferred to Whatmann 3MM 
chromatography paper following electrophoresis and dried under vacuum. Dried gels were 
then exposed to XS-1 film (35x43 cm) and developed using a X-omat processor.
2.2.27. Animal studies.
a) Neurovirulence.
Three week old female BALB/c mice (Bantin and Kingman) were inoculated 
intracerebrally with individual virus stocks. Mice were anaesthetized with halothane and 
25ul of the appropriate virus dilution in PBS/calf was inoculated into the central region of 
the left cerebral hemisphere. Four mice were inoculated with each virus dilution.
; Depending on the known, or postulated neurovirulence phenotype of the viruses being 
tested, doses were in the range 10* to 10? p.f.u./mouse. Stocks were always retitrated on 
the day of inoculation to ensure that the correct dose had been administered.
Mice were observed daily up to 21 days post inoculation for signs of illness or death, and 
the LD50 for each virus was calculated according to the formula of Reed and Muench 
(1938).
b) In vivo growth
The ability of mutant and wild-type virus to replicate in mouse brains following 
intracerebral inoculation was assessed using a mouse model. Twenty-five ul aliquots of 
wild-type virus (10^ p.f.u./mouse) and mutant virus (10^ p.f.u./mouse) were injected into 
the left cerebral hemisphere of 3-week old BALB/c mice. At 0,1, 2, 3, 4 and 5 days post­
inoculation, 2 mice per virus were killed by cervical dislocation, their brains removed and 
homogenized in 1ml PBS/calf. The final volume was measured and recorded, before 
storing at -70°C. When all samples had been collected, they were thawed, briefly
75
Materials and methods
sonicated and progeny virus titrated separately on BHK21/C13 cells. Final titres were 
calculated as mean p.f.u./mouse.
c) In vivo marker rescue.
A neurovirulent phenotype was restored to non-neurovirulent variants using the method of 
in vivo marker rescue. One ug of DNA from a non-neurovirulent virus was transfected 
onto BHK21/C13 cells with a 1-, 10- and 100- fold molar excess of a wild-type fragment 
known to restore neurovirulence (section 2.2.17.). After 2 days, the monolayer in which 
c.p.e. was most extensive was harvested and sonicated briefly. 10'1 and 10"2 dilutions 
were prepared in PBS/calf and 25ul aliquots of each were injected intracerebrally into 3- 
week old BALB/c mice.
If the mice died, their brains were removed, homogenised in PBS/calf, and resultant virus 
titrated on BHK21/C13 cells. Single plaques were isolated and their genomes analysed to 
identify wild-type rescuants. Generally 95-100% of isolated plaques had a wild-type DNA 
profile as non-neurovirulent virus did not replicate in vivo and neurovirulent recombinants 
were selectively amplified.
d) Latency.
As has been described by Clements and Subak-Sharpe (1983, 1988), 4 week old BALB/c 
mice were inoculated in the right rear footpad with various doses of virus in PBS/calf. 
Following inoculation, the virus stocks were retitrated to ensure that the correct dose had 
been administered. After 6 weeks, all surviving mice were dissected and the 9 ipsilateral 
dorsal root ganglia supplying the lower limb of each mouse were separately cultured in 
microtitre plates. They were screened every second day for the presence of infectious 
virus by transferring the culture supernatant to control BHK21/C13 cells. These cells were 
then incubated for 2 days at 37°C, before staining and examination for the presence of 
virus plaques or c.p.e..
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2.2.28. Generation of E.coli containing the expression vector pET34.5.
The intact ICP34.5 open reading frame (ORF) from HSV-1 strain 17+ was cloned into 
pET8c using standard procedures. This recombinant plasmid, pET34.5, was used to 
transform E.coli BL21(DE3) cells containing the T7 RNA polymerase gene under the 
control of the inducible lac UV5 promoter. A glycerol stock was prepared by picking a 
transformed colony into 5ml 2xYT containing 250ug/ml ampicillin and growing overnight 
with shaking at 37°C. An equal volume of sterile glycerol was added and mixed 
thoroughly before aliquoting into 1ml amounts and storing at -70°C.
For each experiment a small amount of frozen bacteria was used to inoculate 1ml 2xYT. 
One hundred ul was plated onto a L-broth agar plate containing 250ug/ml ampicillin, 
which was incubated at 37°C overnight. The following day single colonies were used to 
inoculate larger cultures.
2.2.29. Analysis of ICP34.5 solubility over a range of temperatures.
To ensure that a soluble form of ICP34.5 was produced, solubility was examined over a 
range of growth temperatures. As described above, (section 2.2.28.), a small amount of 
frozen bacteria was plated out to give single colonies. The following day, single colonies 
were used to inoculate 5ml L-broth containing ampicillin. Following growth at 37°C for 
4hrs, T7 RNA polymerase expression and hence ICP34.5 production was induced by the 
addition of IPTG to the growing cultures. These were then either maintained at 37°C for a 
further 1 hr or transferred to 31°C, 28°C or 26°C for lhr. The bacteria were pelleted and 
lysed with lysozyme. The bacterial debris was then pelleted by centrifugation and 
equivalent volumes of pellet and supernatant were analysed by Western blotting for the 
presence of ICP34.5 in the soluble supernatant but not in the pellet which contained all the 
insoluble material.
2.2.30. Expression of ICP34.5 in E.coli.
A 500 ml overnight culture of E.coli BL21(DE3) containing pET8c was diluted 20-fold 
into ten 1 litre cultures which were incubated with shaking at 37°C. On reaching an optical
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density of 0.5 at 600nm, the temperature of the cultures was rapidly decreased to 28°C, 
IPTG added and incubation continued for lhr at 28°C. Cells from the 10 litre culture were 
collected by centrifugation at 5K for 10 minutes in a GSA rotor and resuspended in 100ml 
of 50mM-Hepes, pH7.2, 50mM NaCl.
Bacteria were lysed by addition of lysozyme to a final concentration of 500ug/ml, 
followed by 30 minutes incubation on ice. Cell debris was pelleted by centrifugation at 
15K for 20 minutes in a SS34 rotor, at 4°C and the supernatant, which contained the 
expressed protein, was stored at -70°C.
Protein concentrations were determined using a Bio-Rad protein assay kit according to the 
manufacturers recommended instructions using known concentrations of BSA (in the 
range 0.01-2mg/ml) as standards.
2.2.31. Analytical and quantitative ammonium sulphate fractionation.
To look at ICP34.5 solubility over a range of ammonium sulphate concentrations, 
increasing amounts of a saturated solution of ammonium sulphate were added to lOOul 
aliquots of crude extract. After 30 minutes on ice, samples were clarified by centrifugation 
at 13.5K for 30 min, at 4°C. Pellets were redissolved in 300ul 50mM-Hepes, pH7.2, 
50mM NaCl, and supernatants were brought to a volume of 300ul using the same buffer. 
Pellet and supernatant fractions were analysed by SDS-PAGE.
For purification of ICP34.5, the crude extract was salt-fractionated using ammonium 
sulphate powder. Salt was slowly added to the extract with constant stirring, at room 
temperature, followed by incubation on ice for at least 30 minutes. The protein precipitate 
was collected by centrifugation at 12K for 30 minutes, in an SS34 rotor at 4°C.
2.2.32. Anion-exchange chromatography.
The salt-fractionated material was resuspended in 50mM Hepes, pH7.6, 50mM NaCl and 
applied onto a FPLC Mono Q HR 5/5(lml) or 10/10(8ml) anion-exchange column, which
; had been equilibrated with the same buffer. At this pH the expressed protein did not bind
|
! to the column, whereas the vast majority of the E.coli proteins did. The flowthrough was
i
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collected and stored at -70°C and the column was thoroughly washed with buffer B 
(50mM Hepes pH7.2, 1M NaCl) to remove the bound E.coli proteins, which were 
subsequently discarded.
2.2.33. Purification of ICP34.5 using phenyl sepharose or S-sepharose.
This step was carried out at 4°C. A XK 16 column.with adjustable adaptors (Pharmacia), 
was packed with 50ml of the appropriate matrix. This was equilibrated with 1 column 
volume of Buffer A [1M NaCl or 1.5M(NH4)2SC>4, with 50mM Tris-HCl, (pH range 7-8) 
or 50mM (2-[N-Morpholino]ethanesulfonic acid) (pH range 5.5-6.5)] before loading the 
sample which had been dialysed overnight into the same buffer. After washing the column 
with a further 1 column volume of Buffer A, the protein was eluted using a 500ml 
decreasing salt gradient from either 1.5M (NH4 )2 SC>4 or 1M NaCl and 50mM
appropriate buffer to 50mM buffer alone. Five ml fractions were collected and analysed 
I by SDS-PAGE.
2.2.34. Production of polyclonal ICP34.5 specific antisera.
Rabbit antisera to ICP34.5 were produced using bacterially expressed ICP34.5 as the 
antigen. New Zealand White rabbits were immunized intramuscularly first with 2mg of 
protein containing approximately lOOug ICP34.5 in Freund’s complete adjuvant followed 
by 4 boosts, each at a 14 day interval, using the same amount of antigen but in Freund’s 
incomplete adjuvant. Animals were bled 10 days after each boost and the antisera tested at 
different dilutions against HSV-1 strain F and HSV-1 strain 17+ infected cell extracts for 
reaction with ICP34.5 specific bands.
2.2.35. Pre-incubation of antiserum prior to use in immunofluoresence.
Before use in immunofluoresence studies, the protein antiserum was pre-incubated against 
E.coli BL21(DE3) cell extracts to cut down non-specific binding. The extracts were 
prepared by inoculating a single colony of E.coli BL21(DE3) cells lacking the plasmid 
pET34.5 (section 2.2.28.) from an L-broth agar plate into 5ml L-broth and growing at
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37°C for 8 hr. After pelleting the bacteria, they were resuspended in 5ml boiling mix and 
as much extract as possible was loaded prior to SDS-PAGE. Proteins were transferred 
onto nitrocellulose which was blocked as normal for Western blotting (section 2.2.38.) 
and incubated with the protein antiserum at a 1/100 dilution in PBS / 1% BSA. Following 
incubation at 37°C for 2hrs the antiserum was removed and used directly for 
immunofluoresence.
2.2.36. Immunofluoresence.
Washed, sterilized coverslips were placed at the bottom of 35mm plates (2 or 3 coverslips 
per plate), which were seeded with BHK21/C13 cells at one-half the normal density and 
grown for 16hr at 37°C. The medium was poured off and the cell monolayers washed 
twice with PBS. Cells were infected with 0.2ml virus dilution at a m.o.i. of 0.1 p.f.u./cell. 
After absorption for lhr at 37°C, the cells were overlaid with 3ml ETC 10. Following 
incubation at 37°C for 24hr the medium was removed and the plates washed twice with 
3ml PBS. Three ml methanol was added to each plate and incubation carried out at RT for 
4 minutes. Specific antibodies were then added to the plates at a dilution of 1/100. For the 
peptide antiserum, control reactions were carried out using sera which had been pre­
incubated with the specific peptide. The plates were shaken at 37°C for 30 minutes, then 
washed twice with PBS, before the second antibody - anti-rabbit IgG (whole molecule) 
Fluorescein Isothiocyanate conjugate- was added at 1/80 dilution. This was again shaken 
at 37°C for 30 minutes. Plates were rinsed twice with PBS, before removing the 
coverslips, polishing the underside and mounting them on microscope slides using a small 
amount of fluorcolor. The edges of the coverslips were sealed with clear nail polish and 
the slides were stored in the dark.
2.2.37. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).
SDS-PAGE analysis of proteins was performed in 5 to 12.5% gradient gels cross-linked 
with 5% (w/w) N,N'-methylenebisacrylamide, or 10% gels using 2.5% (w/w) crosslinker. 
Slab gels were cast vertically in a sandwich consisting of 2 glass plates separated by
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1.5mm thick perspex spacers. Typically, 60ml gel mix was prepared using a running gel 
buffer (RGB) which contained 375mM Tris-HCl, pH8.9 and 0.1% (w/v) SDS. 
Polymerization was achieved by the addition of 0.06% (w/v) ammonium persulphate 
(APS), and 0.04% (v/v) N,N,N',N', tetramethylenediamine (TEMED), just prior to 
pouring. A thin layer of butan-2-ol (3-5ml), was poured on top to exclude air and enable 
polymerization of the gel. Prior to adding the stacking gel, the butan-2-ol was removed 
and the surface of the running gel was rinsed several times with distilled water. It was then 
thoroughly dried using filter papers to allow good adhesion between it and the stacking 
gel.
The stacking gel was composed of 5% acrylamide crosslinked with the same ratio of 
N,N’-methylenebisacrylamide used in the resolving gel, in a buffer (SGB), composed of 
0.11M Tris.HCl, pH 6.7 and 0.1%(w/v) SDS. As previously, APS and TEMED were 
added to the gel just prior to pouring and a teflon comb was used to form the wells. 
Samples were boiled for 5 minutes in sample buffer (15ImM Tris-HCl, pH7.6, 
6.28%(w/v) SDS, 0.15%(v/v) 2-mercaptoethanol, 0.31%(v/v) glycerol) before loading on 
the gel, and were run either for 3-4hr at 50mA, or overnight at 8mA (Marsden et al, 1976, 
1978).
Gels were fixed or stained in a solution of methanol: acetic acid: water, 50:7:50, with or 
without 0.2% (w/v) Commiassie Brilliant Blue R250, for lhr at RT, then destained for a 
minimum of 3x 30 minutes in a 5:7:88 solution of methanol: acetic acid: water. Gels were 
either dried down immediately under vacuum and exposed to Kodak XS-1 film, or were 
enhanced in 3 volumes of En^Hance (New England Nuclear) for lhr, washed in water for 
30 minutes, before being dried under vacuum and exposed for fluorography at -70°C.
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2.2.38. Western blotting.
SDS-PAGE was carried out as previously described (section 2.2.37.) and Western blotting 
carried out essentially as described by Towbin (1979). In general two types of protein 
sample were used for Western blotting. The first was infected cell proteins which had 
been harvested into boiling mix at a density of 10 cells/ml, and the second was small 
aliquots of fractions which had been obtained from protein purification columns. After 
separation of the proteins, they were transferred onto nitrocellulose using a Bio-Rad 
blotting apparatus. The foam pads, sheets of Whatmann 3MM paper and the nitrocellulose 
to be used for the transfer were pre-soaked in transfer buffer (192mM glycine, 25mM 
Tris.HCl pH8.3, 20% methanol). The gel was placed on top of the nitrocellulose, 3 sheets 
of 3MM paper and one foam pad. Three further sheets of 3MM paper and foam pad were 
placed on top . The plastic folder was then closed, placed in the transfer kit and blotted at 
I 250mA for a minimum of 3hrs. After this time the nitrocellulose was removed, placed in a 
plastic 'tupperware' tub and blocked for 2x30 minutes using 2% dried milk in PBS/ 
; complete, 0.05% Tween 20. The nitrocellulose was washed for 3x10 minutes in 
I PBS/complete, 0.05% Tween 20, before addition of the first antibody diluted 
appropriately in PBS/complete, 0.05% Tween 20, 1% BSA. Following incubation for 2hr 
at 37°C or overnight at 4°C or RT the nitrocellulose was washed as before. The second 
antibody Protein A coupled to HRP was added at a 1/1000 dilution in PBS/complete, 
0.05% Tween 20, 1% BSA and incubated at 37°C for lhr, after which time the 
nitrocellulose was washed twice with PBS/Tween, and once with PBS alone. To visualize 
the proteins, 60ul 4-chloro-l-naphthol was dissolved in a universal of ice-cold methanol 
and 60ul hydrogen peroxide was added to 100ml PBS/complete. These were mixed and 
poured into the tub containing the nitrocellulose, from which the wash buffer had been 
removed. The tub was covered with tin-foil to exclude light, and checked periodically . 
When the reaction was complete the nitrocellulose was washed in dH20 and dried.
In some cases, proteins were visualized using ECL (Amersham) in accordance with the 
manufacturer’s recommended instructions.
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2.2.39. Immunoprecipitation of gl.
Infected BHK21/C13 cells on 50mm plates were labelled between 3-7hrs post-infection 
with lOOuCi/ml [^^S] L-methionine in 4ml Emet/5C2. The media was removed, the plates 
washed with PBS and the cells lysed by the addition of 1ml extraction buffer (lOmM Tris- 
HCl, pH8.0, 10%(v/v) glycerol, 0.5%(v/v) NP40, 0.5%(w/v) sodium deoxycholate) 
(Showalter et al., 1981). Extracts were incubated at 4°C for lhr, sonicated and clarified by 
centrifugation at 13,000g for 5 minutes in a microfuge.
Extracts (lOOul) were incubated with 5ul gl mAb or control ascites, at 37°C for lhr and 
for a further lhr at 4°C with 70ul of a 50%(w/v) suspension of protein-A-sepharose in 
extraction buffer. Unbound proteins were removed by washing the protein-A-sepharose 
beads 3-4 times with 1ml extraction buffer and proteins were subsequently eluted from the 
pellet by boiling in sample buffer before separation by SDS-PAGE (section 2.2.37).
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Chapter 3- Characterization and overexpression of RL1.
3.1. Characterization of the HSV-1 strain 17+ ncurovirulence locus RL1.
3.1.1. Introduction
In 1986 Chou and Roizman demonstrated that the 'a' sequence contains the promoter- 
regulatory region and transcription initiation sites of a gene located in the 'b' region of the 
HSV-1 strain F genome. From sequence studies and RNA analysis, they predicted that the 
gene encoded a protein of 358 amino acids in size. Using an antipeptide serum raised 
against a Pro-Ala-Thr (PAT) repeal, found 10 limes in the 1ISV-I strain F sequence, they 
identified a protein of Mr 43,500 in HSV-1 strain F, but not in HSV-2 or mock infected 
cells (Ackermann et al., 1986). No equivalent open-reading frame (ORF) was present in 
the published sequence of HSV-1 strain 17+ (Perry and McGcoch, 1988).
In 1990, Chou and Roizman resequenced the HSV-1 strain F ICP34.5 locus. Their data 
now predicted a protein of 263 amino acids in size, but more importantly, their republished 
sequence was almost identical to the published sequence of HSV-1 strain 17+, with the 
only major difference being a 2bp insert in the strain 17+ sequence relative to the strain F 
sequence. The insert resulted in 60% of the strain 17+ sequence including the PAT repeat 
being out of frame which did not correlate with results which had clearly shown that HSV- 
1 strain 17+ carries a neurovirulence determinant at the ICP34.5 locus (Thompson et al., 
1989; MacLean, A. et al.y 1991a). It was therefore crucial to resequence HSV-1 strain 17+ 
in the relevant region in order (i) to resolve this anomaly and verify that IISV-1 strain 17+ 
encoded an ORF for ICP34.5, and (ii) to show llinl lack of ICP34.5 expression alone 
results in loss of neurovirulence of HSV-1 strain 17+.
3.1.2. Reinvestigation of the HSV-1 strain 17+ RL1 sequence.
As a prerequisite to any further work on HSV-1 strain 17+ ICP34.5, it was necessary to 
resequence the HSV-1 strain 17+ RL1 gene. For this purpose, a 1.46kb Alul/Rsal fragment 
(np 125074-np 126530; Perry and McGeoch, 1988) encompassing the entire IRl  copy of
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the RL1 ORF, was subcloned into the Smal site of M13mpl8 and single-stranded 
templates prepared as described in section 2.2.24. The source of this 1.46kb subfragment 
was HSV-1 strain 17+ BamHI k, which had been previously cloned in the vector pAT153. 
This BamHI k clone had previously been demonstrated to restore neurovirulence to the 
non-neurovirulent variant 1716 (MacLean, A., et al., 1991a). Sequence analysis was 
carried out using an oligonucleotide primer (supplied by Mr.A.Dolan) corresponding to 
HSV-1 residues 718 to 736 in the T R l copy of the RL1 ORF (all further sequence 
numbers refer to the T R l copy of RL1). The sequence of interest is shown in figure 3.1.. 
Because of the high G-C content of this region of the genome the gel shown was run by 
Mr.A.Dolan on a sequencing kit designed to maintain the gel at a constant temperature of 
80°C and so aid in the resolution of compressions and other structural abnormalities which 
could not be resolved on a normal gel.
Two differences from the published HSV-1 strain 17+ sequence were found: (i) residue 
818 was G instead of C and (ii) more importantly, residues 823 and 824 were absent. 
Correction of the HSV-1 strain 17+ sequence to that of the newly sequenced clone at 
residues 818 to 824 opens the reading frame proposed by Chou and Roizman (1990) 
showing that HSV-1 strain 17+ contains an ORF equivalent to that of HSV-1 strain F 
(Dolan et al., 1992) (fig.3.2.). This ORF has been designated RL1 (McGcoch et al., 1991) 
and was proposed to encode ICP34.5.
Having confirmed that HSV-1 strain 17+ contains a gene, RL1, which encodes an 1CP34.5 
homologue, we wished to demonstrate the importance of this protein in ncurovirulence 
following intracerebral inoculation of mice. To do this, it was decided to insert an in-frame 
stop-codon close to the initiating ATG of RL1 by site-directed mutagenesis using the M13 
clone described above as a starting template. Marker transfer of this mutated RL1 into the 
HSV-1 strain 17+ genome should result in a variant which is completely non-neurovirulent 
following intracerebral inoculation of mice. However, it soon became clear that site- 
directed mutagenesis was not the best approach to use, due to non-specific hybridization of
Figure 3.1. DNA sequence of the RL1 M13 clone.
An autoradiograph of the DNA sequence of HSV-1 strain 17+ RL1, in the region where the 
expected frame-shift relative to the HSV-1 strain F sequence occurred. Sequences were 
obtained by the dideoxynucleotide sequencing method using T7 DNA polymerase. 
Products were fractionated by electrophoresis in a 6% polyacrylamide gel containing 9M- 
urea which was maintained at approximately 80°C. The sequence refers to the TRl  copy 
of RL1. The sequence around the variable region described in the text and figure 3.2., is 
indicated.
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Figure 3.2. Aligned versions of the ‘franieshifting region’ in the ICT34.5 coding 
sequence
(A) Original sequence for HSV-1 strain 17+ (Perry and McGeoch, 1988), shown as 
residues 814 to 832 of the rightward 5’ to 3’ strand of genomic DNA. (B). Sequence of the 
strain 17+ Xhol £ and new BamHI 1& fragment clones. The bases marked in the sequence 
gel (fig.3.1.) are highlighted by a bar (i— i). The alteration of G-to-C at np 818 and more 
importantly the absence of CG al np 823 and 824 can be clearly seen in l'ig.3.1..(C) Strain 
F version of the ICP34.5 sequence from Chou and Roizman (1990) with their numbering. 
The dots in the second and third sequences represent introduced padding characters. 
Differences between successive sequences are underlined and marked by vertical lines.
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the oligonucleotide to the HSV-1 sequences within the starting template, and an alternative 
approach, described below, was adopted.
3.1.3. Construction of the recombinant plasmid pEAlO.
The 1.46kb Alul/Rsal sub-fragment of HSV-1 BamHI k, which had been cloned into M13 
for sequencing was also cloned into the Smal site of pGEM 3zf(-), to produce the 
recombinant plasmid pGEM34.5 (fig.3.3.).
The RL1 gene contains a unique Ncol restriction enzyme site which contains the initiating 
ATG of the gene and ~95bp downstream from this there is a unique BslEll restriction 
enzyme site. The plasmid, pGEM34.5, was digested with Ncol and BstEII (recognition 
sites for these enzymes are not found in pGEM 3zf(-)) and a synthetic double-stranded 
oligonucleotide was cloned in (fig.3.4.). This oligonucleotide had overhangs 
complementary to BstEII and Ncol restriction enzyme sites and was identical to the RL1 
sequence with the exception of a 6bp insert which introduced an in-frame stop-codon in 
the ICP34.5 ORF leading to the potential production of a truncated protein of 4 amino 
acids. The insert also contained a recognition site for the restriction enzyme Xbal, so that 
recombinant plasmids and viruses could be easily identified.
To ensure that the stop-codon in pEA.10 was in the correct place a fragment of 
approximately 760bp in size which ran from the EcoRI site in the poly linker of pGEM 
3zf(-) to the unique BstEII site at the 5' end of RL1 was cloned from pEA.10 (fig 3.3.). 
The fragment was blunt-ended and cloned into the Smal site of M13mpl8, and sequenced 
using the universal M 13 primer (section 2 .2 .25.) to confirm ilu* position of the .stop-codon 
relative to the initiating ATG of the gene, 'flic .sequence of the plasmid pEA.10 in the 
region around the initiating ATG of RL1 is shown in fig.3.5.. The fragment was inserted 
into the vector in an orientation such that the BstEII site is adjacent to the M13 universal 
primer hybridization site. Thus the non-coding strand of RL1 is read. The positions of the
j
6bp insert and initiating ATG (CAT as the non-coding strand is being read) of the gene arc
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Figure 3.3. Construction of pGEM34.5
A 1.46kb Alul/Rsal fragment (np 125074-np 126530) was isolated from the plasmid 
pBamks. This was cloned into the Smal restriction enzyme site, in the multicloning site of 
pGEM 3zf(-), creating the plasmid pGEM34.5.
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123459
Alul
125074
RL1 I'AG: 125111
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RE I ATG (Ncol): 125859pBamK
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Figure 3.4. Sequence of the synthetic double-stranded oligonucleotide used to 
construct pEA.10.
pGEM34.5 was digested with Ncol and BstEII and a synthetic double-stranded 
oligonucleotide was cloned in. This oligonucleotide had overhangs complementary to 
BstEII and Ncol restriction enzyme sites as indicated and was identical to the RL1 
sequence except that it contained a 6bp insert (underlined in bold ) which introduced an in- 
frame stop-codon in the RL1 ORF and contained a recognition site for the enzyme Xbal 
(T*c t a G_A). The initiating ATG and inserted stop-codon are marked with a bar (— ).
Ncol 'sticky ends'
5' C-ATG-GCC-CGC-CTC-TAO-A GC-CGC-CGC-CAT-CGC-GGC-CCC-CGC-CGC- 
3' CGG-GCO-GAG-ATC-TCG-OCO-GGG-GTA-GCG-CCG-GGG-GCG-GCG-
CCC-CGG-CCG-CCC-GGG-CCC-ACG-GGC-GCC-GTC-CCA-ACC-GCA-CAG-TCC-
GGG-GCC-GGC-GGG-CCC-GGG-TGC-CCG-CGG-CAG-GGT-TGG-CGT-GTC-AGG-
CAG 3’ (91 mer)
GAC-CAT-TG 5' (92 mer) 
BstEII 'sticky ends'
Figure 3.5. DNA sequence of pEA.10 in the region of the initiating ATG of KLI.
A BstEII/EcoRI subfragment of pEA.10 containing the 92bp replaced sequence was 
purified, blunt-ended and cloned into the Smal site of M Bmp 18. It was then sequenced 
using a M13 universal primer to confirm the position of the 6bp insert relative to the 
initiating ATG (CAT as the non-coding strand is being read) of the gene. The entire 
sequence of the 92bp oligonucleotide was identical to the wild-type sequence with the 
exception of the 6bp insert. This gel shows the sequence of the non-coding sliand.
The sequence of the non-coding strand is read here, thus the 3’ end of RLI is at the bottom 
of the gel and the 5’ end at the top.
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indicated, confirming correct insertion of the stop codon. The remainder of the gel shows 
that the oligonucleotide insert is identical to the wild-type sequence which it has replaced.
3.1.4. Construction of a HSV-1 strain 17+ variant, 1771, containing a stop codon at 
the start of RL1.
The plasmid, pEA.10, was linearised for transfection by digestion with the restriction 
enzyme BamHI which cuts once in the multi-cloning site of the vector and was transfected 
onto BHK21/C13 cells with intact HSV-1 strain 17+ DNA as described in section 2.2.17.. 
One hundred and forty-four single plaques were isolated and analysed by preparation of 
32p labelled viral DNA (section 2.2.19.). DNA from each plaque isolate was screened by 
digestion with the restriction enzyme Xbal. Recombinant virus will contain 2 extra Xbal 
restriction enzyme sites, one 51 lbp from the L terminus and the second 51 lbp from the L- 
S junction, (fig.3.6.). This will result in digestion of the 0.5M £ and d bands to 1M bands, 
£ ’ and 51 lbp smaller than the respective wild-type bands and 2, 0.5M bands each of 
51 lbp. The corresponding L-S junction fragments disappear being digested into the 1M 
bands g* and jl’ and 2 new equivalent 0.5M bands and h \  |S1+ 51 lbp, running between 
£ and £ (see fig.3.7.). Due to the large size of the fragments, these alterations, with the 
exception of the loss of a will not significantly alter the Xbal profile. Because mixed 
plaques would not result in the loss of the a band it became obvious that the use of Xbal 
alone was not the best choice for analysis of potential recombinants. As no positive clones 
were identified from the first 144 plaque isolates , the transfection was repeated. This time 
DNA from plaque isolates was double-digested with Xbal and Barnl II where recombinant 
virus will have a more obvious restriction enzyme profile.
Digestion of HSV-1 strain 17+ with BamHI and Xbal gives essentially a BamHI 
restriction enzyme profile with the following minor alterations: BamHI £ is cleaved into 2 
fragments, 1 of 7728bp (e°)which runs just below BamHI g  and another of 1185bp which 
runs between BamHI £’ and d \  BamHI i is cleaved into 2 fragments, I of 6059bp 
(i°)which runs between j and k and another of 581 bp which runs between j ’ and k \  In
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Figure 3.6. Position of the Xbal restriction enzyme sites in the genome of 1771.
This figure shows the HSV-1 strain 17+ genome in the prototype orientation (A). The 
wild-type Xbal restriction enzyme sites are marked and the two additional sites which have 
been introduced into the 1771 genome are indicated (X). (B) Hpal map of HSV-1. (C) 
BamHI map of HSV-1. The dotted vertical line indicates the position of the L-S junction.

Figure 3.7. Xbal restriction enzyme profile of 1771.
Autoradiograph of Xbal DNA digest of HSV-1 strain 17+ and variant 1771 with 2 exta 
Xbal sites 51 lbp from the L terminus and L-S junction. Novel bands are designated by tie 
letter of the band from which they were derived plus a prime symbol. Lanes are labelled it 
the top of each track.
The most obvious difference between the 2 digests is the loss of Xbal a in 1771 (indicaud 
by an arrow).
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addition BamHI i ’ and Bam HI h.’ are cleaved into 2 fragments (107+555bp and 
921+392bp respectively), but these alterations can not be seen on the 0.8% agarose gels 
used.
Digestion of a recombinant containing the additional Xbal sites at np 511 and np 125850 
with BamHI and Xbal gives a similar profile, except that, because of the additional Xbal 
site, BamHI £ is digested into 2 bands of 51 lbp and 2391 bp (s’). The s containing L-S 
junction BamHI k is digested to give 2 fragments, one which is also 239lbp in size and the 
other, the new L-S junction, which is 3598bp (q’) in size and migrates above BamHI q. 
One such isolate was identified (fig.3.8.) and its structure confirmed by Southern blotting a 
BamHI/Xbal digest, using random primed BamHI k as a probe (fig.3.9.). Confirmation of 
the correct Xbal profile (see above) was also determined (fig. 3.7.)
This isolate, which was designated 1771 was plaque-purified a further 3 times before 
growing a stock
3.1.5. Western blotting confirms that 1771 does not produce ICP34.5.
Confirmation that 1771 does not produce 1CP34.5 was provided by Western blotting (fig
3.10.).
Three wild-type HSV-1 strain 17+ and 3 1771 plaque isolates were isolated at random, 
protein extracts prepared from infections with each of the plaques and Western blotted 
(section 2.2.38.). 1CP34.5 production was assayed using the polyclonal anliserum against 
ICP34.5 ^section 3.3.5.) at a 1/15 dilution. ICP34.5 was delecled in wild-type 11SV- 1 
strain 17+ infected cell extracts, whereas ICP34.5 was absent in cells which had been 
infected with 1771. This confirmed the sequencing data that the slop-codon had been 
inserted in-frame in the RL1 ORF.
3.1.6. Neurovirulence of 1771
The neurovirulence of 1771 was determined by estimation of its LD50 value in B ALB/c 
mice compared to the wild-type parental HSV-1 strain 17+ and the RL1 deletion mutant
Figure 3.8. BamHJ/Xbal restriction enzyme profile of 1771.
Autoradiograph of BamHI/Xbal digest of viral DNA. 1771 contains two novel Xbal sites 
51 lbp from the L terminus and L-S junction. Missing bands arc designated (*). Novel 
bands are indicated (►) and are designated by the letter of the band from which they were 
derived plus a prime symbol (‘)- The largest bands produced following digestion of BamHI 
e and i with Xbal are designated e° and i° respectively. Lancs are labelled at the top of each 
track.
17+ 1771
«q*
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Figure 3.9. Southern blot of 1771 using wild-type HSV-1 strain 17+ B ami II k as a 
probe.
Autoradiograph of a Southern blot in which wild-type HSV-1 strain 17+ BamHI k was 
labelled by random priming and used as a probe. The DNA was digested with BamHI and 
Xbal and the fragments separated on a 0.8% agarose gel. Lanes are labelled at the top of 
each track.
Digestion of 17+ with BamHI/Xbal gives an identical profile to that seen with BamHI 
alone, namely detection of k, U and On digestion of 1771 with BamHI and Xbal, BamHI 
k disappears and two novel bands appear; one migrates 51 lbp above BamHI q ( a ’) and the 
other migrates 51 lbp below £ (s’ ). In addition BamHI £ is cleaved into 2 fragments, one of 
51 lbp, which cannot be detected on the percentage gel used and the other £’.
The presence of additional ‘a’ sequences in the novel L-S junction leads to the laddering 
above q.\ This is a consistent finding with L-S junction fragments (Davison and 
Wilkie,1981). The background band running above BamHI k in both 17+ and 1771 is 
consistently seen when probing BamHI digests with BamHI k (MacLean, A., et. al., 1991).
17+ 1771
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3.10. Western blot analysis of 1771.
Detection of ICP34.5 by Western blot analysis, using the polyclonal antiseium (at a 
dilution of 1/15) which had been raised against the E.coli -expressed ICP34.5. Molecular 
weight markers in (kDa) and the position of ICP34.5 are shown on the right hind side. 
Lanes are labelled at the top of the gel.
In HSV-1 strain 17+, ICP34.5 corresponds to a band of 37kDa in size.
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1716. Twenty-five ul aliquots of different doses of strain 17+, 1771 and 1716 were 
inoculated into the left cerebral hemisphere of 3-week old BALB/c mice. Deaths from 
encephalitis were scored lip to 21 days post inoculation and the results are shown in table
3.1. The wild-type parental HSV-1 strain 17+ was inoculated at doses of 10* and 10^ 
p.f.u./mouse. At a dose of 10^ no mice survived, whereas, at a dose of 101, there were 2 
surviving mice giving a LD50 value of 10 p.f.u./mouse. The RL1 deletion variant 1716 
was inoculated at doses of 10  ^ and 10^ p.f.u./animal. As anticipated, (MacLean, A. et al., 
1991a) no animals died at any of the doses, giving a LD50 value of >10^ p.f.u./animal. 
The recombinant virus 1771 did not produce 1CP34.5, as demonstrated by Western 
blotting (section 3.1.5.), it was therefore anticipated that this mutant would he essentially 
non-neurovirulent compared to the wild-type virus, HSV-I strain 17+ and was thus 
inoculated at doses of 10  ^ and 10^ p.f.u./mouse. At these doses 110 animals died, giving a 
LD50 value o f> 106 p.f.u./animal ,thc same as 1716.
3.1.7. Growth of 1771 in vivo.
The HSV-1 strain 17+ variant 1716, and the HSV-2 strain HG52 variant JH2604 have 
been shown to be non-neurovirulent following intracerebral inoculation of mice, due to an 
apparent failure to replicate in mouse brain (Taha et al., 1989a, MacLean, A. et al., 1991a) 
and, in the case of JH2604, failure to produce necrotizing encephalitis (Taha et al., 1990). 
To determine if this inability to replicate was due solely to a failure to produce 1CP34.5, 
the in vivo growth properties of 1771 were examined. Samples of strain 17+ (1()2 p.f.u.) 
and 1771 (105 p.f.u.), were separately injected into the left cerebral hemisphere of 3-wcck 
old BALB/c mice. At various times post-inoculation, two mice per virus were killed, their 
brains removed, homogenized and sonicated in PBS/calf. The final volume was recorded, 
before storing at -70°C. The virus litre in each brain was calculated separately and the 
mean obtained. On day 5, only 1 mouse inoculated with HSV-1 strain 17+ was alive. 
Thus, the HSV-1 strain 17 day 5 timepoint represents the litre of virus from only 1 animal. 
The final litres (fig.3.11.) were calculated as p.f.u./mouse. 'flic parental IISV-I strain 17+
Table 3.1. Neurovirulence of 1771 following intracerebral 
inoculation of 3-week old BALB/c mice.
LD50 (p.f.u./ 
mouse)
lose
virus
2/4 4/4 ND ND ND ND
0/4 0/4ND ND ND >101716 ND
0/4 0/4ND ND ND >101771 ND
*no. of dcalhs/no. injcelcd 
ND= not done.
Figure 3.11. In vivo growth of 1771
The replication kinetics of HSV-1 strain 17+ and 1771 were examined in vivo..Three week 
old BALB/c mice were inoculated intracerebrally into the left cerebral hemisphere with 
10^ (HSV-1 strain 17+) or 10^ (1771) p.f.u./mouse in 25ul PBS/calf. At the times 
indicated post inoculation 2 mice/timepoint were sacrificed (except for HSV-1 strain 17+ 
at day 5- where only 1 mouse had survived) their brains removed, homogenised and the 
resulting homogenale titrated for virus on BHK21/C13 cells. Pitres are expressed as 
p.f.u./mouse. Each timepoint represents the mean litre of two animals (except HSV-1 strain 
17+ at day 5, which represents only 1 animal).
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Figure 3.12 (a). One-cycle growth curve of 1771
The one-cycle growth characteristics of 1771 were compared to wild-type strain 17+ on 
BHK21/C13 cells. Cells were infected at a multiplicity of 10 p.f.u./cell, and following 
absorption at 37°C for lhr, the monolayers were washed twice with PBS/calf , overlaid 
with ETC 10 and incubation continued at 37°C. Plates were harvested at 0, 2, 4, 6, 8, 12 
and 24hrs post-infection and titrated on BHK21/C13 cells.
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Figure 3 12 (b). Multi-cycle growth curve of 1771.
The multi-cycle growth characteristics of 1771 were compared to the wild-type parental 
strain 17+ on BHK21/C13 cells. Cells were infected at a multiplicity of 0.001 p.f.u./cell, 
and following absorption at 37°C for lhr, the monolayers were washed twice with 
PBS/calf and incubation continued at 37°C. Plates were harvested at 0, 2, 4, 6, 12, 24, 36, 
48 and 72 hrs post-infection and titrated on BHK21/C13 cells.
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titre rose rapidly following intracercbral inoculation, reaching a litre of 1x10^ p.f.u./animal 
by day 4-5. In contrast, no replication was detectable in 1771 inoculated animals and the 
input virus was rapidly cleared until by day 3 post-inoculation there was no delectable 
virus (<10p.f.u.).
3.1.8. Growth of 1771 in vitro.
Analysis of the in vitro growth characteristics of 1771 relative to wild-type HSV-1 strain 
17+ was carried out on BHK21/C13 cells. Cells were infected with either 10 p.f.u./cell 
(one-cycle growth experiment), or 0.001 p.f.u./cell (mulli-cycle growth experiment) of 
HSV-1 strain 17+ and 1771. At various times post-infection plates were harvested and 
virus titres calculated by titration on BHK21/C13 cells.
As can be seen from figure 3.12., 1771 grew identically to the wild-type virus in both one- 
cycle (fig.3.12a.) and multi-cycle growth experiments (fig.3.12b.).
3.1.9. Marker rescue of the lesion in 1771.
To show that neurovirulence could be restored to 1771 by rescuing back the wild-type 
RL1 gene, rescuants were produced by the method of in vivo marker rescue (section 
2.2.17.)
To produce arevertantof 1771 (1771R) lug 1771 DNA was transfected onto BHK21/C13 
cells with 1-, 10- and 100- fold molar ratios of the wild-type BamHl k fragment, 
containing RL1. After 2-3 days, the plate in which c.p.e. was most extensive was 
harvested and 25ul of 10" I and 10_2 dilutions (approximately 11)4 to 10^ p.f.u.) injected 
intracerebrally into groups of 4, 3 week old BALB/c mice. Four to six days post­
inoculation, most of the mice began to show signs of neurological disorder (ruffled fur, 
hunched back, tendency to sit alone, lack of interest in food). At this point they were killed 
to prevent any further unnecessary suffering and their brains removed. The brains from 2 
mice were homogenised in PBS/calf, titrated on BHK21/C13 cells and single plaques 
isolated. Small scale stocks of virus were grown in Linbro wells and ^2p labelled DNA
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prepared and analysed as has been previously described (section 2.2.19.). One isolate with 
a wild-type restriction enzyme profile was chosen (data not shown). Three further rounds 
of plaque purification look place before growing up a virus slock. A parallel control 
experiment was carried out using virus from a transfection carried out with 1771 DNA 
alone. In this case no mice died.
3.2 Construction of a HSV-1 strain F ICP34.5 deletion variant.
3.2.1. Introduction.
In an attempt to detect ICP34.5 from HSV-1 strain 17+ infected cells, antisera were raised 
against peptides corresponding to different regions of the predicted RL1 open reading 
frame encoded protein (fig 3.13.). Until recently (MacKay et al., 1993), none of these 
peptide antisera were successful in identifying ICP34.5 in HSV-1 strain 17+ infected cell 
extracts , although one directed against a lenmer of the PAT trimer repeat strongly 
recognised ICP34.5 in HSV-1 strain F infected cell extracts. To confirm the specificity of 
this antiserum, to show that loss of ICP34.5 correlated with a loss of neurovirulence and to 
help study cellular localization of ICP34.5, we decided to construct a HSV-1 strain F 
mutant with a deletion in RLl.This mutant will subsequently be referred to as FI 1.
3.2.2. Construction of F ll.
Construction and characterization of the HSV-1 strain 17+ RL1 deletion niuiant 1716 has 
been previously described (MacLcan, A., et al, 1991a). Dideoxynucleolide sequence 
analysis of this mutant revealed that it was deleted by 759bp in both copies of the long 
repeat region of the genome (fig.3.14.). The deletion removes one complete copy of the 
18bp DR1 element of the 'a' sequence and terminates 1105bp upstream from the 5' end of 
IE gene 1. The novel L-S junction fragment BamHI k of 1716 has previously been cloned 
into pGEM 3zf(-) using standard procedures (Maniatis et al., 1982) and was supplied by 
Dr.A. MacLean. The RL1 deletion from 1716 was marker transferred to HSV-1 strain F by
91
3.13. Antisera raised against peptides from HSV-1 RL1.
Antisera were raised against synthetic oligopeptides from 7 different regions of the 
predicted RL1 encoded protein in an attempt to detect HSV-1 strain 17+ ICP34.5. The 
amino acid sequences of these peptides are listed in the table. Their position in relation to 
the RL1 ORF are indicated in the diagram underneath. Only one, which was raised against 
a tenmer of the PAT repeat detected ICP34.5 in HSV-1 strain F and HSV-1 strain 17+ 
infected cell extracts (MacKay et al., 1993). IB (Br.212) and 2A (L.2I 1) also recognised 
E.coli -expressed ICP34.5 (fig.3.23) although they did not detect ICP34.5 in HSV-1 
infected cell extracts. No sera recognised an 1CP34.5 homologue in HSV-2 strain HG52.
Antipeptide sera Sequence Sera tested and result (a) 
HSV-1 strain F HSV-1 strain 17
1A Y AARL ARRGS W ARE - -
IB (YAARLARRGSWARE)8K7A - -
2A YEAVIGPCLGPEAR - -
2B (YE A VIGPCLGPE AR) 8 K7 A - -
3Ad [(PAT)7]8K7A - -
3Be [PAT)7]8K7A +/- b -
4 (ATP)ioC + + c
5 (ARARALARGAGPANSV)8K7A - -
6 (MARRRRHRGPRRRPRP)8K7A - ND
7 (PGPTGAVPTAQSQVT)8K7A - ND
a) tested in Western blots and immunoprecipitation.
b) faint, the better of the two sera works at 1:10 dilution on Western blot only.
c) these antisera recognise HSV-1 strain 17+ ICP34.5 by Western blot only.
d) these antisera was raised in Half Sandylop rabbits.
e) these antisera were raised in New Zealand White rabbits.
6 7 3,4
NH.
AT(10
COOH
5 amino acid substitutions
HSV-l strain F
263a.a.
conserved region
NH, fAT (5) COOH
IISV-I strain 17+
248a.a.
Figure 3.14. Construction of F l l ,  1716a and FI la.
(A) HSV genome in the inverted long (II) orientation. (B) An enlargement of Bam HI 1^  
The DR1 element of the ‘a’ sequence, RL1, RL2, Alul (A) BamHl (B) and Dral (D) 
restriction enzyme sites are marked. The position of the Alul/Dral fragment used as a 
probe in fig.3.18 is indicated below the line, as is the deletion in 1716/F11. (C) The 
1716/FI 1 deletions were rescued using Xba I g. The dashed line is used to indicate that the 
Xba I g extends beyond the Bam HI site shown.
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co-transfection of intact HSV-1 strain F DNA with 1716 BamHI k, linearized by digestion 
with Xbal which cuts in the vector multi-cloning site. Single plaques were isolated and 
positive clones identified by restriction enzyme analysis of 32p labelled viral DNA. 
Plaque isolates were first screened by looking for a deletion in the terminal fragment Xbal 
g  (fig.3.6 ., 3.15). The deletions in the much larger terminal fragment Xbal d and L-S 
junction fragments a  and & are not obvious. Six positive clones were identified one of 
which was designated the prototype FI 1.. Confirmation that the deletion in FI 1 was in the 
correct region of Xbal g was provided by fine mapping with several other restriction 
enzymes. For later analysis 2 wild-type HSV-1 strain F plaque isolates were also chosen 
and analysed by restriction endonuclease digestion to show they had no obvious genomic 
alterations.
Figure 3.16. shows the Hpal restriction enzyme profile of FI 1. Hpal I is missing and a 
novel band is observed, running just below Hpal rn. Because of site alterations Hpal I of 
HSV-1 strain F corresponds to Hpal m of HSV-1 strain 17+. Again the deletions in the L- 
S junction fragments a and il are not obvious. The size of the deletion in I Ipal I of FI I and 
Hpal in of 1716 as expected is the same.
The BamHI restriction enzyme profile of FI 1 is shown in lig.3.17. In this case the most 
noticable difference between the mutant and wild-type virus is the loss of the L-S junction 
fragment BamHI k and the appearance of a novel band corresponding to a deleted k which 
runs just above BamHI I  Bands running just above BamHI k and the novel k are due to 
the presence of additional ‘a’ sequences. The L terminal fragment BamHI $ is also missing 
and is replaced by a novel band corresponding to deleted a which eo-migrates with the uZy 
doublet. BamHI a and k of HSV-1 strain F have a slightly higher Mr than those of HSV-1 
strain 17+. (Refer to fig.3.6. for Hpal and BamHI restriction enzyme maps of IISV-1 strain 
17+).
F ll was plaque purified a further 3 times before growing up a virus stock. The two wild- 
type isolates - F26 and F120 - were also plaque purified 3 times prior to preparation of 
virus stocks.
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Figure 3.15. Xba I restriction enzyme profile of FI 1.
Autoradiograph of Xba I digest of viral DNA. F26 and F I20 are plaque-purified wild-type 
strain F isolates; FI 1 is the strain F ICP34.5 deletion mutant. Missing bands are designated 
(*). Novel bands are indicated by an arrowhead, and are designated by the letter of the 
band from which they were derived plus a prime symbol ('). Lanes are labelled at the top of 
each track.
17 1716 F11 F120 F26 F
3.16. Hpal restriction enzyme profile of FJ1.
Autoradiograph of Hpal digest of viral DNA. F26 and FI 20 are plaque-purified wild-t)pe 
isolates; F l l  is the strain F ICP34.5 deletion variant. Missing bands are indicated by an 
arrowhead. Novel bands are marked (•). HSV-1 strain F bands are labelled on the left-haid 
side and HSV-1 strain 17+ bands are labelled on the right-hand side. Lanes are labelled at 
the top of each track.
F F120 F26 F11 1716 17+
t
Figure 3.17. BamHI restriction enzyme profile of F ll.
Autoradiograph of a BamHI digest of viral DNA. F26 and F I20 are plaque-purified wild- 
type isolates; FI 1 is the strain F ICP34.5 deletion variant. Missing bands are indicated by 
an arrowhead. Novel bands are marked (•). HSV-1 strain 17+ bands are marked on the 
left-hand side, and HSV-1 strain F bands are marked on the right-hand side. Lancs arc 
labelled at the top of each track.
17+ 1716 F11 F120 F26 F
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Results
3.2.3 Detection of RL1 by Southern Blotting.
Confirmation that F ll  and 1716 did not contain RL1 coding sequences was further 
provided by Southern blotting HSV-1 DNA digested with Alul and Dial (fig.3. IX.). A gel- 
purified AluVDral sub-fragment of HSV-1 strain 17+ BamHI k (np 125074-npl25989) 
(fig.3.14.) which encompasses the entire RL1 ORF was used as a probe. The strain 17+ 
RL1 containing Alul/Dral fragment is smaller than that of HSV-1 strain F and the HSV-1 
strain F isolates F26, F I20 and F11R (section 3.2.5). This is in agreement with the smaller 
size of RL1 which leads to a lower Mr protein product (MacKay et al., 1993). As expected 
FI 1 and 1716 do not hybridize to the Alul/Dral probe confirming they lack llie RL1 ORF. 
Recombinants 1716a and FI la are discussed in 3.2.5..
3.2.4. Neurovirulence of Fl l .
Experiments to determine the neurovirulence of F ll compared to its parent HSV-1 strain 
F, HSV-1 strain 17+ and 1716, by estimation of their LD50 values in BALB/c mice were 
carried out. Twenty-five ul aliquots of F, FI 1 17+ and 1716 were inoculated into the left 
cerebral hemisphere of B ALB/c mice. Deaths from encephalitis were scored up to 21 days 
post- inoculation and the results are shown in table 3.2.. HSV-1 strain F and strain 17+ had 
LD50 values of <10^ p.f.u./animal. However, none of the mice injected with cither 1716 
or F l l  died even with an inoculum as high as 1()7 p.f.u./mouse, giving a LD50 value of 
>10? p.f.u./mouse. It has previously been shown (MacLean, A. et al., 1991a), that the non- 
neurovirulent phenotype of 1716 is caused by its inability to grow, when injected 
inlracercbrally into the mouse brain. As F ll contains exactly the same deletion in its 
genome, it would be reasonable to assume that it also is unable to replicate when injected 
intracerebrally into the mouse brain and hence is unable to cause encephalitis.
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3.18. Detection of RL1 by Southern blotting
HSV-1 DNA of wild-type and recombinant viruses was digested with Alul/Dral and 
fragments separated on a 1.2% agarose gel. RL1 coding sequences were detected using a 
random primed Alul/Dral (np 125074-np 125989) sub-fragment of HSV-1 strain 17+ 
(fig.3.13.)* Molecular weight markers are on the left-hand side. Lancs arc labelled at the 
top of each track. The position of the Alul/Dral fragment hybridizing to the probe is 
indicated by an arrow.
F26 F120 F F11R 17+ 1716 F ll 1716a F1la
2 0 3 6  —
1636  —
1018 —
506 / 517—
Table 3.2. Neurovirulence of FI 1 following intracerebral
inoculation of 3-week old BALB/c mice.
dose
virus 10 2 10 3 10 4
5
10
6
10 10 7 LD50(p.f.u./mouse)
+
17
*
4/4 4/4 ND ND ND ND <10 2
1716 ND ND ND 0/4 0/4 0/4
7
>10
F 4/4 4/4 ND ND ND ND <10 2
F ll ND ND ND 0/4 0/4 0/4
7
>10
* no. of deaths/no. injected. 
ND= not done.
Results
3.2.5. Marker rescue of the lesion in Fll .
To show that neurovirulence could be restored to F ll , by rescuing the RL1 gene, wild- 
type rcscuants were produced by in vivo  marker rescue as described in section 2.2.27c., 
except that to produce the F ll  rescuant (F11R), lug F ll  DNA was transfected onto 
BHK21/C13 cells with 1-, 10- and 100- fold excess amounts of the wild-type HSV-1 strain 
F Xbal g restriction enzyme fragment, which contains the intact RL1 gene. After 2-3 days 
the plate in which c.p.e. was most extensive was harvested and serial 10-fold dilutions 
made. The 10'1 and 10"2 dilutions (containing approximately 10^-10^ p.f.u. ) were then 
injected inlracerebrally into groups of 4, 3-week old BALR/c mice. When the mice died 
the brains from 2 were homogenised in 1ml PBS/calf, single plaques isolated and 32p 
labelled viral DNA prepared and analysed. One isolate with a wild-type profile (figs.3.15.-
3.18.) was chosen for further plaque purification, before preparation of a stock.
MacKay et al. (1993) have previously observed, using an antiserum raised against a 
tcnmcr of the PAT repeat contained in the 1CP34.5 sequence, a significant difference (>30 
fold) between the sensitivity of detection of ICP34.5 of 1ISV-1 strain F compared to 1ISV- 
1 strain 17+. This could be due to different antibody affinities for ICP34.5 of the 2 strains, 
or different levels of protein accumulation in infected cells. If the result of a differential 
level of accumulation it could be due to either a c/.v -acting effect of the RIJ sequence (eg. 
enhanced expression or polypeptide stability) or a trans -acting effect of other virus 
proteins. In an attempt to at least partially answer this question, 2 other recombinant 
viruses were also produced using the method of in vivo marker rescue (fig.3.14.).
FI la was generated by co-lransfecting FI I DNA with a I ISV-1 strain 17 1 fragment (Xbal 
g l spanning the RL1 gene and isolating a plaque isolate with a wild-type DNA profile. 
Similarly, 1716a arose from a cotransfection of 1716 DNA with the same HSV-1 strain F 
fragment (Xbal g) used to construct FI 1R. So, essentially, FI la has a strain F background, 
but contains the strain 17+ RL1 promoter and coding sequences, whereas 1716a contains 
the strain F ICP34.5 promoter and coding sequences in a strain 17+ background. The 
profile of these recombinants was analysed by restriction enzyme analysis and Southern
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blotting. Figure! 3.18 shows a Southern blot of 1716 and FI la digested with Alul/Dral and 
probed with the appropriate random primed Alul/Dral fragment (fig.3.14.). As expected 
the RL1 coding fragment is detected.
The question of differential detection of ICP34.5 of HSV-1 strain F compared to HSV-1 
strain 17+ will be referred to again in a later section (3.3.7.)
3.2.6. Neurovirulence of 1716a and FI la
Experiments to confirm that a wild-type phenotype had been restored to 1716a and FI la 
through recombination with RL1 sequences from HSV-1 strain F and IISV-I strain 17+ 
respectively were carried out by estimation of their LD50 values in BALB/c mice (table 
3.3). It was anticipated that both 1716a and FI la would be neurovirulent following 
intracerebral inoculation of mice. In our laboratory we routinely find that the LD50 value 
of mice injected with HSV-1 strain F is around 10-fold higher than that of mice injected 
with HSV-1 strain 17+, therefore, FI la, which has a HSV-1 strain F background was 
injected al doses of 1()2, 1()3 and 0)4 p.f.u./mouse, whereas 1716a, which has a HSV-1 
strain 17+ background was injected at doses of 1()1, 1()2 and 1()3 p.f.u./mouse. However, 
both 1716a and FI la  had similar LD50 values of 3xl()2 and 1()2 p.f.u./animal 
respectively, although these were slightly higher than the value obtained for HSV-1 strain 
17+ (7 p.f.u./animal). In this experiment 4 animals were injected with IISV-I strain F at a 
dose of 1()2, however none of the animals died. Subsequent titration of (he virus inoculum 
revealed that only 101 p.f.u. had been injected per animal. It has previously been found in 
our laboratory (Dr L. Robertson, personal communication) that this dose of IISV-I strain 
F is not consistently lethal for mice, which has a LD50 value between 10  ^ - 10^ 
p.f.u./mouse.
3.2.7. Latency characteristics of Fl l .
The ability of F l l  to reactivate from latency was examined using the mouse footpad 
model previously described by Clements and Subak-Sharpe (1983, 1988). Groups of 4, 4
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Table 3.3. Neurovirulence of 1716a and F lla  following
intracerebral inoculation of 3-week old BALB/c mice.
virus
1
10
2
10
3
10
4
10
^D50 (p.l'.u./ 
nouse)
+
17
*
3/4 4/4 ND ND 7
F lla ND 1/4 4/4 4/4
2
3x10
1716a 0/4 2/4 4/4 ND
2
10
F 0/4 ND ND ND
l
>10
*no. of deaths/no. injected 
ND= not done.
Results
week old BALB/c mice were inoculated in the right rear footpad with varying doses of F, 
F l l ,  1716 and 17+ and were monitored daily for signs of illness or death. Six weeks post 
inoculation, mice were killed and the 9 ipsilateral ganglia supplying ihe footpad screened 
as described in section 2.2.29d.. The results are summarised in figure 3.19.
At a dose of 10^ p.f.u./mouse, HSV-1 strain 17+ was found to be the most efficient at 
reactivating from latency, with a maximum frequency of -55% explanted ganglia 
reactivating by 8 days post explant. Comparatively HSV-1 strain F showed poor 
reactivation when injected at an equivalent dose- reaching a maximum reactivation 
frequency of -14%, 9 days post explanlalion (fig. 3.19a.). Because of this difference in 
reactivation frequency between the parental wild-type viruses 17+ and F, it was considered 
more valid to compare FI 1 with F and 1716 with 17+.
Taking this into account, F ll  did not show any significant difference in reactivation 
kinetics compared to HSV-1 strain F. At a dose of 10  ^ p.f.u., FI 1 reached a maximum 
reactivation frequency of -7.5%, 10 days post explanlalion. The reactivation frequency 
was found to be dose dependent. When injected at a dose of 10  ^ p.f.u., FI 1 reached a 
maximum reactivation frequency of -10% 9 days posl cxplnnl. and al 10? p.f.u., reached a 
maximum of 25% 8 days post explanl. Similarly, Ihe reactivation of 1710 from latency is 
dose-dependent (Robertson et al., 1992). As has been previously shown, 1716 was 
impaired (15% at a dose of 10? p.f.u./animal) in reactivating from latency compared to the 
wild- type virus (55% at a dose of 10  ^ p.f.u./animal) HSV-1 strain 17+ (fig. 3.19a.) 
(Robertson et al., 1992). In fig. 3.19a. the reactivation characteristics of F, FI I, 17+ and 
1716 at the highest doses of each inoculated are compared. In fig. 3.19b., the dose 
dependent reactivation frequency of F / FI I is shown.
3.2.8. In vitro growth characteristics of Fl l .
Analysis of the in vitro growth characteristics of the HSV-1 strain F variant FI 1 and the
I
| rescuant F11R was carried out on BHK21/C13 cells, using HSV-1 strain 17+ and 1716 as
i
controls. In both one- cycle (fig. 3.20(a).) and multi-cycle (fig.3.20(b).) growth
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3.19. Latency characteristics of Fl l .
The latency characteristics of F ll  were examined using the mouse footpad model. Groups 
of 4 ,4-week old BALB/c mice were inoculated in the right rear footpad with varying doses 
of HSV-1 strain F, FI 1 1716 and HSV-1 strain 17+. Six weeks post-inoculation, mice were 
killed and the 9 ipsilateral ganglia supplying the footpad removed and screened every 
second day for the presence of infectious virus. The frequency of ganglia reactivating at 
each timc-point was calculated as a percentage of the total number of ganglia explanted, 
for each virus at each dilution.
(a). This shows the reactivation frequency of each virus at the highest dose used (1()5 p.f.u. 
HSV-1 strain F and HSV-1 strain 17+; 10? p.f.u. FI 1 and 1716).
(b). The dose dependent reactivation of HSV-1 strain F and F ll.
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Figure 3.20 (a). One-cycle growth curve of FI 1
One-cycle growth experiments of HSV-1 strain 17+, 1716, the wild-type rescuant FI 1R 
and F l l  were carried out in BHK21/C13 cells. Cells were infected at a multiplicity of 10 
p.f.u./cell, and following adsorption at 37°C for 1 hr, the monolayers were washed twice 
with PBS/calf , overlaid with ETC 10 and incubation continued at 37°C. Plates were 
harvested at 0, 2, 4, 6 , 8, 12 and 24 hrs post-infection and titrated on BHK21/C13 cells.
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Figure 3.20 (b). Multi-cycle growth curve of FJ1
Multi-cycle growth experiment of HSV-1 strain 17+, 1716, the wild-type rescuant F11R 
and F l l  were carried out on BHK21/C13 cells. Cells were infected at a multiplicity of 
infection of 0.001 p.f.u./cell, and following adsorption at 37°C for lhr, the monolayers 
were washed twice with PBS/calf and incubation continued at 37°C. Plates were harvested 
at 0, 2, 4, 6, 12, 24, 48 and 72hrs post-infection and titrated on BHK21/C13 cells.
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experiments 17+ and 1716 grew identically as expected (MacLean, A., et al., 1991a). FI 1 
showed no significant impairment in growth compared to the wild-type rcscuanl F11R, 
although in the one-cycle growth experiment FI 1 had an extended lag phase This extended 
lag phase was not evident in the multi-cycle growth experiment. Both F and FI 1 reached 
final litres approximately 10- fold higher than that of strain 17+ or 1716- in the one-cycle 
growth experiment, however all 4 viruses reached comparable final titles in the multi­
cycle growth experiment.
3.2.9. Western blotting to check for ICP34.5 production.
One of the main aims of this study was to show that a loss of ICP34.5 specifically 
correlated with a loss of ncurovirulence. Identification of ICP34.5 was carried out by 
Western blot analysis (fig.3.21.).
Infected cell extracts were prepared and Western blotted as described in section 2.2.38. to 
assay for ICP34.5 expression using peptide antiserum 78 at a 1/50 dilution.
The parental wild type HSV-1 strain F stock, two individual plaque isolates of F ie.F26 
and F120 and the rcscuanl, FI1R, produce 1CP34.5, although there is variation in Mr 
amongst individual HSV-1 strain F isolates. As was described previously (section 3.2.3.) 
HSV-1 strain 17+ produces a smaller version of the protein which is apparently present in 
lesser amounts than in HSV-1 strain F extracts. As expected 1716 and FI 1 do not produce 
ICP34.5.
FI la and 1716a are the two wild-type recombinants. FI la  has a HSV-1 strain F 
background, but contains the strain 17+ RL1 promoter and coding sequences. This variant 
was expected to produce ICP34.5 with the same apparent Mr as that of HSV-1 strain 17+, 
but the apparent Mr is the same as the strain F protein. The band is a doublet, suggesting 
heterogeneity in the size of the RL1 gene within the virus stock. This heterogeneity within 
a virus population is also seen later (fig. 3.32.) in a Western blot of HSV-1 strain 17+ 
using a protein antiscrum and may be due to variation in the number of copies of the DNA 
sequence coding for the PAT repeat.
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Figure 3.21. Western blot analysis of ICP34.5 from FI I infected cells.
Detection of 1CP34.5 by Western blot analysis, using the anti-peptide scrum (at a dilution 
of 1/50) which had been raised against the PAT trimer repeat. Molecular weight markers 
are shown on the right hand side. A and B refer to ICP34.5 of FI la and 1716a respectively. 
Lanes are labelled at the top of each track.

Results
1716a contains the strain F RL1 promoter and coding sequences in a HSV-1 strain 17+ 
background. This virus produces a protein with a similar Mr to that of HSV-1 strain F, but 
in amounts similar to that of HSV-1 strain 17+. 1716a and FI 1R were marker rescued 
using the same fragment of DNA, but in 1716a, with a strain 17+ background, ICP34.5 
production is reduced.
The relative sizes of the FI la and 1716a ICP34.5 correlate with those obtained for the 
RL1 containing fragment by Southern blotting (section 3.2.8.) indicating again, that the 
variation in polypeptide size is probably due to variation in the copy number of the DNA 
coding for the PAT repeat in the polypeptide.
3.2.10. Localization of 1CP34.5 to the cytoplasm of infected cells.
Ackermann et al. (1986) have reported the accumulation of 1CP34.5 largely in the 
cytoplasm of Hep-2 cells. The availability of a peptide antiserum which strongly 
recognises HSV-1 strain F ICP34.5 and is specifically inhibited by preincubation with the 
relevant peptide (MacKay et at., 1993), and the deletion variant FI 1, which provides an 
ideal negative control allowed us to confirm these findings by immunofluorescncc studies. 
Samples were prepared as described in section 2.2.36. and viewed using a Nikon 
Microphot- SA microscope.
When cells were infected with wild- type HSV-1 strain F(fig. 3.22(c)). dense punctate 
patches of fluorcscncc could be seen in the cell cytoplasm, with minimal signs of 
perinuclear staining. Cells which were mock infected or infected with the mutant FI 1 
(fig. 3 .22(a&b)), tended to show a general low level of background fluoresence, with no 
intense patches of staining as observed with the wild- type virus infected cells. A similar 
result was seen when using strain F if the antiserum was preincubated with the peptide 
data not shown) . These results were consistent with those obtained in cell fractionation 
studies (MacKay et al., 1993).
Figure 3.22. Localization of 1CP34.5 in HSV-1 strain F infected cells.
Immunofluoresence of mock (top), F l l  (middle) and HSV-1 strain F (bottom) infected 
cells incubated with peptide antiserum 78 at a 1/100 dilution. Anti-rabbit IgG F1TC 
conjugate was used as the second antibody.
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3.3. Expression of ICP34.5 in E.colL 
3.3.1 Introduction.
The observation that peptide antisera had been raised against 7 different regions of RL1- 
but only 1 head detected ICP34.5 from HSV-1 strain F (MacKay et al., 1993) suggested 
that the homologous protein of HSV-1 strain 17+ may not be detected by this method. To 
show that thee strain 17+ RL1 ORF was capable of expressing a protein we decided to 
express it under the control of a strong promoter. One method used successfully in this 
Institute for tlhe production of R1 and R2 (Lankinen et al, 1991) is the pET system (Sludier 
et. al., 1990), which allows high expression of foreign proteins in E.coli; this method was 
chosen for tlhe expression of ICP34.5. Furthermore, it was intended to use purified 
ICP34.5 to raiise a polyclonal antiscrum, which hopefully would recognise both ICP34.5 in 
HSV-1 strain 17+ infected cells and the homologous protein in HSV-2 strain HG52.
3.3.2. Construction of the expression vector pET34.5.
The intact RL1 ORF from HSV-1 strain 17+ was cloned into pFTSc (fig.3.23.). pETXc 
encodes the T7 gene 10 promoter including the Shine-Dalgarno sequence and initiating 
ATG. The stairting plasmid was pEA.10, which contained a 1.46kb fragment (np 125074- 
np 126530) off HSV-1 strain 17+ cloned into pGEM 3zf(-). Following digestion with Ncol 
and BamHI (iin the vector polylinker) the entire RL1 ORF was released from the initiation 
codon, to ~4Qbp beyond the stop codon of the gene. This fragment was inserted into 
pET8c, which had been digested with Ncol and BamHI generating the plasmid pET34.5.
3.3.3. Induction of ICP34.5 protein synthesis using IPTG.
The recombinant plasmid pET34.5 was used to transform E.coli BL21(DE3) cells 
containing the T7 RNA polymerase gene under the control of the inducible lac UV5 
promoter as described in section 2.2.28.. Expression was first monitored in 5ml cultures 
using 0.05mM IPTG. E.coli BL2l(DE3) cells which had not been transformed with 
pET34.5 were used as a control. One ml aliquots were removed for sampling at various
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Figure 3.23. Construction of pET34.5
pGEM34.5 contains a 1.46kb fragment of HSV-1 strain 17+ (np 125074-np 126530) 
cloned into pGEM3zf(-). This was digested with Ncol and BamHI and the entire RL1 gene 
sequence isolated. pET8c was also digested with Ncol and BamHI and the gene 10 
fragment removed. Purified RL1 and vector fragments were ligated together thus placing 
the entire RL1 ORF immediately downstream of the T7 gene 10 promoter. This plasmid 
was designated pET34.5 >
up 126530
pGEM34.5
Ncol
tip 125074 
B a m H I Ncolpromoter
gene 10
pET8c
Ncol
promoter
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KL1
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times post induction, pelleted in a microfuge and resuspended in 500ul of extraction 
buffer. After boiling, 50ul aliquots of each sample were run on 7.5% SDS-PAGE and 
Western blotted as described in section 2.2.38.. Anliserum 78 was used as the first 
antibody at a 1/50 dilution. As can be seen in figure 3.24, the E.coli BL21(DE3) which 
have not been transformed with the plasmid pET34.5 fail to produce a protein which is 
recognised by the ICP34.5 specific antiserum. In contrast a band of the expected size from 
HSV-1 strain 17+ ICP34.5 was detected lhr post-induction in the bacteria transformed 
with pET34.5 The amount of protein produced did not appear to increase significantly 
with time.
To optimise ICP34.5 production 500ml cultures were induced with concentrations of IPTG 
ranging from O.to 0.4mM. As before, 1ml aliquots were removed for sampling at various 
times post-induction, the bacteria pelleted, and proteins run on 10% SDS-PAGE and 
Western blotted using the ICP34.5 specific peptide antiserum. Figure 3.25. shows samples 
which were removed 1, 2 or 3hrs post-induction with 0.2 or 0.4 mM IPTG. The first 4 
lanes are the uninduced control. It is apparent that 1CP34.5 production occurs even in the 
absence of IPTG, suggesting that the protein is relatively non-toxic to the cells. Up to a 
concentration of 0.2mM IPTG ICP34.5 production was relatively constant. Levels of 
ICP34.5 appeared maximal lhr after induction with IPTG. Thus in all future experiments 
bacteria were harvested lhr post-induction with 0.05mM IPTG. There appeared to be 
fainter ICP34.5 specific bands of lower molecular associated with ICP34.5 production 
(most noticably -25-28K and -30-35K) and these may represent breakdown products due 
to proteases in the bacteria. These were not observed in cxtracls from the smaller cultures 
which had been run on a lower percentage gel.
To further purify ICP34.5 from crude bacterial extracts (section 2.2.30.) the lyscd bacteria 
were separated into a soluble cytosolic fraction and an insoluble bacterial pellet will) (he 
purpose of further purifying the soluble fraction . Unfortunately, when induction took 
place at 37°C, ICP34.5 was retained in the insoluble fraction. Similar problems have been 
found in the production of R2 protein of HSV-1 ribonucleotide reductase (Lankinen et al..
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3.24. Detection by Western blotting, of a band equivalent in size to HSV-1 strain 17+ 
ICP34.5, in E.coli. BL21 cells transformed with pET34.5.
ICP34.5 expression in BL21 cells transformed with pET34.5 at various times post­
induction with 0.05mM IPTG was assayed by Western blotting using the peptide antiserum 
at a 1/50 dilution. Molecular weight markers are on the left-hand side; Lanes are labelled 
at the top of the gel.
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3.25. ICP34.5 expression with various concentrations of IPTG.
The level of expression of ICP34.5 was examined using various concentrations of IPTG. 
Western blotting with the peptide antiserum at a dilution of 1/50 was used to assay ICP34.5 
expression. Molecular weight markers are on the left-hand side ; Lanes are labelled at the 
top of each track. The concentrations of IPTG used are indicated at the bottom of the gel.
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3.26. Recognition of E.coli - expressed 1CP34.5 by antisera which fail to recognise 
ICP34.5 in HSV-1 infected cells.
This figure demonstrates specific recognition of E.coli -expressed ICP34.5 by 2 antisera, 
Br.212 and L.211. Both antisera were used at a 1/15 dilution. No band equivalent to 
ICP34.5 is detected in bacteria which have not been transformed with pET34.5 (-P). +P 
indicates E.coli BL21(DE3) cells transformed with pET34.5. Molecular weight markers 
are on the left-hand side; Lancs are labelled al the top of each track. E.coli BL2I(DE3)  
cell extracts were prepared lhr post-induction with ().05mM IPTG. The arrows indicate the 
position of ICP34.5.
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1991). In the case of R2, following induction with IPTG, the cultures were rapidly reduced 
to 26°C. This procedure produced soluble expressed protein. By investigating various 
induction temperatures (tabic 3.4.) ii was deduced that induclion at 2X°C, produced 
soluble 1CP34.5.
3.3.4. Detection of E.coli - expressed ICP34.5 by Western blotting, using antisera 
which fail to detect ICP34.5 in infected cells.
Two other peptide antisera- Br.212 and L.211 (fig.3.13.) also detected 1CP34.5 expressed 
in E.coli by Western blotting (2.2.3X.), although they had failed to detect ICP34.5 in 
HSV-1 or HSV-2 infected cell extracts (Dr.C. MacLean, personal communication). E.coli 
BL21(DE3) cells which either had (+P), or had not (-P) been transformed with pET34.5 
were grown and harvested as described in section 2.2.30.. Western blotting was carried out 
as described previously (section 2.2.38.) using both antisera at a 1/15 dilution (fig.3.26.). 
A band of the expected size of HSV-1 strain 17+ ICP34.5 was delected in E.coli BL21 
cebs which had been transformed with pET34.5, but not in those which had not been 
transformed with the plasmid. In some experiments, the fainter ICP34.5 specific bands, 
detected using antiserum 78 were also seen.
3.35. Ammonium sulphate fractionation of expressed ICP34.5.
Crude bacterial extracts were prepared as described in section 2.2.30.. Al this stage there 
was about 25mg of total soluble protein per litre of bacterial culture. ICP34.5 solubility 
was examined at ammonium sulphate concentrations ranging from 10-50%. Increasing 
amounts of a saturated solution of ammonium sulphate were added to lOOul aliquots of the 
crude extract (section 2.2.29.). Examples of volumes added per lOOul crude extract are 
shown in table 3.5.. After 30 minutes on ice precipitated protein was pelleted al 4°C. 
Pelbt and supernatant fractions were analysed by 10% SDS-PAGE to determine at which 
amnonium sulphate concentration 1CP34.5 could be fully recovered from the crude 
extiact. ICP34.5 could not easily be identified by Commassie blue staining of gels as there
1 0 1
Table 3.4. Solubility of E.coli -expressed ICP34.5 
when expressed at a variety of temperatures.
\solubilit>
inductiohv
lempcralurbv
1CP34.5 
detected in 
pellet 
(insoluble)
1CP34.5 
detected in 
supernatant 
(soluble)
0
37 C + -
0
31 C +/- 47-
0
28 C - +
0
26 C - +
+ : protein mainly detected in this fraction 
+/- : relatively equal amounts of protein found 
both fractions
-: very little protein detected in this fraction
Table 3.5. Precipitation of crude extract using a 
saturated solution of ammonium sulphate.
volume 
crude extract
final %
ammonium
sulphate
volume 4M 
solution added
lOOul 5 5.3ul
lOOul 10 ll.lu l
lOOul 15 17.7ul
lOOul 20 25 ul
lOOul 25 33.4ul
lOOul 30 42.8ul
lOOul 35 53.9ul
lOOul 40 66.7ul
lOOul 45 81.Oul
lOOul 50 lOOul
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were many host bacterial bands of a similar si/e and intensity. Figure 3.27. shows 
Commassie blue stained ammonium sulphate supernatant and pellet fractions from 42- 
55%. As explained above ICP34.5 is not apparent in the gel but it serves to show the 
number of other contaminating E.coli bands in the sample following ammonium sulphate 
fractionation. The expected position of ICP34.5, based on Western blotting, is indicated. It 
soon became clear that this was not the best way of detecting ICP34.5 in the pellet 
fractions, therefore it was detected by Western blot using peptide antiserum 78 (fig.3.28). 
Analysis of supernatant and pellet fractions showed that ICP34.5 started to precipitate at 
an ammonium sulphate concentration between 10 and 20%, and that increasing amounts 
precipitated up to 40% salt. At this point there was still small amounts of ICP34.5 in the 
supernatant fractions, however, at 50% ammonium sulphate, all 1CP34.5 was precipitated. 
Therefore, the procedure was scaled up and all further preparations of ICP34.5 were 
precipitated with 50% ammonium sulphate. The protein delected by anliserum 78 was 
confirmed as ICP34.5 by its absence when the antiserum was preincubated with the 
relevant peptide (fig.3.29.). In all gels where ammonium sulphate fractions are shown, 
saturated ammonium sulphate, to a final concentration equal to tlial of the highest 
concentration used for analysis (50% or 60%) has been added to the pellet fractions, prior 
to running on the gel. This was done so that the osmotic pressure in each track is even, 
hence preventing distortion of the gel. Following precipitation with 50% ammonium 
sulphate the total protein concentration was now approximately lOmg/litre of starting 
culture.
3.3.6. Partial purification of 1CP34.5 using anion-excliange chromatography.
Many attempts were made to find a column and conditions of pH at which ICP34.5 bound. 
In almost every case it was found that either the protein did not bind, or it bound but was 
eluted over almost the entire gradient, making purification almost impossible (table 3 .6 .). 
One such case is demonstrated in fig.3.30.. Here an XK 16 column was packed with 10ml 
S-sepharose (Pharmacia) and equilibrated with 100ml buffer A, (in this case 50mM NaCl,
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3.27. Ammonium sulphate fractionation of 1CP34.5 from crude bacterial extracts.
Saturated ammonium sulphate was added to the crude extract and following centrifugation, 
the pellets (P) and supernatants (S) from the fractions indicated were loaded on the gel. 
The expected position of the band representing ICP34.5 is indicated (■). Both pellet and 
supernatant fractions correspond to an equal volume of crude extract and were equalized to 
60% (NH4)2S04 prior to loading onto the gel. Molecular weight markers are on the left- 
hand side.
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Figure 3.28. Purification of 1CP34.5 by ammonium sulphate fractionation.
Saturated ammonium sulphate (10%, 20%, 30%, 40% and 50%) was added to crude extract 
and after centrifugation, equal volumes of supernatant and pellet fractions were loaded 
onto a gel. Following electrophoresis, the proteins were transferred to nitrocellulose and 
Western blotting was carried out using peptide antiserum 78, at a 1/50 dilution. The 
relative quantity of ICP34.5 in the pellet and supernatant fractions at each salt 
concentration was compared.

Figure 3.29. Western blotting of ammonium sulphate Tractions to confirm tlie 
presence of ICP34.5
Saturated ammonium sulphate was added to crude extract. After centrifugation, the pellets 
from the fractions indicated were loaded onto a gel. Following electrophoresis, the proteins 
were transferred to nitrocellulose and Western blotted using peptide antiserum 78, al a 1/50 
dilution, without (A) or with (B) pre-incubation with the relevant peptide. The large arrow 
indicates the position of ICP34.5. In (A), an air-bubble between the 50% and 60'% 
ammonium sulphate fractions has blocked the efficient transfer of proteins onto tlhe 
nitrocellulose.
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Table 3.6. Columns and conditions tested for purification of 
E.coli- expressed ICP34.5
Column pH/buffer result
1) MonoS pH 6.5/ MES no binding
pH 5.5/ MES no binding
pH 7.2/Tris-HCl some binding 
(aggregation 7)
2) Mono Q pH 8.0/ Tris-HCl no binding
pH 7.6/ HEPES no binding
pH 6.8/ HEPES no binding
pH 6.0/ MES no binding
3) Phenyl sepharose pH 7.6/ Tris-HCl low yields 
(~lmg total protein/ liter 
crude extract)
4) S-sepharose pH 7.6/Tris-HCl Some binding 
(aggregation ?)
5) DNA-cellulose* pH 7.6/ HEPES no binding.
*Dr.F.Amina, personal communication.
In 1-4 the source of ICP34.5 was ammonium s ' e fractionated crude 
bacterial extracts whereas in number 5, the source of 1CP34.5 was from HSV-1 
strain F infected cell extracts.
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3.30. Purification of 1CP34.5 using S-sepliarose.
Gradient elution of salt-fractionated E.coli expressed 1CP34.5 was carried out using a 
10ml S-sepharose column. (A) Commassie-blue stained SDS-PAGE. Lane numbers 
correspond to the fraction numbers. Only every second fraction was run. Molecular weight 
markers are on the right-hand side. F and W correspond to the flowthrough and wash 
fractions respectively. The positions of ICP34.5 and the lower molecular weight 1CP34.5 
associated band are indicated (•). (B) Confirmation of the band corresponding to E.coli 
expressed ICP34.5 was provided by Western blotting the flowthrough fraction using 
peptide antiserum 78 at a 1/50 dilution. ICP34.5 is indicated by an arrow. The position of 
the lower 30kD associated band is also indicated (►).
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50nM M.E.S, pH6.5) at 4°C. Two litre equivalent of crude extract, which had been 
partially purified by taking a 50% (NH4 )2SC>4 cut was applied to the column and after 
wa:hing with 1 column volume of buffer A, a 100ml gradient was applied to the column 
ranging from 50mM NaCl, 50mM (2-[N-MorpholinoJethanesulfonic acid)(M.E.S.), pH6.5 
to !M NaCl, 50mM M.E.S., pH 6.5 . Two ml fractions were collected and analysed by 
SD3-PAGE. At first it appeared that the protein had not bound to the column at all, but 
clo;er examination of the wash and fractions from the gradient revealed that the protein 
hac bound and was being gradually washed off rather than specifically eluted. It is 
possible that the E.coli -expressed ICP34.5 aggregates either with itself, or with other 
praeins in the crude extract thus preventing specific binding of the protein to the column 
marix and causing the protein either to flow through the column or to be eluted with other 
praeins in the sample. Some proteins which are at a high concentration in solution are 
known to form aggregates, and this may be the situation in the crude extract. However in a 
concentrated solution they tend to be more stable and thus a compromise must be reached. 
In tie case of ICP34.5, reducing the concentration of the solution by increasing the volume 
of tie sample with buffer did not appear to improve elution.
A nore satisfactory approach to purify ICP34.5 was attained by anion exchange FPLC. In 
thiscase, the majority of the E.coli proteins in the sample bound but the expressed protein 
did not. As the protein pellets from the ammonium sulphate fractionation were generally 
restspended in 50mM NaCl, 50mM Tris-CI pH 7.6 it was decided that this would be the 
easest buffer to try first. A Mono Q 5/5 HR column was equilibrated first with buffer B 
(IN NaCl, 50mM Tris-Cl,pH7.6) and then buffer A (50mM NaCl, 50mM Tris-CI ,pH7.6) 
before application of the sample. The binding capacity of this column is approximately 
25ng protein, which in this case is equivalent to 2.5 litres of ammonium sulphate 
fractionated material. Fractions of lml were collected and analysed by SDS-PAGE. An 
exanple of consecutive flow-through fractions is shown in fig.3.31.. Although there are 
still some contaminating bacterial bands, purification of ICP34.5 was greatly enhanced 
(set fig. 3.27. for an idea of the increase in purity). Since the protein concentration was
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3.31. Partial-purification of 1CP34.5 using Anion-exchange chromatography.
Salt-fractionated E.coli - expressed 1CP34.5 was further purified on a Mono Q HR 5/5 
column. A total of 25mg (40ml volume) was loaded on the column. Flowthrough fractions 
were collected and bound proteins were washed off using a buffer containing 1M salt. Lane 
numbers of the Commassie blue stained gel correspond to consecutive flowthrough 
fractions. Molecular weight markers are shown on the right-hand side. The arrow indicates 
the 37kd ICP34.5 polypeptide and# represents the associated 3()kd band.

Results
only about 1 mg/litre starting material alter anion exchange FPLC, further purification of 
the protein was not attempted due to the risk of losing all material. It was considered that 
the protein would be sufficiently pure to be used for the production of a polyclonal 
antiserum.
3.3.7. Polyclonal antisera production and detection of ICP34.5 in HSV-1 infected 
cells.
Two rabbit antisera to ICP34.5 were produced using concentrated samples of partially 
purified ICP34.5. Two mg of protein (containing approximately lOOug E.coli -expressed 
ICP34.5) were used for each immunization and both rabbits given 4 boosts before being 
bled out. Various dilutions of the antisera were used to try and detect ICP34.5 in both 
HSV-1 and HSV-2 infected cell extracts by Western blotting. Antibody incubation was 
carried out at temperatures of 4°C, RT and 37°C. Incubation of the antiserum overnight, at 
RT, at a 1/20 dilution was chosen as the preferred conditions. Only 1 of the 2 antisera 
recognised ICP34.5 in HSV-1 infected cell extracts. Neither anliserum recognised an 
ICP34.5 homologue in HSV-2 strain HG52, even at a dilution as low as 1/10 (dala nol 
shown).
It has previously been shown that HSV-1 strain 17+ produces a lower Mr ICP34.5 than 
HSV-1 strain F (MacKay et al., 1993). This difference is due at least partly to an amino 
acid sequence, PAT, repeated 10 times in the HSV-1 strain F protein, but only 5 times in 
the HSV-1 strain 17+ protein. Peptide antiserum, 78, was -30 fold less sensitive at 
detecting the HSV-l strain 17+ protein than the HSV-1 strain F protein (MacKay et al., 
1993) ind this could be due to one (or both) of the following reasons: either in HSV-1 
strain 17+ infected cells compared to HSV-1 strain F infected cells there are lower levels 
of ICP54.5 synthesized, or because the peptide antiserum was raised against 10 copies of 
the PAr repeat, the difference could simply be due to antibody affinity differences.
Using the rabbit polyclonal antiserum, HSV-1 strain 17+ 1CP34.5 was detected at 
comparable levels to the HSV-1 strain F polypeptide (fig.3.32.) indicating that the
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Figure 3.32. Detection of ICP34.5 in HSV-1 infected cells using tlie protein antisera.
Specific recognition of bands corresponding to 1CP34.5 in HSV-1 strain F and HSV-1 
strain 17+ infected cells using the protein antiserum at a 1/20 dilution. Bands were 
visualised using ECL (Amersham). Lanes are labelled at the top of each track. Molecular 
weight markers are on the left-hand side.
M F 17* 1716
90K+
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previous differences in detection had been due to antibody affinity differences and that the 
protein accumulated to equivalent levels in cells infected with either strain. In HSV-1 
strain 17+ infected cell extracts, 2 bands are delected which are absent from cells infected 
with the RL1 deletion variant 1716, one corresponding to ICP34.5 which is indicated, and 
another fainter one running just below ICP34.5. It would be reasonable to assume that the 
HSV-1 strain 17+ stock is heterogeneous with respect to the number of copies of the DNA 
sequence coding for the PAT repeat and this lower Mr band represents an ICP34.5 
polypeptide with less than the believed 5 copies of PAT. If as we suspect, the previous 
differences in detection of the strain 17+ polypeptide compared to the strain F polypeptide 
were due to antibody affinity differences, this would explain why the lower molecular 
weight band has not previously been observed using the peptide antiserum. Alternatively, 
this lower molecular weight band may simply be a breakdown product of the larger 
polypeptide. If ICP34.5 is degraded or processed in infected cells, the previous difficulties 
in detection of the protein would be explicable.
Unfortunately the polyclonal antiserum produced did not have as high an affinity as had 
been anticipated and was no more sensitive at delecting HSV-1 strain F 1CP34.5 than the 
available peptide antiserum. We were unable to detect ICP34.5 from HSV-1 strain F, 
HSV-1 strain 17+ and HSV-2 strain HG52 by immunoprecipitation (data not shown).
3.3.8. Detection of ICP34.5 by immunofluorescence.
During the course of this study HSV-1 strain F ICP34.5 was localized to the cytoplasm of 
infected cells by immunofluoresence using the antipeptide serum, 78 (section 3.2.10.). 
These experiments were repeated using the polyclonal antiserum. Before use the 
polyclonal antiserum was preincubated with E.coli cell extracts to cut down non-specific 
binding (section 2.2.35.). Slides were prepared as described previously except that the 
cells were incubated with the first antibody under 3 different conditions: (i) RT, I hr; (ii) 
37°C, 30minutes; (iii) 37°C, lhr. The best results were obtained when incubation was 
carried out at 37°C for lhr.
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As observed previously, no distinct localized staining could be detected in mock 
(fig.3.33a.) or RL1 deletion mutant (in this case 1771) (fig.3.33b.) infected cells whereas 
dense punctate patches of staining were observed in Ihe cytoplasm of slrain 17 * infected 
cells (fig.3.33c.) Thus the distribution of ICP34.5 following both HSV-1 strain 17+ and 
HSV-1 strain F infection appears identical.
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Figure 3.33. Localization of 1CP34.5 to the cytoplasm of HSV-1 strain 17+ infected 
cells using the rabbit protein antiserum.
Immunofluoresence of mock (top), 1771 (middle) and HSV-1 strain 17+ (bottom) infected 
cells incubated with the ICP34.5 rabbit protein antiserum a 1/50 dilution. Anti-rabbit IgG 
FITC conjugate was used as the second antibody.
Results
Chapter 4- Characterization of a Us deletion variant
4.1. Introduction
During the analysis of single plaque isolates from a transfection, an isolate was identified 
which had an apparent deletion in the short unique(Us) region of the HSV-1 genome. This 
variant had a small plaque morphology on BHK21/C13 cells and in both one-cycle and 
multi-cycle growth analysis, it had an extended lag phase, although it reached final litres 
equivalent to the wild-type virus HSV-1 strain 17+. This suggested that the variant, 
designated 1772, had a defect in either adsorption, penetration or cell-to-cell spread 
following infection of BHK21/C13 cells. I decided to determine the precise location of the 
deletion in 1772 and attempt to further characterize its apparent growth defect.
4.2. Isolation of 1772 and localization of the deletion in Us.
While analysing single plaques, one variant was isolated which had an apparent 500-700bp 
deletion in the BamHl j restriction enzyme fragment (fig.4.1.) within the Us region of the
HSV-1 genome (see fig.3.6 for HSV-1 strain 17+ BamHI restriction enzyme map). 
Confirmation that the deletion was in BamHI j was provided by Southern blotting (section 
2 .2 .21 .).
One ug of both wild-type HSV-1 strain 17+ DNA and 1772 DNA was digesled with 
BamHI and the resulting fragments separated on 0.8% agarose gels. Four duplicate sheets 
of nylon membrane were prepared as described in section 2.2.21. and the DNA probed 
with 4 separate randomly primed subfragments from the wild-type BamHI j restriction 
enzyme fragment. These probes are listed below.
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Figure 4.1. BamHI restriction enzyme profile of 1772.
Autoradiograph of a BamHI digest of viral DNA. The wild-type BamHI restriction enzyme 
fragments are indicated on the right-hand side. The novel 1772 BamHI j fragment is 
marked by an arrow and is designated by the letter of the band from which it was derived 
plus a prime symbol (‘). Lanes are labelled at the lop of each track.
- I
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Probe Restriction fragment Nucleotide positions* Size
1 BamHI - PvuII 136288-138072 1784bp
2 Pvull - BamHI 138574-142746 4172hp
3 BstXI - BstXI 139371-139844 473bp
4 BstXI - BamHI 139844-142746 2902bp
* According to McGeoch et.al.( 1988a).
It was hoped that Southern blotting using these 4 separate probes would help localise the 
deletion in 1772. However this was not the case. Similar results were obtained with all 4 
probes (see fig 4.2. for examples). In each case, the probe hybridized to a 6.4kb band the 
expected size of BamHI j in the HSV-1 strain 17+ digest, but to a 5.7-5.9kb band in the 
1772 digest. This result did however, confirm that the deletion was in BamHI j.
Proteins encoded by this region of the HSV-1 genome are a protein kinase, gG, gD, US5, 
gl and gE (US3-7) (fig. 4.3.). Because 1772 had a small plaque morphology on 
BHK21/C13 cells it was likely that one of the “non-essential” glycoproteins (Longncckcr 
and Roizman, 1986, 1987; Longnecker et al., 1987) was either totally or partially deleted 
and we decided to sequence the end-points of the deletion to identify which gene(s) the 
deletion affected.
4.3. Sequence analysis of 1772
For sequence analysis of 1772, the BamHI j restriction enzyme fragment from this variant 
was cloned into the BamHI restriction enzyme site of pGEM 3zf(-). Restriction enzyme 
analysis was carried out to localize a fragment, of suitable size for sequencing (~lkb), 
which contained the 1772 deletion.
Digestion of wild-type HSV-1 strain 17+ BamHI j ,  cloned into pGEM 3zf(-), with BstXI 
and SacI (recognition sites for these enzymes are not found in pGEM3zf(-)) gives 6 
fragments; 1 ~4.7kb in size which contains the plasmid backbone and 1.6kb of HSV-1 
sequence, and 5 other HSV-1 fragments of 1503, 573, 311, 633 and 1883bp.
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Figure 4.2. Detection of BamHI j by Southern blotting.
An autoradiograph of a Southern blot of BamHI digested HSV-1 strain 17+ and 1772 DNA 
probed with 2 subfragments from BamHI j (see page 108). The deleted BamHI j band in 
1771 is marked j ’. M is a molecular weight marker tract. The 4172bp probe contains 
contaminating pAT153 sequences which hybridize to the 1.6kb fragment in the marker 
tract.
M 17* 1772 M 1772 17*
4172 bp proto# 2902 bp proto#
Figure 4.3. Genetic content of the BamHI j restriction enzyme fragment.
Diagramatic representation of the genes encoded in the BamHI j restriction enzyme 
fragment. Nucleotide positions (McGeoch et a i, 1988a) are shown on the top line. The 
position of the termination-codon of gD (np 139601), the initiation-codon of gl (np 
139785) and the termination-codon of gl (np 140955) are marked, and their positions 
indicated with arrowheads.
The deletion in 1772 was mapped to a 1.4kb BslXI/SacI sub-fragment of Bamlll j from 
which a BstXI (B) and a SacI (S) restriction enzyme site had been deleted. Sequence 
analysis of this fragment revealed that 1772 has a 630bp deletion which removes the 
initiating methionine of gl and extends to the 3’ part of the gene.
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Results
Digestion of 1772 BamHI j cloned into pGEM 3zf(-) gives only 4 fragments; the ~4.7kb 
fragment containing the plasmid backbone, the 1883bp and the 1503bp fragments. The 
573, 311 and 633bp fragments (which are adjacent to each oilier on llic IISV-I genome) 
are missing and are replaced by a single fragment of ~800bp. This indicates that the 
deletion in 1772 had removed 2 restriction enzyme sites- a BstXI site at np 139811 and a 
SacI site at np 140155-and the deletion is thus contained within a sub-fragment of BamHI j 
(np 139371- np 140788) which is 1.4kb in the wild-type virus HSV-1 strain 17+, but only 
~800bp in 1772.
This fragment was purified, blunt-ended and cloned into M l3. Il was sequenced in bolli 
directions as described in section 2.2.25. using a M13 universal primer (fig.4.4). This 
revealed that 1772 had a 630bp deletion removing np 139780-np 140409. The deletion was 
in the region of Us encoding gl and removed the initiating ATG of the gene and 625bp of 
the 5’ end; 546bp of the 3’ end of the gene were left intact. The sequence of 1772 showed 
100% homology ( -200  bases were read) with the published sequence of this region on 
either side of the deletion (fig 4.5.), showing that there was no rearrangement at the 
deletion endpoints.
4.4. Immunoprecipitation of gl using MAb 3104.
Cells infected with HSV-1 strain 17+ or 1772 were labelled 3-7hrs post-infection with 
methionine, harvested into 1ml extraction buffer and imnumoprccipilatcd using MAb 
3104, specific for gl (section 2.2.39.). In extracts from HSV-1 strain 17+ infected cells 
MAb 3104 precipitates both the immature form of gl (pgl) and mature forms of gl 
(fig.4.6.). Due to their association in infected cells with gl, gE in both the immature (pgE) 
and mature (gE) forms are coprecipitated by the MAb 3104-gI complex. The amount of 
coprecipitation of gE with the MAb 3104-gI complex is known to vary from experiment to 
experiment, and can be disrupted by heat and SDS (Johnson et al., 1988).
Neither gl or gE were precipitated by MAb 3104 in mock or 1772 infected cells, 
confirming the sequencing data which had revealed that in 1772, gl is deleted. The
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Figure 4.4. Sequence analysis of 1772.
An autoradiograph of the DNA sequence of the HSV-1 strain 17+ variant 1772, showing 
the position of the deletion which removes np 139780-np 140409. Sequences were 
obtained by the dideoxynucleotide sequencing method using T7 DNA polymerase.
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Figure 4.5. Computer analysis of tlie 1772 deletion.
Computer analysis of the 1772 deletion was carried out on a MicroVAX computer using 
the University of Wisconsin Computer Genetics Group software package. The sequenced 
fragment of 1772 shows 100% homology with the published sequence of HSV-1 strain 17+ 
on either side of the deletion. The sequence of the BstXI/SacI BamHI j sub-fragment from 
1772 is on the top line, the wild-type HSV-1 strain 17+ sequence is on the bottom line. 
Homologous sequences are indicated by vertical bars. The nucleotide numbers of the last 
undeleted base on either side of the deletion arc marked.
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Figure 4.6. Immunoprecipitation of gi using MAb 3104.
Immunoprecipitation of gi and gE and their precursors, pgl and pgE respectively. 
BHK21/C13 cells were labelled with 35s methionine from 3-7hrs post infection. Extracts 
were precipitated with either ascites control or MAb 3104 specific for gi . The positions of 
g i , gE, pgl and pgE are indicated. The molecular mass markers are indicated on the left- 
hand side. Tracks are labelled at the top of the gel.
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Results
specificity was indicated by the failure to precipitate gi or gE polypeptides with control 
ascites.
4.5. In vitro growth characteristics of 1772
The in vitro growth characteristics of 1772 were determined on BHK21/C13 cells and 
compared to the wild-type virus HSV-1 strain 17+. In multi-cycle growth experiments 
1772 had an extended lag phase in comparison to the wild-type virus., although this lag 
was not as obvious in one-cycle growth experiments. Both HSV-1 strain 17+ and 1772 had 
comparable final litres (fig 4.7(a).&4.7 (b).). This indicated that 1772 was delayed in entry 
into BHK21/C13 cells and suggested a defect in adsorption, penetration or cell fusion. The 
stocks of HSV-1 strain 17+ and 1772 had similar particle:p.f.u. ratios; 14:1 and 5:1 
respectively, indicating the extended lag phase was not due to interference by non- 
infectious particles.
4.6. Kinetics of polypeptide synthesis by 1772
To examine whether 1772 was delayed in the initiation of protein synthesis following 
infection of BHK21/C13 cells, we looked at the kinetics of synthesis of each class of 
polypeptide following 1772 infection. Cells were infected with wild-type HSV-1 strain 
17+ and 1772 at a m.o.i. of 5 p.f.u./cell and harvested at various times post-infection. 
Proteins were separated by SDS-PAGE and analysed by Western blot as described in 
section 2.2.37.. Synthesis of all classes of HSV-1 polypeptides was examined; Vmwl 10 as 
a representative immediate-early polypeptide; 65KDBP, a representative early polypeptide 
and 21K a member of the true-late class of HSV-1 polypeptides.
Initial experiments indicated that 1772 was delayed in the initiation of synthesis of all 
classes of HSV-1 polypeptides. This was consistent with a delay in entry into BHK21/C13 
cells. However, when different extracts were prepared and the experiments repeated, no 
difference was observed between the wild-type virus and 1772. Subsequent experiments
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Figure 4.7 (a). One-cycle growth curve of 1772.
One-cycle growth curve of HSV-1 strain 17+ and 1772. BHK21/C13 cells were infected at 
a m.o.i. of 10 p.f.u./cell, and following absorption at 37°C for lhr, the monolayers were 
washed twice with PBS/calf, and incubation continued at 37°C. Plates were harvested at 0,
2,4, 6 , 8,12, and 24 hrs post-infection and titrated on BHK21/C13 cells.
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Figure 4.7 (b). Multicycle growth curve of 1772.
A multicycle growth curve of HSV-1 strain 17+ and 1772 was carried out on BHK21/C13 
cells. Cells were infected at a m.o.i. of 0.001 p.f.u./cell, and following adsorption at 37°C 
for lhr, the monolayers were washed twice with PBS/calf and incubation continued at 
37°C. Plates were harvested at 0, 2, 4, 6, 8, 12, 24, 36,48 and 72 hrs post-infection and 
titrated on BHK21/C13 cells.
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Results
have yielded variable results, therefore we are unable to conclude whether or not 1772 is 
delayed in the initiation of protein synthesis following infection of BHK21/C13 cells.
4.7. Adsorption and penetration of 1772 onto cells.
HSV-1 glycoproteins play a crucial role in the initial stages of virus adsorption and 
penetration into tissue culture cells. Although gi has not previously been reported to play a 
role in virus adsorption or penetration in tissue culture it is possible that in some cell types 
gi may play a role in these initial stages of virus infection.
The ability of 1772 to adsorb to and penetrate BI4K21/CI3 cells was compared to the wild- 
type virus HSV-1 strain 17+ as described in sections 2.2.4. and 2.2.5. In both cases no 
difference in adsorption / penetration kinetics was observed between the wild-type virus 
and 1772 (fig 4.8. & fig 4.9.). Attempts to examine the percentage of input virus adsorbed 
to cells were unsuccessful due to poor labelling <of virion preparations. It is possible that 
1772 is defective in cell-to-cell spread and this wais later analysed.
4.8. Analysis of cell-to-cell spread of 1772
To ascertain whether cell-to-cell spread is impaired during 1772 infection, we determined 
the effect of the presence of neutralizing antibodies (human serum) in the growth media on 
virus titre. The rationale for this experiment was tlhat if gi plays a role in direct cell-to-cell 
spread, the presence of neutralizing antibodies should cause a reduction in virus titre as 
virus cannot spread via the alternative pathway which is through absorption of released 
virus. The results are summarized in figure 4.10.
In the absence of neutralizing antibody in the overlay, 1772 reached comparable titres to 
the wild-type virus HSV-1 strain 17+ again with at delay in the lag phase. However, in the 
presence of human serum, the titre of 1772 was reduced by -30 fold compared to the wild- 
type virus after 96hrs growth on BHK21/C13 cells and c.p.e. was much less extensive 
indicating poorer spread of the virus. These results indicate that gi does play a direct role
Figure 4.8. Adsorption of 1772 onto cells.
Pre-cooled BHK21/C13 cells on 50mm plates were infected with 400 p.f.u./plale HSV-1 
strain 17+ or 1772 at 4°C. 0, 15, 30, 45, 60, 80, 100 , 120 and 240 minutes post-infection 
unadsorbed virus was removed by washing twice with PBS/calf and the plates overlaid 
with 4ml EMC 10%. Following incubation at 37°C for 2 days, plates were stained and the 
number of plaques on each counted. Bound virus was calculated as a percentage of final 
virus bound at T=240. Each limcpoint represents the mean of 3 individual plates.
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Figure 4.9. Penetration of 1772 into cells.
Pre-cooled BHK21/C13 cells were infected with 400 p.f.u. HSV-1 strain 17+ or 1772. 
Following absorption at 4°C for lhr, plates were washed twice to remove any unabsorbed 
virus, overlaid with 4mls ETC 10 and incubated at 37°C to enable virus penetration. 0, 5, 
10, 20, 30, 45 and 60 minutes post-incubation at 37°C, media was removed, lml citrate 
buffer added to inactivate unpenetrated virus, and incubation continued at RT for a further 
5 minutes. Plates were washed twice with PBS/calf to remove the citrate buffer, overlaid 
with 4mls EMC10% and incubated at 37°C for 2 days. Plates were stained and the number 
of plaques on each counted. Virus penetration at each timepoint was calculated as a 
percentage of the virus bound at T= 60. Each timepoint represents the mean of 3 individual 
plates.
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Figure 4.10. Analysis of cell-to-cell spread in 1772.
Confluent monolayers of B H K 21/C 13 cells were infected with 0.001 p.f.u HvSV-1 strain 
17+ or 1772. After absorption at 3 7 °C  for lhr, plates were washed twice with PBS/calf, 
overlaid with ETC 10 +/- neutralizing antibodies (human serum) and incubation continued 
at 37 °C . Plates were harvested at 0, 8, 24 , 36, 48, 56, 72 and 96 hrs post-infection and 
titrated on B H K 21/C 13 cells.
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Results
in cell-to-cell transmission of HSV-1 strain 17+. As expected the rale of HSV-1 growth 
was inhibited by the presence of human serum.
4.9. Neurovirulence of 1772
Previous studies (Meigner et a i, 1988; Nishiyama et ah, 1993) have examined the 
neurovirulence of all genes in the Us region of the HSV-1 genome, with the exception of 
US7. In PRV gp63, the HSV-1 gl homologue, is required in conjunction with the HSV-1 
gE homologue (gl) for viral neurotropism. Viral mutants with deletions in either (or both ) 
of these genes are unable to infect specific classes of neurons in the rat retina.
The ncurovirulcnce of 1772 was determined by estimation of its LD50 value following 
intracerebral inoculation of 3-week old BALB/c mice compared to the wild-type virus 
HSV-1 strain 17+. As we could not anticipate the virulence of 1772 it was injected at a 
range of doses (10^-10^ p.f.u./mouse). The wild-type virus was injected at doses of 1()1 
and 1C)2. The results are shown in tabic 4.1..
As expected the wild-type virus was highly virulent, with only 1 survivor at a dose of I()l» 
giving a LD50 of 7 p.f.u./mouse. All deaths occurred by day 6 post-inoculation.
In contrast 1772’s neurovirulence was attenuated . When injected at doses of 10^ or 10^ all 
mice died, but not until an average of 4 days post-inoculation. Two mice died at doses of 
10^ and 10^ post-inoculation, but again there was a delay in the time of death (6-7 days 
post-inoculation). No mice died at a dose of 1()2 p.f.u./mouse, giving an LD50 of 3.6 xlO^ 
p.f.u./mousc. These results indicate lhatgl may play an important role in infection of some 
cell types in vivo as is observed with its PRV homologue. Unfortunately time constraint 
did not allow us to look at 1772 virulence via a peripheral route of inoculation.
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Table 4.1. Neurovirulence of 1772 following intracerebral 
inoculation of 3-week old BALB/c mice.
^* s4 jo se
virus
1
10
2
10
3
10
4
10
s
10
6
10
LD50 p.l'.u./ 
mouse
17 3/4 4/4 ND ND ND ND 7
1772 ND 0/4 2/4 2/4 4/4 4/4 3.6x10 '
*no. of deaths/ no. injected 
ND= not done.
Chapter 5 - Discussion
Discussion
5.1.1. Objectives
The work presented in this thesis had three main objectives: (i) to verily that the region 
between VmwllO and the ‘a’ sequence contains an ORF coding for 1CP34.5 in HSV-1 
strain 17+, (ii) to confirm, in HSV-1 strain 17+> that this protein plays a crucial role in 
neurovirulence following intracerebral inoculation of mice , and (iii) to further characterize 
ICP34.5.
5.1.2. Reinvestigation of the HSV-1 strain 17+ RL1 sequence.
The existence of a neurovirulence determinant in IR l and the adjacent region of U l was first 
demonstrated by Thompson et al. (1983). These workers had previously found that the 
HSV1/2 intertypic recombinant RE6 (Marsden et al., 1978) was completely non- 
neurovirulent in mice following intracercbral inoculation of 3.2x 10? p.f.u.. Since 10 p.f.u. 
of either HSV-1 strain 17+ or HSV-2 strain HG52 (the “parental” strains of this 
recombinant) were lethal for mice on intracercbral inoculation, RE6 was al least 10 million­
fold less neurovirulent than the wild-type strains from which it was derived (Thompson and 
Stevens, 1983b). By transfecting intact RE6 DNA with cloned fragments of DNA from 
HSV-1 strain 17+ onto tissue culture cells , and selecting for neurovirulent recombinants in 
vivo, it was revealed that HSV-1 information residing between 0.71 and 0.83m.u. encoded 
a gene function(s) which was a determinant of ncurovirulence in HSV-1 strain 17+ 
(Thompson et al., 1983). Further in vitro recombination / in vivo selection experiments 
demonstrated that recombination with a cosmid clone of the HSV-1 strain 17+ Hindlll £ 
fragment (0.64-0.87 m.u.) could restore a neurovirulent phenotype to RE6 . Recombinants 
generated with this fragment had LD50 values 5 orders of magnitude lower than RE6 , with a 
LD50= 1.1x 103 (Thompson et al., 1985). In this study however, other recombinants were 
generated which had LD50 values intermediate between RE6 and wild-type virus (egs. 
1x10^ and 2.2x10^). Sequence analysis was not carried out across the ‘restored’ sequences 
in any rescuant, complicating interpretation of these results. Subsequently, it was found that
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sequences residing between 0.698 and 0.721 m.u. could confer partial neurovirulence on 
RE6 . Recombinants generated with cloned DNA spanning this region were only 50-fold 
more neurovirulent that RE6 (Thompson and Wagner, 1988), but again sequence analysis 
was not carried out on the ‘restored’ fragments. These anomalies were not discussed in later 
papers, and the authors went on to demonstrate that a 1.6kb cloned fragment (SstI/ XhoII, 
0.82-0.832m.u.) conferred a highly neurovirulent phenotype to RE6 (Thompson et a l, 
1989).
In our laboratory, this region of the HSV-2 strain HG52 genome had previously been found 
to encode neurovirulence related sequences (Taha et a l, 1989a, 1989b), which were not 
required for virus growth in vitro. A variant, JM2604, with a l.5kb deletion within each 
copy of R l, between 0 to 0.02 and 0.81 to 0.83 map units was isolated (Harland and 
Brown, 1985). This deletion removed 1 complete copy of the 17bp DR 1 element of the ‘a’ 
sequence and terminated 522bp upstream of the 5’ end of RL2 (Taha et al., 1989b). 
Following intracerebral inoculation of mice, JH2604 was completely non-neurovirulent and 
failed to replicate in mouse brain (Taha et a l, 1989a). These findings pointed to sequences, 
located between the ‘a’ sequence and VmwllO, coding for a protein involved in 
neurovirulence in both HSV-2 strain HG52 and HSV-1 strain 17+.
In HSV-1 strain F, one gene product had been localised within the smallest fragment capable 
of restoring a highly neurovirulent phenotype to both JH2604 and RE6 (Ackermann et al, 
1986; Chou and Roizman, 1986). By means of an antibody produced against 10 copies of 
the trimer Pro-Ala-Thr (PAT), encoded by the HSV-1 strain F RL1 ORF, which predicted a 
protein of 358 amino acids in size, a 43.5K protein was specifically detected in HSV-1 strain 
F infected cell extracts. This protein was designated 1CP34.5 (Ackermann et a l, 1986) and 
was shown to be a determinant of HSV-1 strain F neurovirulence (Chou et a l, 1990).
In HSV-1 strain 17+, the ORF ascribed to 1CP34.5 was “thoroughly disrupted” (McGeoch 
et a l, 1988a; Perry and McGeoch, 1988) and the existence of a gene in this locality could 
not be positively established. In 1990, when Chou and Roizman republished the sequence of 
the gene encoding ICP34.5 in HSV-1 strain F they made 25 alterations to the sequence 
published in 1986 and reported that the gene contained only 263 codons. The HSV-1 strain
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F revised sequence was now almost identical to the published HSV-1 strain 17+ sequence 
(Perry and McGeoch, 1988), with the only major difference being a 2bp insert in the HSV-1 
strain 17+ sequence which rendered 60% of the HSV-1 strain 17+ sequence (including the 
PAT repeat) out of frame. The ORF identified hy Chou and Roizman (1990) was conserved 
in two other “limited passage” strains but not in HSV-1 strain 17+. This was attributed to the 
alleged multipassage history of HSV-1 strain 17+ which it was claimed, led to the 
accumulation of mutations. However if ICP34.5 was not produced by HSV-1 strain 17+ it 
should at least be modified in neurovirulence if not totally non-neurovirulenl compared to 
other wild-type viruses. This is obviously not the case (see table 3.1.). In fact HSV-1 strain 
17+ is more neurovirulent than HSV-1 strain F (see table 3.3.).
In our laboratory, the isolation and characterization of a deletion variant, 1716 (MacLean, 
A., et a l, 1991a) demonstrated that the region spanning the deleted sequences in JH2604 
was also required for neurovirulence in HSV-1 strain 17+. Sequence analysis of 1716 
revealed that it had a 759bp deletion which removed 1 complete 18bp DR1 element from the 
‘a’ sequence and terminated 1 lOSbp upstream of the 5’ end of Vmw 110. 1716 was found to 
be totally non-neurovirulcnt following intracerebral inoculation of BALB/c mice with a LD50 
of 7x10^ p.f.u./mouse compared to <10 p.f.u./mouse for the parental wild-type strain 17+. 
Analysis of the in vivo growth kinetics of 1716 demonstrated that the non-neurovirulent 
phenotype was due to an inability to replicate in mouse brain. Rescuants of 1716 had LD50 
values identical to those of wild-type HSV-1 strain 17+.
The initial stage of this project involved reanalysis of the HSV-1 strain 17+ sequence at the 
terminus of the long repeat, in the region where the putative frame-shifl occurred. For this 
purpose a 1.46kb subfragment of the BamHI k fragment (np 125074-np 126530) was 
cloned into M13 and sequenced. At the same time, an independently produced Xhol £ clone 
comprising the region spanning the disputed bases was sequenced by Mr A.Dolan in Dr D.J. 
McGeoch’s laboratory. In both cases, the number of bases was identical to that in the 
published sequence of HSV-1 strain F but not to that in the strain 17+ published sequence. 
This showed that the original sequence obtained for this locus of HSV-1 strain 17+ was
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inaccurate and probably came from an atypical plasmid clone. The agreement between the 
sequences of the Xhol £ and BamHI k subfragmcnt clones, and the ability of the sequenced 
BamHI k subfragment to restore neurovirulence (MacLean, A., et al., 1991a; this thesis) 
argue strongly that the shorter version of the sequence (residues 823 and 824 removed) must 
represent HSV-1 strain 17+ genomic DNA correctly. Correction of the strain 17+ sequence 
to that of the newly sequenced clones (Dolan et al., 1992) opens the reading frame proposed 
by Chou and Roizman (1990) to encode a protein of 248 amino acids with an apparent Mr of 
26184. This ORF has been designated RL1 (McGeoch et al., 1991).
The difficulties which arose over the sequencing of this genomic region and which originally 
cast doubts on the ability of a “non-coding” sequence in strain 17+ to confer ncurovirulcnce 
emphasizes the need to rapidly redetermine the sequence of any intrastrain differences which 
may arise in the future and reinforces the value in determining the equivalent HSV-2 
sequence. Colinear regions of homology between HSV-1 and HSV-2 may reveal genes 
which play an important role in the viral life-cycle and which would be otherwise 
unidentified. This is illustrated by recent determination of the HSV-2 strain HG52 sequence 
in R l  and the adjoining parts of U l (McGeoch et al., 1991), and in which comparison of 
the HSV-2 UL56 gene sequence with its HSV-1 counterpart revealed an apparent frame-shift 
adjacent to the 3? end of the HSV-1 ORF. Re-analysis of both sequences confirmed that the 
HSV-2 sequence was correct, but that in determining the HSV-1 sequence a compression 
had been incorrectly resolved (McGeoch et al., 1988a; Perry and McGeoch, 1988). Thus 
UL56 of both HSV-1 and HSV-2 possesses an uncharged and highly hydrophobic section 
of 18 amino acids which could constitute a membrane-spanning domain, suggesting that 
UL56 is a membrane associated protein.
Having demonstrated that HSV-1 strain 17+ contains a gene, RL1, which encodes an 
ICP34.5 homologue, we wished (i) to confirm that this ORF was translated and (ii) to 
confirm the importance of this gene in neurovirulence. Several approaches were taken: (i) 
insertion of a stop-codon in only 1 frame into the predicted RL1 ORF to demonstrate that 
this led to a non-neurovirulent phenotype and (ii) expression of ICP34.5 under the control of
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a strong E.coli promoter and detection of the protein using pre-existing peptide antisera. 
Purification of the E.coli -expressed protein also allowed generation of anlisera which 
subsequently recognised 1CP34.5 in HSV-1 strain 17+ infected cell extracts.
5.1.3. Construction and characterization of a HSV-1 strain 17+ RL1 variant.
No HSV-1 strain 17+ mutants with lesions solely in the RL1 ORF have previously been 
described, although Chou et al (1990) have partially confirmed the coding assignment of the 
homologous protein in HSV-1 strain F, by inserting a six-frame stop-codon ~90bp from the 
initiating ATG. However, this mutation would also affect overlapping reading frames. 
Recently the identification of a novel promoter downstream of RLI (figure 5 .1), from which 
two transcripts of 0.9kb and 4kb, anlisense to RLI have been detected by Northern blotting 
(Bohenzky et al., 1993), has potentially complicated the analysis of existing RLI mutants. 
The 3’ ends of these transcripts have not been mapped, but they can be detected in cells 
infected with HSV-1 mutants lacking the LAT promoter and are therefore not processed 
forms of LAT. Verification that lack of synthesis of ICP34.5 alone, was responsible for a 
non-neurovirulent phenotype was achieved through the construction and characterization of a 
HSV-1 strain 17+ RLI variant, 1771, with a stop-codon in only the ICP34.5 reading frame, 
9 base pairs downstream from the initialing ATG.
It was initially decided to insert an in-frame stop-codon close to the initiating ATG of RLI 
by site-directed mutagenesis using as a starting template, the M13 clone which had been 
used to resequence the gene. However, it soon became clear that this was not the best 
approach to use. Although oligonucleotides 18-42 bases long were used under high 
stringency conditions, they consistently either hybridized non-spccilically to the M13 
template or failed to hybridize; this could be attributed to the high G+C content of Rl  
(71.6% G+C; Perry and McGeoch, 1988), and the high G+C content of the oligonucleotides 
used. The high G+C content of the oligonucleotides may also have led to the formation of 
secondary structures which prevented correct annealing. Similar results have been found 
with HSV-2 RLI (Miss S. Bdour, personal communication); using the same starling 
template, site-directed mutagenesis has been successful in some regions of RLI, but not in
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Figure 5.1. Position of the novel promoter indentifled by Bohenzksky etal. (1993). 
Diagramatic representation of the HSV-1 genome with an expanded region Hanking the L- 
S junction composed of the BamHI restriction enzyme fragment k (np 123459-np 129403). 
The promoter fragment is indicated by a hatched box. The position of the putative TATA 
box (which is located 54bp downstream of the SacI site) is indicated (T). The solid arrows 
denote the mRNAs for RL2, RSI, RL2, and the primary transcript of LAT. The symbols 
for restriction enzyme sites are as follows: Bm, BamHI; Bs, BstEII; D, Dral; N, Ncol; Sc, 
SacI; Sp, Sphl; St, Stul.
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others, presumably clue to variations in the G+C content of the regions undergoing mutation. 
Interestingly, Mr A.Dolan (personal communication) has been unable to successfully 
amplify by PCR, the region spanning RLI despite success in other regions of the genome; 
this again, is probably due to the high G+C content of Rl. As an alternative approach, an in­
frame stop-codon was introduced into the RLI ORF using the plasmid pEA. 10 whose 
construction was described in an earlier section. The only disadvantage with this method 
was the large size of the oligonucleotide linkers used (91mer and 92mer) and the possibility 
that aberrant bases could be introduced into the RLI sequence. This was however 
eliminated, by sequencing the entire 92bp insert, which confirmed that it was identical to the 
wild-type RLI sequence, except for the 6bp insert.
1771 was totally non-neurovirulent following intracercbral inoculation of 3-week old 
BALB/c mice with a LD50>1()6 p.f.u./mouse compared to clOp.f.u./mousc for the wild- 
type HSV-1 strain 17+. The LD50 values of 1771 and 1716 are 7-fold lower than the 
published LD50 value of 1716 (MacLean, A., et a l, 1991a), but it should be pointed out 
that in this thesis 1771 and 1716 were only injected al doses up to 10^ p.f.u./mouse. The 
non-neurovirulent phenotype of 1771 was shown to be due to an inability to replicate in 
mouse brain, with no detectable virus present at 3 days post-inoculation. It would seem 
unlikely that the virus detected at days 1 and 2 posl-inoculalion is newly replicated virus, but 
this cannot presently be discounted. Like 1716, (MacLean, A., et al., 1991a) 1771 is not 
impaired in growth in vitro in BHK21/C13 cells. In confluent mouse embryo fibroblast 3T6 
cells 1771 reaches a final titre ~4 logs lower than the wild-type HSV-1 strain 17+ and its 
growth pattern is indistinguishable from that of 1716 (Dr. S.M. Brown, personal 
communication). This tissue culture system apparently reflects the in vivo phenotype of 
RLI negative virus, and correlates with in vivo growth data available for both 1771 and 
1716 (MacLean, A., et a l, 1992; section 3.1.7). The replication defect observed in variants 
which fail to produce ICP34.5, is tissue and/or cell type specific as 1716 replicates in mouse 
peripheral tissue (Robertson et a l,  1992) As both 1716 and 1771 replicate in 
undifferentiated F9 cells (Dr S.M. Brown, personal communication) (a mouse embryo
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testicular carcinoma cell line) this would indicate that the replication delect is not host 
specific.
The mechanism by which ICP34.5 enables growth in the nervous system is unclear. It is 
unlikely that ICP34.5 is involved in attachment, penetration or uncoating as both HSV-1 and 
HSV-2 variants which fail to synthesize 1CP34.5 can establish and reactivate from latent 
infection in mice (Thompson e ta l ,  1989; MacLean et a i, 1991b; Robertson et at., 1992), 
demonstrating that virus can at least enter neurons. In addition, as far as we can determine 
ICP34.5 is not present in virions or associated with membranes (MacKay et a i, 1993). One 
possible explanation for the apparent growth difference of ICP34.5 negative variant between 
cells of neuronal and other cells of nonneuronal origin could be Mint in cells eg. 
BHK21/C13, MDK or Vero cells, and peripheral tissues in vivo where ICP34.5 deletion 
variants are not impaired in growth, a cellular homologue can compensate for the lack of 
production of ICP34.5; this homologue may not however, be present in cells of neuronal 
origin or certain other defined cell types.
The precise role which ICP34.5 plays in the virus life cycle is unclear, but a recent study in 
one neuroblastoma cell line (Chou and Roizman, 1992) claimed that in the absence of 
ICP34.5, apoptosis occurred following infection with HSV-1. Infection of this one 
neuroblastoma cell line with mutants incapable of expressing ICP34.5 results in shutoff of 
cellular protein synthesis and no virus replication. Infection of these cells with wild-type 
virus results in sustained protein synthesis and production of infectious progeny. No such 
defect was seen in the Vero cells used as controls. However the mutant 1716 fails to induce 
cell-death or apoptosis in tissue culture (Dr S.M. Brown, personal communication).
Two homologues of 1CP34.5 which originate from 2 quite unrelated sources have recently 
been described (Barnett and McGeoch, 1991; Sussman et al., 1992) - MyD116, a murine 
myeloid differentiation primary response gene, and LMW23-NL, an ORF in the African 
Swine Fever Virus genome. Although the function of LMW23-NL is unknown, its 
similarity with genes involved in myeloid cell differentiation and viral host range suggest a 
possible role for it in African Swine Fever host range.
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Although they differ in size, 1CP34.5, MyDl 16 and LMN23-NL contain a centrally located 
acidic region with a highly conserved, hydrophilic 56-amino acid domain located al the 
carboxy terminus. LMN23-NL and ICP34.5 both contain a highly basic amino terminus 
composed of 8 to 10 lysine and arginine residues. In the conserved domain, LMW23-NL 
and MyDl 16, show 78% overall conservation, whereas LMW23-NL and ICP34.5 have 
55% overall conservation. These sequence determinations suggest that in HSV-1 and HSV-2 
the carboxylerminus of the protein, is the region most highly conserved in all these proteins, 
constitutes an important functional domain. Furthermore, mutations affecting the conserved 
domain of HSV-2 strain HG52 RL1 completely abolish neurovirulence (Miss S. Bdour, 
personal communication).
In summary having confirmed that the HSV-1 strain 17+ genome encodes a HSV-1 strain F 
ICP34.5 homologue we have constructed a HSV-1 strain 17+ RL1 deletion variant 1771 
with a stop-codon in only the ICP34.5 reading frame. This mutant has been used to 
demonstrate conclusively that deletion of 1CP34.5 alone is sufficient to abolish 
neurovirulence following intracerebral inoculation of mice with HSV-1 strain 17+.
5.1.4. Construction and characterization of an HSV-1 strain F ICP34.5 
deletion variant.
In a previous attempt to detect ICP34.5 from HSV-1 strain 17+ infected cells, synthetic 
oligopeptides representing different regions of the predicted open reading frame were used to 
generate antisera (figure 3.13.). Until recently (MacKay et a l, 1993), none of these peptide 
antisera were successful in identifying ICP34.5 in HSV-1 strain 17+ infected cells, although 
1 which was directed against 10 copies of the PAT repeat strongly recognised ICP34.5 in 
HSV-1 strain F infected cell lysates. Another antiserum directed against 5 copies of the PAT 
repeat weakly recognised HSV-1 strain F 1CP34.5 in infected cell lysates.
The strain F deletion variant, FI 1, was constructed to confirm the specifity of the antiserum 
against the PAT tenmer, to use as a negative control in ICP34.5 localization studies and to 
show that loss of 1CP34.5 expression specifically correlated with a loss of neurovirulence.
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The simplest method for construction of this variant was to linearise a plasmid, containing a 
HSV-1 strain 17+ fragment spanning the 1716 deletion, and to cotransfect this onto 
BHK21/C13 cells along with intact HSV-1 strain F DNA. An isolate with a genome profile 
identical to 1716 was then selected for further analysis.
1716 and F ll  are totally non-neurovirulent following intracerebral inoculation, with LD50 
values of >10^ p.f.u./mouse. By comparison HSV-1 strain 17+ and HSV-1 strain F had 
LD50 values of <1()2 p.f.u./mouse. It has previously been shown (MacLean, A., et a l, 
1991a) that the non-neurovirulent phenotype of 1716 is caused by its inability to replicate in 
mouse brain. As F ll  contains exactly the same RL1 deletion in its genome, it would be 
reasonable to assume that it also, is unable to replicate when injected inlracerebrally into 
mouse brain.
The main aim of this study was to demonstrate that a lack of synthesis of ICP34.5 correlated 
with a loss of neurovirulence. By Western blot analysis of infected cell extracts, it was 
demonstrated that FI 1 did not produce 1CP34.5. In conjunction with neurovirulence studies 
of F ll we confirmed that lack of synthesis of 1CP34.5 specifically correlated with the 
acquisition of an non-neurovirulent phenotype.
Ackermann et al. (1986) have reported the accumulation of HSV-1 strain F ICP34.5 largely 
in the cytoplasm of Hep-2 cells, and these results have been confirmed for HSV-1 strain 17+ 
using cell fractionation studies (MacKay et al, 1993). BHK21/C13 infected cell extracts 
were separated into cytosolic and membrane fractions with all detectable ICP34.5 being 
found in the cytosolic fraction. Similarly when infected cells were separated into nuclear and 
cytoplasmic fractions, less than 1/320 of 1CP34.5 was present in the nucleus with the 
remainder in the cytoplasm. This result was confirmed by immunofluorescence using the 
wild-type HSV-1 strain F and FI 1 as a negative control. 1CP34.5 was localised in discrete 
punctate patches within the cytoplasm, suggesting possible localization of the protein in 
specific cytoplasmic organelles eg. golgi apparatus or ribosomes.
The major difference between 1716 and FI 1 is the ability of these 2 viruses to reactivate 
from latency. In a previous study (Robertson et a l, 1992) the RL1 deletion variant 1716 
was found to be impaired in reactivation from latency compared to the wild-type virus - a
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result which was confirmed in this study. Reactivation of both 1716 and FI 1 from latency is 
dose-dependent. HSV-1 strain F appeared to establish and reactivate from latency in 
significantly fewer ganglia than HSV-1 strain 17+ (15% of ganglia infected with HSV-1 
strain F reactivating compared to 55% of ganglia infected with HSV-1 strain 17+), a 
consistent finding in our laboratory (Dr. L.Robertson, Dr. A. MacLean, personal 
communication). Taking this into account, F ll did not .show any difference in reactivation 
kinetics compared to HSV-1 strain F. F ll in not impaired in reactivation from latency 
compared to HSV-1 strain F, although it is impaired in reactivation from latency compared to 
HSV-1 strain 17+
The LD50 of HSV-1 strain F is consistently I log higher Ilia 11 1 hat of IISV-I strain 17+ 
following intracerebral inoculation of mice, which implies poorer replication of the virus in 
vivo. If HSV-1 strain F also replicates less efficiently than HSV-1 strain 17+ in the DRG 
following inoculation al the periphery, less virus will be available for establishment of a 
latent infection, leading to poorer reactivation kinetics for HSV-1 strain F compared to HSV- 
1 strain 17+. This could explain the lack of difference in reactivation frequency between F 
and F ll. This hypothesis could be tested by comparing the replication kinetics of both HSV- 
1 strain F and HSV-1 strain 17+ in DRG, and their LD50S, following footpad inoculation 
MacLean e ta l  (1991b) have previously demonstrated that the HSV-2 strain HG52 mutant, 
2604, which has a similar deletion in its genome to F ll and 1716 is not impaired in 
reactivating from latency compared to the wild-type parental virus. Following inoculation 
with JH2604 at a dose of 10  ^ p.f.u., virus reactivated from 74% of ganglia, while at the 
same dose of HSV-2 strain HG52, virus reactivated from 81% of ganglia. It would thus 
appear that the factors which determine establishment and/or reactivation from latency differ 
depending on the viral background. These factors also seem to be separate from those 
affecting neuro virulence.
It is possible that the functional domain of LAT and hence the effect which the deletions in 
JH2604 and 1716 have on LAT, varies between HSV-2 strain HG52 and HSV-1 strain 17+. 
Recent comparison of HSV-2 strain HG52 R^ with its HSV-1 strain 17+ counterpart
(McGeoch et al., 1991) has demonstrated that the sequence of the LAT transcript is
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dissimilar, whereas the probable LAT promoter region of HSV-2 strain HG52 shows 
similarities to that of HSV-1 strain 17+. Hence the regions of the LAT transcript deleted in 
JH2604 and 1716 may differ. If a functional domain of LAT is deleted in 1716 but not 
JH2604 this might account for the reactivation kinetics observed with the 2 viruses. Analysis 
of the latency characteristics of 1771 with only 1 inserted slop-codon and hence minimal 
effect on the antisense LAT should answer this question.
During the course of this study, 2 other recombinant wild-type viruses, 1716a and FI la 
were constructed. 1716a contains the HSV-1 strain F RL1 promoter and 5’ coding 
sequences in a strain 17+ background, whereas FI la contains the IISV-I strain 17+ RLI 
promoter and 5’ coding sequences in a strain F background. If ICP34.5 is underproduced in 
HSV-1 strain 17+, and this is a function of the viral background, then 1716a would 
synthesize lower amounts of the protein than FI la. The results obtained are ambiguous. 
Both FI la  and 1716a produce a protein with a similar Mr to that of HSV-1 strain F (as 
confirmed by Western blotting) suggesting that other viral gene(s) are also involved in 
1CF34.5 production and processing. The idea that ICP34.5 is underproduced in HSV-1 
strain 17+, rather than being less strongly recognised by the peptide antiserum might be 
supported by the fact that 1716a and FUR were marker rescued using the same fragment of 
DNA, but in 1716a, with a strain 17+ background, strain F ICP34.5 is apparently 
underproduced. However this does not correlate with later evidence obtained using the 
polyclonal antiserum, which clearly indicates that ICP34.5 is produced in similar quantities 
in HSV-1 strain F and HSV-1 strain 17+. Natural variation in the number of copies the DNA 
sequence encoding the PAT repeat within the 1716a stock, would lead to the presence of 
isolates with fewer copies of the PAT repeat. These might not be detected due to poor 
antibody affinity of the peptide antiserum. Two other HSV-1 strains, MGH-10 and CVG-2 
sequenced by Chou and Roizman (1990) had 6 copies of the PAT repeat, so it would not be 
unreasonable to assume that natural variation in the number of PAT repeats could occur. 
Alternatively, infection with 1716a may be poorer and hence the apparent underproduction 
of protein.
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Confirmation that the wild-type phenotype had been restored to FI la and 1716a was 
provided by determination of their LD50 values in B ALB/c mice following inlracerebral 
inoculation. In both cases the neurovirulent phenotype was found to be restored to the 
recombinant virus to a level comparable with HSV-1 strain F.
It is interesting to note that HSV-1 strain F, which was isolated from a recurrent facial 
lesion, is of moderate virulence, with a 50% lethal dose of approximately 100 p.f.u. by 
intracerebral inoculation of mice. In contrast, MGH-10, derived from a case of human 
encephalitis, has a 50% lethal dose of 1 to 5 p.f.u. by the same route in identical mouse 
strains (Meigner et a i , 1988). Similarly, in our system the LD50 of HSV-1 strain F is 
consistently around 1 log higher than that of HSV-1 strain I7+. ll is possible that these 
observed differences in HSV-1 neurovirulence could be ascribed to differences in the 
nucleotide sequence, in particular the PAT copy number of ICP34.5 with strains having 
fewer copies of the PAT repeat being more neurovirulent. This hypothesis has not been 
tested. Alternatively, it could be due to alterations elsewhere in the genome.
5.1.5. Over-expression of RLI in a bacterial system, and partial purification 
of ICP34.5.
We chose to express ICP34.5 in E.coli for several reasons: (i) ICP34.5 had not previously 
been detected in HSV-1 strain 17+ infected cells, probably due to a low level of synthesis. 
By placing the gene under the control of a strong promoter we hoped to be able to detect a 
protein product using pre-existing peptide antisera, (ii) Al the initiation of this project we 
were concerned that we would be unable to detect ICP34.5 in HSV-1 strain 17+ infected 
cells using peptide antisera. By expressing the protein in a bacterial expression system, we 
hoped to raise polyclonal anti-ICP34.5 sera which would specifically recognise ICP34.5 in 
HSV-1 strain 17+ infected cells and might also detect the semi-conserved polypeptide in 
HSV-2 strain HG52 infected cells, (iii) MacKay et al. (1993) have recently optimized our 
assay conditions such that a peptide antiserum raised against 10 copies of the PAT repeat 
specifically recognises ICP34.5 in HSV-1 strain F and HSV-1 strain 17+ infected cells. The 
level of detection of ICP34.5 in HSV-1 strain 17+ was 30-fold lower than in HSV-1 strain
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F; a polyclonal antiserum would enable determination of whether the differences in the levels 
of detection between the HSV-1 strain 17+ and HSV-1 strain F polypeptides were real, or 
merely due to antibody affinity differences, and (iv) purification of the E.coli -expressed 
ICP34.5 might have enabled us to undertake functional studies.
The E.coli pET system (Studier et a i, 1990) has previously been used for high level 
expression of HSV-1 R1 (Furlong et a i, 1991) and R2 (Lankinen et al., 1991) and was 
chosen for expression of the entire ORF of ICP34.5. However, ICP34.5 was not expressed 
at a particularly high level in this system (-1% R1 (Furlong e ta l,  1991)). Several attempts 
were made to increase the level of production of ICP34.5 in this system. Variation in growth 
temperatures had no effect on the quantity of 1CP34.5 produced, neither did addition of 
ampicillin, at various stages of growth, to ensure maintenance of pET34.5 within the E.coli 
cells. When single plaques from a plate were used to inoculate 500ml cultures directly, the 
quantity of ICP34.5 decreased by -50%. In no case was an obvious increase in the level of 
ICP34.5 production detected and there did not appear to be any significant fluctuations in the 
quantity of 1CP34.5 produced in individual experiments.
When cultures were maintained at 37°C following induction, ICP34.5 was produced in an 
insoluble form. Subsequent experiments revealed that lowering the growth temperature of 
the cultures to 28°C following induction was sufficient to enable production of soluble 
E.coli -expressed ICP34.5. Because 1CP34.5 was not expressed to high levels and thus was 
not a major constituent of the bacterial lysate, and previous studies using the peptide antisera 
indicated that it might not be highly immunogenic, we fell it necessary to remove as many 
contaminating bands from the crude extract before using it for the production of polyclonal 
antisera. A two stage programme was developed for the parlial purification ICP34.5. The 
first stage in purification was ammonium sulphate fractionation. By 50% ammonium 
sulphate, almost all ICP34.5 had been precipitated from crude bacterial extract, therefore this 
percentage ammonium sulphate was routinely used for purification. As a second step, 
several columns were tested for 1CP34.5 binding at various pH ranges and salt 
concentrations, but in almost every case the protein failed to bind. When it did bind, the 
protein tended to elute over almost the entire salt gradient suggesting that the E.coli
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expressed ICP34.5 was aggregating with other proteins in the sample. Although the 
theoretical isoelectrical point of ICP34.5 is 4.3, the protein failed to hind to a mono P 
column in the pH range 4-6 (Dr. M. Denheen, personal communication). Again this could be 
due to aggregation of the protein in solution preventing binding to the column or alternatively 
the protein may be folded in such a manner that charged amino acids are screened.
Using the MonoQ as the second step in purification was a compromise; although ICP34.5 
did not bind to this column, most bacterial bands did and thus the flowthrough gave larger 
and purer yields of protein than any other column tested. Despite this, only small amounts of 
protein remained following purification using the MonoQ column. We did not consider it 
necessary therefore to attempt further purification of the protein prior to use as an 
immunogen.
Two New Zealand While rabbits were immunized intramuscularly, first with 2mg total 
protein (approximately lOOug ICP34.5) in Freund’s complete adjuvant followed by 4 
boosts, each at a 14 day interval, using the same amount of antigen but in Freund’s 
incomplete adjuvant. Rabbits were bled 10 days after each boost and the antisera tested at 
different dilutions against HSV-1 strain F and HSV-1 strain 17+ infected cell extracts for 
reaction with ICP34.5 specific bands. After 5 injections only I rabbit had produced an 
immune response, with an antibody litre which appeared to have plaleaued. This animal was 
bled out and its serum used as the polyclonal anti-ICP34.5 scrum.
The polyclonal antiserum did not have as high an affinity as had been hoped and was 
actually no more sensitive at detecting the HSV-1 strain F polypeptide than the peptide 
antiserum which was already available. However, the protein antiserum recognised HSV-1 
strain F and HSV-1 strain 17+ ICP34.5 with equivalent sensitivity, demonstrating that 
previous differences in detection level (MacKay etal., 1993) were due to antibody affinity 
differences and that the level of ICP34.5 accumulation in cells infected with each strain is 
similar. We were unable to detect HSV-2 strain HG52 ICP34.5 using either 
immunoprecipitalion or Western blotting. In immunofluoresence studies, this antiscrum was 
used in conjunction with 1771, to confirm our previous results which had demonstrated the 
localization of 1CP34.5 in discrete punctate patches, specifically in the cytoplasm of infected
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cells. This work demonstrates that the distribution of ICP34.5 in infected cells is similar 
following HSV-1 strain F and HSV-1 strain 17+ infection.
In summary we have used partially purified E.coli -expressed ICP34.5 lo produce in rabbits 
a polyclonal anti-ICP34.5 serum which specifically delects ICP34.5 in HSV-1 strain F and 
HSV-1 strain 17+ infected cell lysates. We have demonstrated that the level of ICP34.5 
accumulation is similar following HSV-1 strain F and HSV-1 strain 17+ infection, indicating 
that previous observed discrepencies in the level of detection between the two strains were 
due to antibody affinity differences. The polyclonal antiserum was also used to specifically 
localize ICP34.5 to the cytoplasm of 1 IS V-1 si rain 17+ infected cells.
5.1.6. Characterization of 1772, a deletion variant in Us*
The Us region of the HSV-1 genome encodes 13 predicted ORFs (McGeoch et al., 1985; 
Georgeopoulou et al., 1993). With the exception of gD, these are all dispensible for growth 
in tissue culture (Post and Roizman, 1981; Longnecker and Roizman, 1986; Umcne, 1986; 
Longnccker et a i, 1987; Weber et a i, 1987; Georgeopoulou et a i, 1993) .The isolation of a 
spontaneous Us deletion variant from a transfection experiment was unexpected. In general 
where spontaneous HSV variants have previously been isolated and described, the deletions 
have involved one of the repeat regions and adjacent unique sequences (Brown et a i, 1984; 
Harland and Brown, 1985; Longnecker and Roizman, 1986; Umene, 1986; Brown and 
Harland, 1987), suggesting that these act as illegitimate ‘hotspots’ for recombination. 
Following plaque purification and titration on BHK21/C13 cells, it was observed that 1772 
produced small discrete plaques, which did not have a normal wild-type morphology. This 
phenotype was indicative of a defect in cell-to-cell spread, a property which has not 
previously been ascribed to any gene in Us. Restriction endonuclease and sequence analysis 
localized the deletion in 1772 to the BamHI restriction enzyme fragment and subsequently to 
US7 encoding gl. 1772 has a 630bp deletion which removes the initiating ATG of US7 and 
extends to the 3’ end of the gene. Confirmation that US7 was deleted in 1772 was provided 
by immunoprecipitation using the previously well characterized MAb 3104 (Johnson et a i,
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1988). This MAb precipitated proteins with the expected size of gl and pgl and also gE and 
pgE from HSV-1 strain 17+ infected cells, but not from mock or 1772 infected cells.
Initial characterization of 1772 involved analysis of the in vitro growth characteristics of this 
variant. In one-cycle, but especially multi-cycle growth analysis, 1772 had an extended lag 
phase, although it reached final litres comparable to the wild-type virus. Longnecker et.al. 
(1987) demonstrated that deletion of gl did not affect the ability of the virus to replicate in 
tissue culture, but they did not carry out detailed growth analysis of their US7 deletion 
variant, hence they did not observe this extended lag phase during the initial stages of 
growth in tissue culture. If 1772 has a defect in adsorption or penetration into BHK21/C13 
cells, this would explain the apparent initial delay in initiation of infection. Entry of 
herpesviruses into their host cells is believed to occur by fusion of the viral and cellular 
membranes (reviewed by Spear, 1993). Since 1772 appeared to be defective in the initial 
stages of viral growth, we thought it was possible that entry of the virus into the cells and 
initiation of the infectious cycle could be affected by the lack of gl. However, no difference 
in the time of initiation of immediate-early, early or late protein synthesis in BHK21/CI3 
cells could be detected, and no difference in the rates of adsorption of wild-type and gl" 
virus to BHK21/C13 cells was observed. It is possible that the percentage of 1772 
adsorbing to cells in tissue culture is impaired, however experiments to determine if this was 
the case were unsuccessful due to poor labelling of virion preparations. Development of 
resistance to low pH ie. virus penetration, between the wild-type and gl" virus was also 
similar. Virus preparations of 1772 and HSV-1 strain 17+ had comparable parlicle:p.f.u. 
ratios, ruling out, the possibility of interfering virus particles in the 1772 preparation. Thus, 
if gl plays an auxiliary role in the fusion of the viral and cellular membranes during virus 
entry into cells, the effect is too subtle to be detected by the assays we have used. Through 
the incorporation of neutralizing antibodies in the overlay it was demonstrated that gl plays a 
direct role in cell-to-cell spread.
Following intracerebral inoculation of mice, 1772 was intermediate in neurovirulence with a 
LD50= 3.6x10^ p.f.u./mouse compared to 7 p.f.u./mouse for the wild-type virus HSV-1 
strain 17+- Although the actual mean time to death was not calculated, this variant was
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impaired in growth in vivo. If injected with HSV-1 strain 17+ at doses of 10^ or 1()6 , mice 
would be expected to die within 24-48 hrs. However when injected with equivalent doses of 
1772, the mean time to death was approximately 4 days. It could be postulated that in vivo, 
wild-type virus spreads either (or both) by direct cell-to-cell transmission or via adsorption 
to uninfected cells of virus that has been released from infected cells. As 1772 is impaired in 
direct cell-to-cell spread, virus will still spread via the other pathway, and this accounts for 
the reduced virulence. 1772 should similarly be impaired in virulence following peripheral 
inoculation. In PRV, both gl and gp63 (the HSV-1 gE and gl homologues respectively) are 
known to play a role in virulence in both pigs, the natural host of this virus (Kimman et al., 
1992) and mice (Peelers et al., 1993). gp63 forms a complex with gl and Ihe phenotypes of 
gl, gp63 and gl + gp63 mutants are similar (Zuckermann et al., 1988) suggesting that the 
complex of gp63 and gl is the functional unit. Evidence that gl (and thus gp63) is involved 
in cell-to-cell transmission of the virus was recently reported (Zsak et al., 1992). We have 
demonstrated this for gl and believe this accounts for the observed in vivo phenotype of 
M il .
The physiological role played by Fc receptors in the replicative cycles of herpesviruses 
remains unclear. It has been postulated that the Fc receptor protects the virus, or virus 
infected cell from host immune attack by binding IgG, thus preventing immune recognition , 
or sterically hindering destruction by IgG or Fc-dependent effector cells (Cosh/ et al., 1977; 
Lehner et a l, 1975; Westmoreland and Wadkins, 1974). Adler et a i (1978) demonstrated 
that IgG aggregates protect HSV-1 infected cells from complement-mediated cytolysis or 
destruction by sensitized lymphocytes, while Dowler and Vellri (1984) demonstrated that 
HSV-2 virions can resist neutralization by HSV-2 specific antisera by binding non-immune 
IgG.
The Fc portion of IgG is the region of the molecule responsible for mediating important 
effector functions, such as complement activation and antibody-dependent cellular 
cytotoxicity (for overview see Roitl el.al., 1985). Therefore, binding of the Fc end of 
immune IgG could modify the effectiveness of IgG mediated attack. Recently, Frank and 
Friedman (1989) demonstrated that the HSV-1 Fc receptor can bind the Fc domain of IgG
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which has its antigenic target (in this case a viral glycoprotein) bound at the Fab domain, and 
thus protects the virus from antibody and complement-dependent neutralization.
It has recently been shown that expression of gE alone results in the induction of Fc receptor 
activity, while expression of gl alone gives no detectable Fc binding; hence IISV-I has the 
potential to induce 2 Fc receptors- a high affinity receptor comprising gl and gE which binds 
monomeric IgG and a lower affinity receptor comprising gE alone, which binds IgG 
complexes (Bell et a l , 1990; Dublin et al., 1990). The presence of gl could enhance binding 
of IgG by gE in 2 ways; either indirectly by altering the confirmation of gE to increase the 
affinity of its Fc receptor-binding domain, or directly by interacting with gE to form a new 
high-affinily Fc-binding domain. If 1772 produces only a low affinity Fc-receptor as would 
be suggested by the results obtained by Bell et al .(1990) and Dublin et a l (1990), virus 
infected cells may be more susceptible to immune cytolysis and this could perhaps account 
for the reduction in neurovirulence of 1772.
In PRV however, the gl-gp63 complex does not appear to have IgG Fc-receptor activity 
(Zuckermann et al., 1988). Thus the significance of the gE-gl complex Fc-reccptor 
expression in HSV-1 virulence is unknown. Although an Fc-receptor could decrease the 
effects of antibody on infected cells, its reported absence from PRV and PRV-infecled cells 
suggests that the Fc-receptor is not of major importance for the expression of virulence of 
herpesviruses.
5.2. Future prospects
We have confirmed that ICP34.5 plays a crucial role in neurovirulence following 
intracerebral inoculation of mice, and it may now be possible to define the functional regions 
of RLI. Further defined lesions could be constructed along the length of RLI eg. at the PAT 
repeat, before the 63 amino acid region of conservation between HSV-2 strain HG52 and 
HSV-1 strain 17+ and at various positions within the 63 amino acid conserved domain. It 
should also be possible to construct a RLI variant in which the 5’ end of RLI is deleted, 
through the use of oligonucleotide-linkers. Analysis of the neurovirulence phenotype of the
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resulting variants may indicate the functional regions of the gene and help to define the 
precise role which this protein plays in vivo.
The latency characteristics of 1716 and FI 1 are currently being examined using a mouse 
corneal model to determine if the results obtained correlate with those obtained using the 
footpad model. Preliminary results have indicated that in the corneal model, 1716 compared 
to the wild-type virus is impaired in reactivation from latency to an even greater extent than is 
observed using the footpad model (Dr. J. Spivak, personal communication). The reason for 
this defect is at present unclear, but the possibility that ICP34.5 is involved in establishment 
and/or reactivation from latency is currently under investigation. Through characterization of 
the latency characteristics of 1771, we should be able to determine if the impairment of 1716 
in reactivation from latency is due to an effect of the large genomic deletion on the LAT 
transcriptional unit, or due to the lack of synthesis of ICP34.5.
1716 is impaired in growth in DRG of mice ; if 1771 is similarly impaired in growth at this 
anatomical site we can definitively conclude that ICP34.5 is required for cell and/ or 
tissue specific growth. These studies are currently on-going.
Detection of HSV-2 strain HG52 ICP34.5 will require a higher litre and more sensitive 
antiserum. There are obvious routes to be taken to achieve this. An alternative expression 
system eg. baculovirus or a GST-fusion might give higher expression of ICP34.5 and 
higher levels of starting material for purification. Use of an alternative expression system 
may not however, overcome the problems of protein aggregation. As an alternative approach 
5’ deletions are currently being made in the existing PET construct in the hope that a smaller 
truncated version of the protein will be more readily purified. For an antiserum to cross-react 
with HSV-2 strain HG52 ICP34.5, it will probably be necessary to raise antisera against an 
expressed protein in which the 63 amino acid region of homology between HSV-1 strain 
17+ and HSV-2 strain HG52 has been conserved. As 1CP34.5 is a small protein (248 amino 
acids in strain 17+) this limits the alterations which can be made and it may be necessary to 
express the HG52 polypeptide to successfully raise an anliscrum which recognises it in 
infected cells. It is hoped in the long term that ICP34.5 will be purified to homogeneity, for 
use in monoclonal antibody production and functional studies. In conjunction with further
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defined lesions in the RLI ORF monoclonal antibodies will be used to determine the 
functional regions of ICP34.5.
To further characterize the growth defect in 1772, a wild-type rescuanl should be 
constructed, to exclude the possibility that a mutation elsewhere in the viral genome is 
contributing to the observed phenotype. If, by rescuing the gl deleted sequences, wild-type 
growth characteristics and wild-type ncurovirulence are restored, we can conclude that gl 
plays a role in cell-to-cell spread.
In PRV glycoproteins gl, gp63 and gill are the homologues of glycoproteins gE, gl and gC 
respectively of HSV-1 (Petroviskis e tu i, 1986; Robbins et al., 1986a). Mutants defective in 
only gl, gp63 or gill exhibit a marginal decrease in neurovirulence compared to wild-type 
virus. In contrast double mutants either gl" gill" or gp63" gill" are non-neurovirulent for 
mice, chickens and pigs (Mettenleitcr et a i, 1987,1988). gill plays a role in virus adsorption 
to cells in tissue culture (Schreurs et a i, 1988), whereas gl (and also gp63) is involved in 
cell-to-cell transmission of virus (Zsak et a i, 1992). Thus the lack of virulence of a gill" gl" 
(gp63) virus is probably attributable to its inability to spread by either mode.
In HSV-1 gC is required for viral adsorption onto cells (Kuhn et a i, 1990; llerold et a i, 
1991). If we assume that gl is required for cell-to-cell transmission, then a variant lacking 
both of these glycoproteins would be unable to spread via either adsorption of released virus 
or cell-to-cell transmission. A HSV-1 variant of this nature might be expected to be non- 
neurovirulent and thus useful for the development of a live attenuated HSV vaccine. 
Inoculated virus would be localized at the site of infection which would enable the 
production of a host-immune response, but subsequent spread of the virus via post-synaptic 
transport, and thus involvement of the nervous system would be unlikely.
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HSV-1 strain 17+ TTTAAAGCCGCGGCGGCGGGCAGCCCGGGCCCCCCGCG GCCGAGACTAGCGAGTTAGACAGGCAAGCAC-TACTCGC
HSV-1 strain F T - -  G
HG52 strain HG52 C - G GCC CAACA G TG G A CCA GG T C CT GG G
HSV-1 strain 17+ 
HSV-1 strain F 
HSV-2 strain HG52
CTCTGCACGCACATGCTTGCCTGTCAAACTCTACCACCCCGGCACGCTCTCTGTCT-
GGT A TG GAGTG A G CGGCT GGGCCTACGCCGAGCCCAGCCG
HSV-1 strain 17+ 
HSV-1 strain F 
HSV-2 strain HG52
 CCATG
CCCG
DNA sequence alignment of HSV-1 strains 17+ and F, and HSV-2 strain HG52 in the promoter region of 
the gene encoding ICP34.5, starting with the proposed RLl TATA boxes (Chou and Roizman, 1990; 
McGeoch et.al., 1991). The sequences are for the leftward 5' to 3' strands in IRl . Nucleodide 
changes in HSV-1 strain F and HSV-2 strain HG52 are indicated below the HSV-1 strain 17+ sequence. 
All other nucleotides are identical. Absence of a base is indicated (-).The initiating methionine 
of RLl is underlined.
HSV-1 strain 17+ 
HSV-1 strain F 
HSV-2 strain HG52 
LMW23-NL 
MyD116
VRF S PHVRVRHLV-VWASAARLARRGSWARERADRARFRRRVAEAEAVIGPCLGPEARARALAR 
VRFSPHVRVRHLV-VWASAARLARRGSWARERADRARFRRRVAEAEAVIGPCLGPEARARALAR 
VCFSPRVQVRHLV-AWETAARLARRGSWARERADRDFRRRRVAAAEAVIGPCLEPEARARARAR
VYFATDDI LIKVR-EADDIDRKGPWEQAAVDRIRFQRRIADTEKILSAVLLRKKLNPMEHR
VHFAEKVTVHFLA-VWAGPAQAARRGPWEQFARDRSRFARRIAQAEEKLGPYLTPDSRARAWAR
Conserved carboxy-terminal domains of HSV-1 strains 17+ and F, HSV-2 strain HG52, 
African Swine Fever ORF LMW23-NL and MyDll6.
